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“In my occasional attempts to work with clinical colleagues, I encountered a 
kind o f ‘two cultures’ problem [...]. Most clinicians, even academic ones, and 
basic scientists, even those trained originally as physicians, do not necessarily 
converse easily. They know different things, seem to speak different dialects, 
have somewhat different goals and standards, and even organize their days 
differently — clinicians arriving early, scientists arriving late - hampering 
opportunities to meet. Clinicians often lack the laboratory support that would 
be required to store and keep track o f patient materials for research, they are 
extremely busy, and their primary responsibilities lie outside o f the laboratory. 
Furthermore, the time from biological discovery to clinical advance can be 
extraordinarily long, and the process may be encumbered with administrative 
and regulatory hurdles. These things can try the patience o f those accustomed 
to frequent gratification in the laboratory.”
Harold Varmus, Nobel Laureate in Medicine - The A r t  and Politics of Science.
Outline o f  the thesis
Outline of the  thesis
Classically, in the last century there have 
been three treatment modalities in cancer: 
surgery, radiotherapy and medical therapy 
(which concerns chemotherapeutics, hor­
mones, immunotherapy, and more recently 
targeted therapy). Immunotherapy con­
cerns the use o f the patients’ own immune 
system to fight cancer.
There are several possibilities to reinforce 
anti-cancer immunity: make tum or cells 
m ore susceptible for im m une-attack, 
strengthen the effector cells that kill tumor 
cells or alarm and activate the directors o f 
the immune system. The latter approach is 
used in dendritic cell (DC) vaccination.
DCs are the orchestrators o f immune res­
ponses, they activate and direct the effec­
tor arm o f the immune system towards the 
cancer cells. Several years ago techniques 
were developed to culture large quantities 
o f DCs from peripheral blood, providing 
the opportunity to manufacture a cancer- 
specific vaccine, consisting o f the patients’ 
own DCs that are activated and loaded 
with immunogenic particles o f tum or cells 
(antigens) for clinical administration. After 
administration, the DCs migrate to lymph 
nodes and activate T  cells, which subse­
quently proliferate and spread throughout 
the body to kill the cancer cells that ex­
press the same antigen.
At least, that is how it works in theory... 
Reality unfortunately is less straightfor­
ward. DC vaccination includes many in­
trinsic variables, such as the type o f DC, 
the type o f antigen, the m ethod o f 
antigen-loading, the route o f administra­
tion, the treatment schedule, the m onitor­
ing o f immune responses and the type and 
stage o f cancer. In addition, there are sev­
eral hurdles to overcome, especially the 
many levels o f immune suppression that 
may be present in the cancer patient.
This thesis focuses on clinical studies in 
which patients with melanoma or colorec­
tal cancer were vaccinated with DCs. Sev­
eral variables were tested, often with 
vaccine-induced immune response as end­
point. In addition, in vitro studies were per­
formed focussing on DC antigen loading 
strategy and the effect o f cytotoxic anti­
cancer drugs on DC function and tumor 
cell immunogenicity.
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General Introduction
Adaptedfrom:
Lesterhuis WJ, de Vries IJ, Adema GJ, Punt CJ. 
Dendritic cell-based vaccines in cancer immunotherapy: 
an update on clinical and immunological results. 
Annals of Oncology 2004;15 Suppl 4:iv145-51
Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. 
Dendritic cell immunotherapy: mapping the way.
Nature Medicine 2004;10(5):475-80.

General Introduction
Chapter 1
The immunogenicity of tumors has been established. Non-specific stimulation of 
immunity, such as by cytokine therapy, has been shown to induce durable clinical 
remissions in metastatic disease1. The identification and molecular characteriza­
tion of tumor-associated antigens in the last 10-15 years has allowed the develop­
ment of immunotherapy targeted specifically at the tumor. Dendritic cells (DCs) are 
the professional antigen-presenting cells of the immune system, with the potential 
to either stimulate or inhibit immune responses. As such, they are currently ap­
plied in clinical studies in cancer patients with the goal of inducing a tumor-specific 
T cell response.
IMMUNOBIOLOGY OF DENDRITIC CELLS
DCs reside in peripheral tissues where they 
act as the sentinels o f the immune system, 
continuously patrolling the environment in 
search o f antigen (figure 1a). At this stage 
they possess an ‘immature’ phenotype, 
which is mainly characterized by a low sur­
face expression o f MHC class I and II 
molecules and costimulatory molecules2. 
Immature DCs are specialized in the rec­
ognition and uptake o f antigen. Exoge­
nous antigens are internalized and proc­
essed by DCs, and the antigenic peptides 
are presented in the MHC class II com­
plexes on the cell surface. Endogenous an­
tigens, such as unstable self-proteins or vi­
ral proteins, are cleaved into peptides by 
proteasomes and assembled into stable 
MHC class I-peptide complexes in the en- 
doplasmatic reticulum which are subse­
quently transported to the cell surface. O f 
importance for DC-based vaccines in can­
cer immunotherapy is the finding that in­
te rna lized  an tigens from  exogenous 
sources, such as apoptotic or necrotic tu­
m or cells, may also be presented in MHC 
class I3. Thus, DCs may present tum or an­
tigens to both CD4+ and CD8+ T cells.
In the presence o f a ‘danger’ signal, de­
rived from tissue damage or microbial 
products, DCs undergo an activation proc­
ess called maturation4. This maturation 
process involves a cascade o f events that 
convert the DC into a cell that is excep­
tionally well equipped for antigen presen­
tation and T cell activation. During matu­
ration DCs upregulate chemokine recep­
tors CCR7 and CD62L which leads to mi­
gration to secondary lymphoid organs. 
Furthermore, surface expression o f MHC 
class I and II, co-stimulatory molecules 
CD80, CD86 and CD40, and CD83 are 
upregulated, the latter functioning as a 
maturation marker for DCs2.
In the lymph nodes DCs interact with high 
numbers o f T  cells. Two signals are essen­
tial for T cell activation: the interaction be­
tween the MHC-peptide complex and the 
T  cell receptor (‘signal 1’), and a co­
stimulatory signal from the DC to the T 
cell (‘signal 2’). A third signal determines 
the differentiation pathway o f the T  cell. 
This ‘signal 3’ is induced by several envi­
ronmental factors that may skew the dif­
ferentiation o f CD4+ T cells into Th1, 
Th2 and possibly regulatory T  cells5. The 
activated T cells subsequently leave the 
lymph nodes and circulate through the 
body in search o f antigen.
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FACTORS THAT DETERMINE DENDRITIC 
CELL VACCINE EFFICACY 
DC Subsets
Since DCs constitute only about 0.2% per­
cent o f peripheral blood leukocytes, sev­
eral ways to generate DCs from precursors 
have been investigated. Immature DCs cul­
tured from monocytes by adding GM-CSF 
and IL-4 to the culture medium allow the 
generation o f large quantities o f clinical 
grade DCs6,7. Further maturation may be 
achieved by adding cytokines such as 
T N F a , prostaglandin E2, IL-1^, IL-6 or 
monocyte conditioned medium8,9. Most 
clinical studies to date have used this 
m ethod to generate DCs (figure 1b). The 
main disadvantage o f culturing DCs from 
monocytes lies in the laborious and costly 
nature o f the culture protocol. DCs de­
rived from CD34+ precursors in the blood 
are also used in vaccination protocols. 
They consist o f two distinct populations, 
one with Langerhans cell-like properties 
and the other term ed interstitial/dermal 
DCs with properties resembling m ono­
cyte- derived D Cs10.
Also, blood DCs can be obtained by sev­
eral enrichment steps after leukapheresis. 
However this usually requires repeated 
leukaphereses due to the low numbers o f 
blood D Cs11.
Lastly, DCs may be induced in vivo by the 
administration o f DC growth factors. For 
this purpose Flt3L has been investigated in 
patients with resectable metastases o f co­
lorectal cancer12. Increased numbers o f 
DCs were observed in both resected tu­
m or specimens as well as in peripheral 
blood. These findings demonstrate that in 
vivo expansion o f the blood DC pool in 
cancer patients is feasible and may be an 
alternative to the laborious ex vivo culturing 
procedures.
10
Antigen loading of DCs
In order to induce an immune response in 
cancer patients, DCs should present the 
relevant tum or antigens. For this purpose 
m ost clinical studies so far have used DCs 
pulsed with autologous tum or lysate or 
MHC class I peptides. Tumor lysate has 
the advantage that the antigen does not 
have to be identified, but has the disadvan­
tages that sufficient tum or material is 
needed for preparation o f the lysate and 
that it is impossible to m onitor immune 
responses as the antigens are not known. 
Tumor antigen-derived peptides have the 
advantage that many peptides are com­
mercially available. However, the half-life 
o f MHC-peptide complexes is relatively 
short and the immune response, if any, is 
restricted to the epitope(s) used. It has 
been described however that antigen- 
spreading may occur: killing o f tum or cells 
after vaccination against a single epitope 
results in release o f other tum or antigens. 
These antigens are subsequently taken up 
by DCs and presented to T  cells, resulting 
in T  cell responses against antigens which 
were not included in the vaccine13.
MHC class II peptides also allow the acti­
vation o f CD4+ T helper cells14,15. A more 
recent m ethod o f antigen-loading con­
cerns the use o f transfection o f DCs with 
either whole tum or RNA or RNA encod­
ing a specific cancer antigen16. Also fusion 
o f tum or cells with DCs has shown to be 
feasible, resulting in effective antigen- 
presentation17.
It remains to be established which type of 
antigens (i.e. for example tum or differen­
tiation antigens, cancer-germline genes, 
broadly expressed tum or antigens such as 
TERT18 or unique tum or antigens) are 
most suited in terms o f the induction of 
anti-tumor immune responses.
Chapter 1
Maturation
In  the majority o f  clinical studies im m a­
ture or semi-mature D Cs have been used19. 
M atu ra tio n  can  be ach ieved  by co- 
culturing the D Cs w ith several stimuli such 
as cytokines20, pathogen associated trig­
gers4 or endogenous ‘danger signals’ such 
as heat shock proteins21. It is as yet no t 
know n w hether full-blown D C  activation 
enhances the immunogenicity o f  a D C 
vaccine. Fully activated DCs may on the 
one hand be superior T h l  inducers, bu t on 
the o ther hand may quickly loose their ca­
pacity to  produce IL-12, which could be a 
potential draw-back in a vaccination set­
ting22. T he optim al m ode o f  D C  m atura­
tion has therefore no t been established. In  
this respect it should be noted  that cur­
rently used markers to identify m ature 
D Cs do no t cover all functional properties.
Route of administration
D Cs interact w ith T  cells in the peripheral 
lym phoid organs. Therefore the migration 
o f  antigen loaded D Cs to those areas is 
essential. Mice models have shown that 
after intravenous injection m ost D Cs end 
up in highly vascularized organs, such as 
the spleen and the lungs23’24. D Cs that are 
injected subcutaneously or intradermally 
remain for the greater part at the site o f  
injection, although intraderm al injection 
leads to a higher D C  yield in draining 
lym ph nodes in mice25. We found that in- 
tranodal injection results in a m uch higher 
accumulation o f  D Cs in lym ph nodes 
com pared to intraderm al vaccination. This 
concerned no t only the injected node, but 
also in subsequent draining nodes26. A 
study in m elanom a patients found a small 
increase in peptide-specific T  cell
Figure 1. The induction of antigen-specific T cells in vivo, (a) Antigen is taken up in peripheral tis­
sues by immature DCs. In the presence of a danger signal the DCs mature and migrate to draining 
lymph nodes, where they present the antigen in combination with a co-stimulatory signal, thereby acti­
vating T cells. The activated antigen-specific T cells proliferate and migrate out of the lymph node to­
wards the site of the antigen, (b) Current strategies in DC vaccination. DCs cultured directly from 
blood, from monocytes or CD34+ progenitor cells can be loaded with antigen ex vivo and adminis­
tered to cancer patients after a culture in the presence of maturation stimuli such as pro-inflammatory 
cytokines.
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responses after intranodal injection as 
compared to intradermal or intravenous 
injection27. Others compared vaccination 
with blood DCs administered via three dif­
ferent routes in advanced prostate cancer 
patients: intradermal, intravenous and in­
tralymphatic injection28. T  cell responses 
occurred regardless o f the route o f deliv­
ery. There was however a difference in T 
and B cell responses, with an absent IFNy- 
secretion in the intravenous group, and 
less antibody production in the intralym­
phatic and intradermal groups. This sug­
gests that the type o f immune response 
may depend on the route o f DC admini­
stration. The same authors showed in mice 
that intravenous injection o f DCs is essen­
tial for immune responses against lung 
melanoma metastases, whereas subcutane­
ous vaccination is essential for the re­
sponse against non-visceral metastases29. 
These observations may relate to the inter­
actions between DCs and different types 
o f T cells in lymph nodes and spleen that 
are differentially involved in controlling 
tumors at different sites, and /o r to differ­
ent homing patterns o f the activated T 
cells. These results provide a rationale to 
combine different routes o f DC admini­
stration.
DC VACCINATION TRIALS IN CANCER 
PATIENTS 
Melanoma
Melanoma is the m ost studied cancer type 
in DC immunotherapy. This is mainly due 
to the fact that in melanoma a large variety 
o f tumor-associated antigens have been 
characterized, consisting o f tum or differ­
entiation antigens such as gp100 and ty­
rosinase and tumor-specific antigens such 
as MAGE-330.
In the first reported study in advanced 
melanoma patients monocyte-derived DCs
loaded with peptides or tum or lysate were 
injected intranodally31. O ut o f 16 patients 
2 complete remissions and two partial re­
missions were observed. The results o f 
further trials with DCs cultured in the 
presence o f maturation stimuli are sum­
marized in table 1.
Several studies have used mature m ono­
cyte- derived peptide-pulsed DCs injected 
via different routes in advanced stage IV 
melanoma patients, using different culture 
protocols15,20,27’32’33 (table 1). In all these 
studies antigen-specific T  cells were de­
tected in peripheral blood or in biopsies o f 
delayed type hypersensitivity (DTH) reac­
tions, and clinical responses were ob­
served. A correlation between clinical out­
come and antigen-specific T  cell response 
was found in a minority o f these studies. 
This may relate to the fact that m ost stud­
ies m onitor T  cell responses in peripheral 
blood. We have focused on the detection 
o f T  cells in D TH  biopsies and found a 
correlation betw een the presence o f 
antigen-specific DTH-infiltrating T  cells 
and clinical response33.
An interesting observation was made in 
advanced melanoma patients vaccinated 
with monocyte-derived DCs that were 
pulsed with a single melanoma peptide: the 
only clinically responding patient showed 
evidence o f spreading o f T  cell reactivity 
against other antigens as well, indicating 
that determinant spreading is o f impor­
tance for the induction o f clinical respons-
es13
An alternative to monocyte-derived DCs 
are CD34+ progenitor-derived DCs, con­
sisting o f CD1a+ CD14- Langerhans cells 
and CD1a± CD14+ interstitial D Cs10,34. 
Banchereau and colleagues vaccinated 
stage IV melanoma patients with multiple 
MHC class I peptides loaded on CD34+ 
progenitor-derived D C s10. Clinical re­
sponses were observed, which were sig-
12
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nificantly correlated with T  cell responses 
against the used m elanom a antigens 
(summarized in table 1).
BOX 1- M in im um  quality criteria for designing 
clinical trials o f DC vaccines
Description of vaccine preparation according to GMP 
guidelines
Quality control for ex Wvo-generated DCs (see Box 2)
Description of patient characteristics
- Clinical stage at -m e of inclusion
- Prior treatment
- Documented progressive disease
Description of trial design
- Start/end dates of trial
- Pa-ent selec-on
- Route of administra-on
- Number of DCs
- Vaccina-on schedule
- Sampling -m e points
Clear documentation and definition of clinical response,
for example by World Health Organiza-on or RECIST 
criteria (to provide insight into the biological ac-vity of a 
DC vaccine, it can be appropriate to deviate from these 
criteria, provided that the new criteria are predefined 
and clearly described)
Description of clinical outcome of all patients (to evalu­
ate the outcome of a study, pa-ents must be followed 
for a sufficiently long period of -m e)
Description of immunological measures before and 
after vaccination
- Presence of an-gen-specific T cells
- An-body -ters (if relevant)
- An-gen expression on tumor cells
Proposed assays
- An-gen-specific CD4+ and CD8+ T-cell counts in periph­
eral blood
- Delayed-type hypersensi-vity biopsies
- Phenotypic analysis (including tetramer analysis)
- Func-onal analysis (including ELISpot, cytokine produc- 
-on  or cytotoxicity)
- Analysis of T-cell receptor repertoire
- Measurement of an-gen-specific an-body -ters in se­
rum
- Measurement of an-gen loss variants (if tumor is avail­
able)
- Immunohistochemistry
Hematologic malignancies
Malignancies o f B cell origin express a 
m onoclonal im m unog lob in , carry ing  
unique tumor-specific antigenic determi­
nants in the variable regions, called idio- 
type35. These idiotypes can be isolated 
from B cell malignancies and subsequently 
be used as an antigen for the induction of 
CD4+ and CD8+ T cells. In contrast to 
the antigens used in solid tumors, this an­
tigen is thus not only tumor-specific but 
also patient-specific.
The first clinical results using autologous 
antigen-loaded DCs concerned 4 patients 
with follicular non-Hodgkin lymphoma11. 
Blood DCs were enriched from peripheral 
blood mononuclear cells and loaded with 
idiotype after several enrichment steps. A 
follow-up o f this trial was published in 
which also patients in first remission after 
cytoreductive chemotherapy were includ- 
ed35. Some patients received DCs that 
were loaded with idiotype immunoglobulin 
coupled to keyhole limpet haemocyanin 
(KLH), a protein providing a-specific 
CD4+ T cell help. Most patients devel­
oped anti-idiotype T  cell responses and 
some objective clinical responses were ob­
served. Interestingly, booster injections of 
idiotype coupled to KLH induced clinical 
responses in patients that initially pro­
gressed on DC therapy.
Several studies have focussed on the appli­
cation o f  idiotype-pulsed m onocyte- 
derived DCs in multiple myeloma patients 
36-40. Clinical and immunological responses 
were infrequent, which may relate to the 
use o f immature DCs in m ost studies.
An interesting observation was made in 
two patients with cutaneous T  cell lym­
phoma: after disease progression upon 
discontinuation o f vaccination, a second 
clinical remission was achieved after revac-
cination41.
Gastro-intestinal malignancies
In colorectal cancer the m ost widely used 
antigen for loading on DCs is carcinoem- 
bryonic antigen (CEA)42.
13
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Figure 2. DC immunotherapy: mapping the way. Early clinical trials clearly demonstrate the potency 
of DC therapy, but there are still too many variables preventing its introduction as a standard cancer 
treatment. There is a strong need for standardization and quality control of this technique. Additional 
research driven (pre)clinical studies must be carried to provide to evaluate the most effective DC sub­
types, the optimal conditioning and activation stimuli, the optimal antigen-loading strategy and route of 
administration and the optimal dose and frequency of DC vaccinations.
Patients with CEA-expressing malignan­
cies have been treated with Flt3L ex­
panded, in vitro-enriched b lood DCs, 
pulsed with a modified CEA-peptide. 
Antigen-specific immune responses and 
objective clinical responses were observ- 
ed43. Interestingly, a correlation between 
clinical response and the magnitude o f the 
expansion o f tetramer positive cytotoxic T 
cells in peripheral blood was found. 
Monocyte-derived DCs transfected with 
RNA encoding tum or antigens is an alter­
native m ethod o f antigen loading in DC- 
based immunotherapy. Specific T cell reac­
tivity was demonstrated in a patient with 
advanced CEA-expressing cancer o f un­
known origin upon  vaccination w ith 
monocyte-derived TN Fa-m aturated DCs 
transfected with CEA-RNA44.
In a study using immature DCs pulsed 
with MAGE-3, an antigen which is ex­
pressed in a variety o f gastro-intestinal
tumors, antigen-specific T  cell reactivity in 
peripheral blood and minor tum or regres­
sions were observed45.
Urological malignancies
In renal cell carcinoma studies with imma­
ture tumor-lysate pulsed DCs have not re­
sulted in either immunological or clinical 
responses46-48. One study used T N F a /  
PG E2 maturated monocyte-derived DCs 
that were either loaded with autologous 
tum or lysate or tum or lysate from an allo­
geneic tum or cell line49. Clinical responses 
were restricted to patients that were vacci­
nated with autologous lysate-pulsed DCs. 
Patients with metastatic prostate cancer 
have been vaccinated with recombinant 
prostatic acid phosphatase-pulsed mature 
blood DCs resulting in proliferative T  cell 
responses against the protein, however no 
clinical responses occurred28.
14
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The immunogenicity o f DCs transfected 
with whole tum or RNA or RNA encoding 
prostate-specific antigen has been investi­
gated in patients with metastatic renal can­
cer and prostate cancer50,51. Due to the 
PSA-transfection the DCs underwent phe­
notypical changes with upregulation o f 
CD83 and CD86. In  m ost patients 
antigen-specific IFNy-producing T cell re­
sponses were detected, which support the 
immunogenicity o f this mode o f antigen 
loading.
Other malignancies
MUC-1 and H E R -2/neu peptide-pulsed 
monocyte-derived DCs have been used in 
breast and ovarian cancer patients resulting 
in peptide-specific cytotoxic T  cell re­
sponses in peripheral blood and some 
long-term clinical responses52.
Epstein Barr Virus peptide-pulsed m ono­
cyte- derived DCs in nasopharyngeal car­
cinoma have resulted in antigen-specific T 
cell responses in peripheral blood up to 3 
months after vaccination, and partial re­
sponses were noted53.
O ther tum or types that have been investi­
gated using DC vaccines include hepato­
cellular carcinoma, pancreatic tumors, ad­
renal carcinom a, cholangiocarcinom a, 
parathyroid carcinoma, non-small cel lung 
cancer, head and neck cancer, sarcoma, 
bladder cancer, glioma and pediatric 
malignancies54-58.
In all these studies DCs were cultured 
without maturating stimuli. Although some 
specific T  cell responses and clinical re­
sponses were seen in these studies, results 
may be improved using mature DCs.
BOX 2- Q uality criteria for DC vaccines
There is a strong need for standardiza-on and quality 
control of DC vaccines. The release criteria define the 
proper descrip-on of the vaccine prepara-on. Criteria 
describing the DC vaccine, including quality control, 
should be described in publica-ons regarding DC vacci­
na-on trials. DCs should be grown w ithout fetal calf se­
rum, preferably in serum-free media. If frozen DCs are 
used, quality control should be carried out after samples 
are
thawed. The op-onal criteria are important in valida-ng 
the an-gen-presen-ng capacity of the cultured DCs. 
These tests are not required for every vaccine prepara­
-on .
Release criteria:
Microbiological controls
Nega-ve for bacterial and fungal contamina-on 
Purity
>80% as determined by flow  cytometry, light scatter or 
staining w ith non-DC lineage markers.
Morphology
Immature: loosly adherent, floa-ng, roundish cells with 
some extensions
Mature: loosely attached, veiled and clustered cells 
Phenotype
Monocyte-derived:
Immature: CD14-/low,CD83-,CD80-/low,CD86low,MHC class 
I+,MHC class II+,CCR5+
Mature: CD83+,CD80+,CD86+,MHC class I+,MHC class II+, 
CCR7+
CD34+ cell-derived:
In te rs --a l: CD14+,CD1a+/- ,CD83+,CD80+,CD86+, MHC 
class I+,MHC class II+
Langerhans cells: CD14- ,CD1a+,CD83+,CD80+, CD86+, 
MHC class I+,MHC class II+
Viability
>70% as determined by Trypan blue exclusion 
Optional validation criteria:
Stability of DC phenotype
Determined after one and two days of subsequent cul­
ture in medium either w ithout or w ith cytokines 
Washout test': DCs must remain viable and maintain 
the ir characteris-c morphology and phenotype over two 
days in medium w ithout cytokines (characteris-c of fully 
mature and stable DCs)
Induction of immune response:
Mixed lymphocyte reac-on: T-cell prolifera-on at DC/ 
PBMC (peripheral blood mononuclear cell) ra-o of 1:20 
in at least one donor
Recogni-on of loaded an-gen by T cells, as determined 
by cytotoxicity assay or cytokine produc-on (especially 
important when an-gen is loaded before freezing) 
Antigen-loaded state
(Only possible when DCs are loaded w ith well-defined 
an-gens, such as pep-des, proteins or RNA) 
An-gen-specific s -m u la -o n  assay: tests ab ility  of 
an-gen-loaded DCs to s-mulate an-gen-specific T cells 
(from T-cell lines or reporter cell lines transfected w ith T- 
cell receptor and reporter constructs)
15
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Culture method Dose/schedule Route No.
pts.
T cell 
resp.
Clinical re­
sponse
Ref.
Melanoma IL-4/GM-CSF/FCS moDC 106 q 1 wk x 5-10 i.n. 16 n.d. 2CR, 3PR 31
IL-4/GM-CSF/IL-1 p/IL-6/TNFa/ 
PGE2 moDC
3-12x106 q 2 wks x 5 s.c.+i.d.+i.v 13 11 - 20
IL-4/GM-CSF/IL-1 p/IL-6/TNFa/ 
PGE2 moDC
2-6x106 q 2 wks x 5 s.c. 30 13 8 SD, 1 CR 15
Calcium-ionophore/IL-2/IL-12
moDC
5-50x106 q 2 wks x 4 i.v./i.d./i.n. 28 13 3 PR 27
IL-4/GM-CSF/IL-1 p/IL-6/TNFa/ 
PGE2 moDC
8-12x106 q 2 wks x 6 i.n. 11 5 3 SD 32
IL-4/GM-CSF/MCM/ TNFa/ 
PGE2 moDC
10-30x106 q 2 wks x 3 i.d.+i.v. 10 2 4 SD, 1 PR 33
CD34+/Flt3L/GM-CSF/TNFa 0.1-1.0x106 q 2wks x 4 s.c. 18 16 3CR, 3PR, 3SD 10
CD34+/IL-3/IL-6/SCF/ IL-4/GM- 
CSF/TNFa
5-50x106 q 2 wks x 4 i.v. 14 2 6 SD, 1 PR 34
NHL Blood DC + Id 2-17x106 q 4 wks x 4 i.v. 10 8 2CR, 1PR, 1 
molR
1135
NHL after CT Blood DC + Id/Id-KLH 4-10x106 q 4 wks x4 i.v. 25 9 18 PF, 4 CR of 
RD
35
MM IL-4/GM-CSF/IL-1p/TNFa moDC 20x106 q 2 wks x 3 s.c. 5 4 3 SD, 1 decrease 
M protein
37
MM after SCT Blood DC + Id 2-8x106 q 4 wks x 2 i.v. 12 2 9 PF 36
Cutaneous T Cell 
Lymphoma
IL-4/GM-CSF/IL-1 p/IL-6/TNFa 
moDC
1x106 x median 9.5 i.n. 10 3 4 PR, 1 CR 41
Colorectal cancer Flt3 expanded enriched blood 
DC
107-1010 q 4 wks x 2 i.v. 12 7 2 CR, 2 SD, 1 
MR
43
Prostate cancer IL-4/GM-CSF/RNA transfected 10-50 x106 q 2 wks x 3 i.v.+i.d. 13 13 - 50
Blood DC 0.3-40x106 q 4 wks x 2 i.v./i.l./i.d. 21 21 - 28
RCC IL-4/GM-CSF/IL-1 p/IL-6/TNFa/ 
PGE2 moDC
5-10x106 q 4 wks x 3-13 i.v./i.d. 35 5 2 CR, 1 PR 49
Breast and Ovarian 
cancer
IL-4/GM-CSF/TNFa moDC 2-17x106 q 2 wks x 3 s.c. 10 5 1 SD, 1 CR 52
Nasopharyngealcar- IL-4/GM-CSF/TNFa moDC Dose not given x 4 i.n. 16 9 2 PR 53
cinoma
Table 1. Results of dendritic cell-based vaccines. Included are studies in which DCs were used that 
were cultured in the presence of maturing stimuli. Number of patients: the number of patients that 
have received at least one vaccination. T cell responses: number of patients in which peptide/tumor 
specific T cell responses were detected Abbreviations: NHL, Non-Hodgkin lymphoma; CT, chemo­
therapy; MM, multiple myeloma; SCT stem cell transplantation; RCC, renal cell carcinoma; moDCs, 
monocyte-derived DCs; GM-CSF, granulocyte macrophage-colony stimulating factor; IL, interleukin; 
TN Fa, tumor necrosis factor alpha; PGE2, prostaglandin E2; MCM, monocyte-conditioned medium; 
CD34+, CD34+ progenitor derived DCs; Id, idiotype; i.n., intranodal; s.c., subcutaneous; i.d. intrader­
mal; i.v. intravenous; i.l., intralymphatic; n.d. not documented; CR, complete response; PR partial re­
sponse; SD, stable disease; molR, molecular response; PF, progression-free; RD, residual disease; MxR 
mixed response
16
Chapter 1
RECENT DEVELOPMENTS
New developments in DC therapy soon to 
be tested in clinical studies include the tar­
geting o f DCs in vivo via DC-specific 
molecules which may circumvent the 
problem o f laborious ex vivo culturing and 
antigen-loading protocols59. Furthermore, 
the depletion o f C D 4+ /C D 25+  regula­
tory T  cells which have the ability to sup­
press T  cell mediated immunity may be a 
way o f enhancing the potency o f the DC 
vaccine-induced im m une responses60. 
Lastly, plasmacytoid DCs may be an attrac­
tive DC-subtype in vaccination o f cancer 
patients as they have the capacity to infil­
trate tumors, induce primary T  cell re­
sponses and secrete large amounts o f type 
I interferons61.
CONCLUSIONS
Generation o f large quantities o f DCs for 
clinical use is feasible, and this applies to 
monocyte-derived DCs, CD34 progenitor- 
derived DCs and blood DCs. Vaccination 
with DCs appears to be safe, and immuno­
logical responses as well as durable clinical 
remissions have been observed. More im­
portantly, in several trials a correlation be­
tween immunological and clinical outcome 
has been demonstrated. These studies have 
greatly enhanced our knowledge o f the 
induction o f anti-tumor immunity in can­
cer patients. For reasons o f comparison 
details on culture methods as well as phe­
notypical data o f the administered DCs 
should be provided in scientific publica­
tions (Box 1)19. Release criteria o f the vac­
cine should at least contain purity, viability 
and mature phenotype (Box 2). Current 
questions regarding the optimal DC sub­
set, culture method, mode o f maturation, 
route o f administration, antigen loading 
and role o f adjuvants should be addressed 
in small-scale studies with extensive im-
munomonitoring as primary parameter for 
efficacy (figure 2). Given these questions, 
as well as the theoretical options to further 
improve DC vaccines it is too early to put 
DC vaccines to the test o f randomized 
comparison in phase III trials.
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Maturation of dendritic cells is a prerequisite for inducing 
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We have investigated the capacity of immature and mature monocyte-derived 
dendritic cells (DCs ) pulsed with melanoma-associated peptides (gp100 and tyrosi­
nase ) to induce a primary cytotoxic T lymphocyte response in vivo.
Advanced HLA-A2.1+ melanoma patients were vaccinated with peptide- and key­
hole limpet hemocyanin (KLH ) -pulsed DCs, either immature (9 patients ) or ma­
tured by monocyte-conditioned medium/TNF-alpha/PGE2 (10 patients ).
All patients vaccinated with mature DCs showed a pronounced proliferative T cell 
and humoral response against KLH. By contrast, KLH responses were absent in 
most of the patients vaccinated with immature DCs. Delayed type hypersensitivity 
(DTH) reactions against antigen-pulsed DCs were only observed in patients vacci­
nated with mature DCs and not in patients vaccinated with immature DCs. MHC- 
peptide tetramer staining of DTH-derived T cells revealed the presence of specific T 
cells recognizing the melanoma-associated peptides in one patient. In a second 
patient, DTH-derived T cells showed specific lysis of tumor cells expressing the an­
tigens used for DC pulsing. Only patients vaccinated with mature DCs showed ob­
jective clinical responses. Interestingly, both patients with long-term progression­
free survival (22 and > 40 months ), were both vaccinated with mature DCs and 
demonstrated antigen-specific T cell reactivity of DTH-derived T cells.
We conclude that mature DCs are superior to immature DCs in the induc&on of 
immunological responses in melanoma patients, which may translate into im­
proved clinical results.
INTRODUCTION
D endritic cells (DCs) constitute a family o f  
antigen-presenting cells defined by their 
m orphology and their unique capacity to 
initiate a prim ary im m une response1. It has 
been shown that D Cs pulsed w ith M HC 
class I peptides are po ten t inducers o f  a 
cytotoxic T  lymphocyte (CTL) response in 
vitro2. Furtherm ore, the presence o f  DCs
23
in tum or tissue has been correlated w ith a 
favorable clinical prognosis3’4. Therefore 
D Cs are thought to play a pivotal role in 
the induction o f  T  cell-mediated anti­
tum or responses in vivo1’5’6.
The use o f  peptide-pulsed D Cs in anti­
tum or vaccination trials has been facili­
tated by the availability o f  class I-restricted 
peptides derived from  tum or-associated
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an tig en s  such  as g p 1 0 0 , ty ro sin ase , 
M A GE, and NY-ESO-1, the ability to 
grow large num bers o f  D Cs from  m ono­
cytes, and the finding that antigen-pulsed 
D Cs are able to induce specific CTL reac­
tivity in vitro2,7,8. Recent studies have 
dem onstrated the safety and the ability o f  
antigen-loaded DCs to induce an immune 
response in hum ans9-12. Evidence is accu­
mulating that the type o f  D Cs and the 
route o f  adm inistration play a critical role 
in determ ining the quality and quantity o f  
the im m une response13,14. We recently 
showed that m igration o f  D Cs is highly 
dependent on their m aturation status15. To 
further optim ize clinical efficacy, D C  vac­
cination strategies need m ore investigation. 
Im m ature D Cs are characterized by the 
presence o f  M H C class I and class II 
molecules and low expression o f  costim u­
latory molecules CD80, CD86 and CD40. 
U pon inflam m ation or infection, im m ature 
D Cs take up antigen, followed by a com ­
plex m aturation and activation process that 
is characterized by an up-regulation o f  
antigen-presenting M HC molecules and 
costim ulatory molecules, as well as a 
switch in their adhesion- and chemokine- 
receptor repertoire 16,17.
In  this study we com pare the efficacy o f  
im m ature and m ature D Cs in inducing an 
im m une response in advanced stage IV 
m elanom a patients. M elanom a is well 
suited to explore vaccination strategies be­
cause it is one o f  the m ore im m unogenic 
tum ors in which melanom a-associated an­
tigens, like gp100 and tyrosinase, and spe­
cific T  cell responses towards these anti­
gens have been identified 18,19. D Cs used 
fo r  v a c c in a t io n  w e re  p u ls e d  w ith  
HLA-A2.1-binding peptides derived from  
gp100 and tyrosinase, and keyhole lim pet 
hem ocyanin (KLH)9. T he latter was used 
to provide T  cell help and to verify the 
im m unogenicity o f  the two D C  popula­
24
tions as well as com petence o f  the pa­
tients’ im m une system to m ount an im ­
m une response.
The results o f  this study implicate that 
m aturation o f  D Cs is a crucial step for the 
induction o f  T- and B cell responses in 
m elanom a patients and a correlation w ith a 
favorable clinical outcom e is suggested.
MATERIALS AND METHODS
Patient criteria
Inclusion criteria were: histologic evidence of 
metastatic melanoma, progressive disease, meas­
urable disease parameters, focal or diffuse expres­
sion of gp100 and/or tyrosinase in at least one 
metastasis as determined by immunohistochemis- 
try, HLA-A2.1 phenotype, WHO performance 
status 0 or 1, and written informed consent. Pa­
tients were staged according to the 2001 AJCC 
staging system: patients with distant non-visceral 
metastases were categorized as stage M1a, pa­
tients with metastasis to the lung were categorized 
as stage M1b, and patients with metastases to any 
other visceral site or with an elevated serum LDH 
were categorized as stage M1c20. Patients with 
clinical signs of brain metastases, serious con­
comitant disease or a history of second malig­
nancy were excluded. Prior treatment was allowed, 
provided a treatment-free period of at least four 
weeks was observed and all related toxicity had 
resolved. Approval from the local regulatory 
committee was obtained.
Clinical protocol and immunization schedule
In eligible patients a leukapheresis was performed 
from which DCs were generated. The protocol 
consisted of two parts. In the first part, antigen- 
pulsed DCs were administered 3 times at bi­
weekly intervals, either intravenously (i.v.) and 
subcutaneously (s.c.) or i.v. and intradermally 
(i.d.). In the second part, patients without tumor 
progression received 3 monthly vaccinations with 
peptides alone (100 g) and KLH (2 g), either s.c. 
or i.d. as in the first part of the study. Prior to 
each vaccination 80 ml of blood was collected for 
immunological monitoring.
A clinical response was defined as stable disease 
for more than 4 months or any partial or com­
plete response. Stable disease and partial response 
were defined according to WHO criteria21. Toxic­
ity was assessed according to NCI common toxic­
ity criteria. Progression free survival was calcu­
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lated from the day of the first vaccination. Pa­
tients were evaluated for response after complet­
ing the first and second part of the protocol and 
every three months thereafter.
Patients who remained free of disease progres­
sion were eligible for 2 maintenance cycles at six 
months interval, each consisting of 3 bi-weekly 
intranodal vaccinations in a clinically tumor-free, 
usually inguinal lymph node region under ultra­
sound guidance with mature DCs, pulsed with 
modified gp100-, and tyrosinase peptides and 
KLH22,23. Intranodal administration was chosen 
for maintenance treatment because in a related 
study we observed a more pronounced migration 
of DCs to distant lymph nodes after intranodal 
injection in comparison with intradermal injec­
tion15.
Antibodies and immunostaining
To characterize and compare the phenotype of 
the DC populations, flow cytometry was per­
formed using either FITC-conjugated or PE- 
conjugated mAbs. The following FITC- 
conjugated mAbs were used: anti-HLA class I 
(W6/32), and anti-HLA DR/DP (Q5/13); and 
PE-conjugated mAbs: anti-CD80 (Becton Dickin­
son, Mountain View, CA), anti-CD14, anti-CD83 
(both Beckman Coulter, Mijdrecht, The Nether­
lands), and anti-CD86 (Pharmingen, San Diego, 
CA).
For immunohistochemistry the following mAb 
were used: HMB-45 (Dako, Glostrup, Denmark) 
against gp100 and T311 (Novocastra, Newcastle, 
UK) against tyrosinase24.
DCs: Preparation, characterization, and route 
of administration
DCs were generated as described previously25. 
Briefly, peripheral blood mononuclear cells 
(PBMC) were isolated by Percoll (1.073) density 
gradient centrifugation (Pharmacia, 30 min, 4°C, 
2100 rpm) after leukapheresis. PBMC were 
washed and 1x1010 cells were used for the gen­
eration of monocyte-conditioned medium 
(MCM)26. From the remaining PBMC, mono­
cytes were isolated by either counterflow centrifu­
gation (the first 3 patients) or by adherence to 
plastic (all other patients). Monocytes isolated by 
elutriation were cultured at 15x106 per 75 cm2 
tissue culture flasks (Costar, Badhoevedorp, The 
Netherlands) in 20 ml of interleukin (IL)-4 (500 
U/ml Schering-Plough International, Kenilworth, 
USA), granulocyte monocyte-colony stimulating 
factor ([GM-CSF] 800 U/ml, Schering-Plough 
International, Kenilworth, USA) and 2% human
serum ([HS] bloodbank Rivierenland, Nijmegen, 
The Netherlands)-containing X-VIVO 15 me­
dium (BioWhittaker, Walkersville, MD). The cells 
were harvested on day 9. In case adherence to 
plastic was used for isolation of the monocytes, 
immature DCs were cultured from adherent 
PBMC in 10 ml of X-VIVO 15 medium of which 
half was replaced on day 1 with X-VIVO 15 me­
dium supplemented with IL-4 and GM-CSF and 
cells were harvested on day six25,27. The first 4 
patients were vaccinated i.v. and s.c. with these 
immature DCs25, but analysis of the s.c. injection 
site revealed that most DCs did not migrate from 
the injection site (data not shown). Based on this 
finding and our data from murine experiments28, 
we switched from s.c. to i.d. together with i.v. vac­
cinations. The injected immature DCs were char­
acterized by the presence of MHC class I and 
class II, a moderate expression level of CD86 and 
a low expression of CD14, CD80 and CD83 (fig­
ure 1).
Mature DCs were cultured as immature DCs from 
adherent PBMC with addition of autologous 
MCM enriched with 10 g/ml PGE2 (Pharmacia 
& Upjohn, Puurs, Belgium) and 10 ng/ml tumor 
necrosis factor (TNF)-a (kindly provided by Dr. 
Adolf, Bender, Vienna, Austria), on day 7 (30%, 
v/v)29. This procedure gave rise to mature DCs 
on day 9 as demonstrated by high expression lev­
els of MHC class I and II, CD80, CD83 and 
CD86 and absence of CD14 (figure 1)25. Both 
immature as well mature DC preparations were 
endotoxin free.
Cryopreservaton of PBMC and DCs
All DCs were cultured directly after leukapheresis 
and frozen as immature or mature DCs for multi­
ple vaccinations. DCs and PBMC were frozen 
using a cryo 1°C freezing container (Nalgene, 
Rochester, NY, USA) which was put in -80°C for 
24 hours, in freezing medium consisting of 50% 
XVIVO-15 (5% HS), 40% human serum albumin 
and 10% DMSO (final concentration, Sigma). 
Cells were frozen in 1 ml per vial containing a 
maximum of 40x106 cells25.
Cells were thawed in a 37°C water bath after 
which the cells were washed once in cold medium 
and once in medium of room temperature before 
further use. We previously showed that the recov­
ery of viable immature DCs (69±15%) did not 
differ from that of mature DCs (65±10%)25.
Peptide pulsing and KLH loading
DCs were pulsed with wild type peptides, 
gp100:154-167, gp100:280-288 or modified pep­
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tides (gp100:154-167 QA, gp100: 280-288 AV) 
and wild type tyrosinase 369-37616’22’23’30’31. Puls­
ing was done directly after harvesting or after 
thawing. On the day of vaccination, we added 
peptides (50 g/ml) for 90 min and kept DCs at 
37°C /5% CO2. Thereafter, fresh peptides (25 g/ 
ml) were added and DCs were kept at room tem­
perature for 60 min. After peptide loading, DCs 
were washed once in 0.9% sodium chloride and 
resuspended in 0.2 ml or 1 ml for i.d/s.c. or i.v. 
injections, respectively. At day 3 of the cell culture 
10 Mg/ml KLH (Calbiochem, USA) was added to 
both immature and mature DCs.
Delayed Type Hypersensitivity
One to two weeks after the three DC vaccinations 
a delayed type hypersensitivity (DTH) skin test 
was performed. Briefly, unpulsed DCs, DCs 
pulsed with peptides, DCs pulsed with KLH, and 
DCs pulsed with peptides plus KLH (2x105 DCs 
each) were injected i.d. in the skin of the back of 
the patients at four different sites. The diameter 
(in millimeters) of induration was measured after 
48 hours, each time by the same investigator 
(M.J.P.G.), and an induration of more than 2 mm 
was considered positive.
From positive DTH sites, punch biopsies (6 mm) 
were obtained under local anesthesia. Biopsies 
were cut in half, one part for immunohistochem- 
istry and the other part was cut in small pieces 
and cultured in RPMI/7%HS supplemented with 
IL-2 (100 U/ml). Every 7 days, half of the me­
dium was replaced by fresh IL-2-containg RPMI/ 
7%HS. After 2 to 4 weeks of culturing, T cells 
were tested for antigen recognition in a cytotoxic­
ity assay or tested for tetramer binding.
Humoral response to KLH
Antibodies against KLH were measured in the 
serum of vaccinated patients by enzyme-linked 
immunosorbent assays (ELISA) as described by 
Holtl et al32. Briefly, 96-well plates were coated 
overnight at 4oC with the protein KLH (25 g/ml) 
in phosphate buffered saline (0.1 ml/well). After 
washing the plates, different concentrations of 
patient serum (range 1 in 100 to 1 in 500,000) 
were added for 1 hour at room temperature. After 
extensive washing, specific Ab (total IgG, IgG1, 
IgG2, and IgG4) labeled with horseradish peroxi­
dase were allowed to bind for 1 hour at room 
temperature. Peroxidase activity was revealed us­
ing 3,3’ 5,5-tetramethyl-benzidine as substrate and 
measured in a microtiter plate reader at 450 nm. A 
positive signal at a 1 in 400 dilution of the pa­
tients’ serum was considered positive.
Proliferative response and cytokine production 
to KLH
Cellular responses against KLH were measured in 
a proliferation assay. Briefly, 1x105 PBMC, iso­
lated from blood samples taken before each vac­
cination, were plated per well of a 96-well tissue 
culture micro plate either in the presence of KLH 
or without. After 16 hours of culture, super- 
natants (50 ^l) were taken and IL-2, IL-4, IL-5, 
IL-10, TNF-a, and interferon (IFN)-y were 
measured by a cytometric bead array (Th1/Th2 
Cytokine CBA 1; BD Pharmingen, San Diego, 
CA) according to the manufacturer’s instructions. 
After 4 days of culture, 1 ^Ci/well of tritiated 
thymidine was added, incorporation of tritiated 
thymidine was measured in a beta-counter. A pro­
liferation index >2 was considered positive.
MHC tetramer staining
Tetrameric-MHC complexes were kindly provided 
by dr. R Luiten and dr. H. Spits from the Nether­
lands Cancer Institute (Amsterdam, The Nether- 
lands)33. Each tetramer was validated by staining 
against a CTL line specific for HLA-A2 in asso­
ciation with the peptide of interest.
PBMC (1x105 cells in 10 l^) were incubated with 
PE-labeled tetrameric-MHC complexes for 1 
hour at RT. After washing the samples were ana­
lyzed by flow cytometry.
Cytotoxicity assay
Cytotoxic activity of DTH-infiltrated lympho­
cytes was measured using the chromium release 
assay as described previously34. Briefly, target cells 
HLA-A2.1 positive BLM either transfected with 
control antigen G250, or with the antigens of 
study gp100 or tyrosinase were incubated with 
100 Ci Na2[51Cr]O4 (Amersham, Bucks, UK) for 
45 min at 37°C. After extensive washing, 
chromium-labeled BLM (103) were mixed with 
unlabeled K562 cells (ratio 1:10) and added to 
lymphocytes (105 cells) in triplicate wells of a 
round bottom microtiter plate (total volume 150 
l). After a 4-hour incubation, 100 ^l of the super­
natant was harvested and its radioactivity content 
was measured. The specific percentage of cyto­
toxicity was defined by: [(experimental release - 
spontaneous release) ^ (maximum release — spon­
taneous release)] x 100%.
IFN-y ELISPOT assay
Production of IFN-y in response to the peptides 
used for DC pulsing was determined by the EL- 
ISPOT assay as described previously35. In short, 
CD8+ T cells (105) and T2 cells (7.5 x 104/well)
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with the peptides (final concentration 50 ^g/ml) 
were incubated for 20 h at 37°C on multiscreen 
HA plates (Millipore, Bedford, MA) which were 
coated with anti-human IFN-y. Captured cytokine 
was detected by biotinylated mAb anti-human 
IFN-y, avidin-peroxidase complex and peroxidase 
staining. Spot numbers were automatically deter­
mined with the use of computer-assisted video
image analysis.
RESULTS 
Patents Characteristics
In  this study, a total o f  19 stage IV  mela­
nom a patients were vaccinated, 9 with 
im m ature D Cs and 10 w ith m ature DCs. 
Patient characteristics are shown in table 1. 
B oth  groups were com parable considering 
age, sex and previous therapy. A higher 
num ber o f  patients vaccinated w ith m ature 
D Cs had a perform ance status 0, bu t in 
this group there were also m ore patients 
w ith a m ore advanced stage o f  disease (ta­
ble 1).
Toxicity and side effects
N o severe toxicity (com m on toxicity crite­
ria grade III-IV) occurred. In  patients vac­
cinated w ith im m ature DCs, mild fatigue, 
anorexia and nausea b u t no fever was ob­
served. However, fever (38 °C) developed 
in 2  ou t o f  10 patients vaccinated w ith m a­
ture D Cs after the second vaccination, and 
in 7 ou t o f  10 after the th ird  vaccination. 
F urtherm ore, erythem a was observed at 
the injection site o f  the second or third 
vaccination only after vaccination w ith m a­
ture DCs.
Proliferation and cytokine production of 
PBMC upon stimulation with KLH
To determ ine the ability o f  im m ature ver­
sus m ature D Cs to m ount an im m une re­
sponse against K LH , PBM C collected and 
frozen after each D C  vaccination were 
thawed and analyzed for the presence o f
KLH-reactive T  cells in a proliferation as­
say. Patients receiving m ature D Cs (n=10) 
showed a strong proliferative response 
against K L H  that could already be de­
tected after a single D C  vaccination (figure 
2).
P atien t S e x /
a g e
P reviou s
therapy
PS S ta g e
Imm-1 M /33 RT, H T 0 M1a
Imm-2 M /55 RLND, RT 1 M1c
Imm-3 F/56 RLND 1 M1b
Imm-4 M /52 RLND, DTIC 1 M1c
Imm-5 F/78 - 1 M1b
Imm-6 M /48 RLND, IFN 0 M1c
Imm-7 M /41 RLND, 2xMT 0 M1c
Imm-8 M /62 RLND, MT 0 M1c
Imm-9 M /46 RLND 0 M1a
Mat-1 M /22 - 0 M1c
Mat-2 M /59 RLND, MT, IFN 0 M1c
Mat-3 F/33 RLND 0 M1c
Mat-4 F/35 RLND 0 M1c
Mat-5 M /63 RLND 1 M1c
Mat-6 M /57 RLND, IFN 0 M1b
Mat-7 M /73 RT 0 M1b
Mat-8 M /54 RLND, IFN 0 M1c
Mat-9 F/50 R L N D , 2xM T , 
IFN
0 M1c
Table 1. Patent characteristics. PS: perform
ance status (WHO); RT: radiotherapy; HT: hyper­
thermia; MT: metastasectomy (in all patients of 
non-visceral metastases); IFN: interferon- 
a,;DTIC: dacarbazine; RLND: regional lymph 
node dissection.
The observation that this response was no t 
further augm ented after the second and 
third D C  vaccination or after adm inistra­
tion o f  K L H  protein i.d. suggests that a 
single D C  vaccination was sufficient to o b ­
ta in  m axim al p ro life ra tiv e  re sp o n ses  
against KLH.
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Figure 1. DC phenotype. CD83, CD86, and MHC class II expression on DCs used for all vaccinations 
(first vaccination fresh DCs, thereafter frozen DCs). Imm designates vaccination with immature DCs 
(CD83neg-low) and Mat with mature DCs(CD83hlgh). CD83, CD86, and MHC class II expression (dark 
overlays) were measured by flow cytometry, grey lines represent the isotype-matched control.
This may also explain why we did n o t ob­
serve a clear correlation between the in­
crease in proliferation and the num ber of 
injected D Cs (table 2). By contrast, we ob­
served no significant increase in K LH - 
specific proliferation of PBM C derived 
from  patients vaccinated once w ith im m a­
ture D Cs (n=9) (figure 2). Proliferative re­
sponses m easured after subsequent im m a­
ture D C  vaccinations, either i.v./s.c. or 
i.v./i.d. rem ained m uch less pronounced 
w hen com pared to PBM C from  patients 
vaccinated w ith equal num bers o f  m ature 
D Cs (table 2).
To determ ine the type o f  the induced im ­
m une response, PBM C obtained after 3
vaccinations w ith either im m ature or m a­
ture DCs were stimulated w ith K L H  for 
16 hours and cytokine production was 
measured. N o  cytokine production was 
observed by PBM C after 3 vaccinations 
w ith im m ature D Cs (figure 2). However, 
PBM C from  patients vaccinated w ith m a­
ture DCs produced high am ounts o f  IL-2 
(60 pg /m l), T N F -a  (212 pg /m l), and 
IFN y (398 pg/m l) bu t no IL-4 in response 
to K L H  (figure 2). F rom  these results we 
conclude that m ature D Cs induce a T  
helper 1 (Th1) response.
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Figure 2. KLH-specific proliferation of PBMC before and after DC vaccination. Patients were vacci­
nated either with immature DCs (a) or mature DCs (b). One representative patient for each DC subset 
is shown (closed bars PBMC without KLH; open bars PBMC with KLH). Results of the proliferation 
to KLH of all patients are shown in table 2. Cytokine production by PBMC of patients vaccinated 3 
times either with mature (Mat-7; c, d) or immature DCs (Imm-6; e, f): unstimulated PBMC (c, e) and 
PBMC stimulated with KLH (d, f).
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Figure 3. Humoral responses against KLH. Representative humoral responses against KLH in the se­
rum of patients vaccinated either with immature DCs (Imm-6) or mature DCs (Mat-3). Serum was ob­
tained before (...), after each subsequent DC vaccination (— , number indicates number of DC vacci­
nations) and after vaccination with KLH protein (-----). Total IgG antibodies with specificity for KLH
were detected by ELISA in KLH-coated microtiter plates. Isotype-specific secondary antibodies were 
used to detect IgG1, IgG2, and IgG4 (patient Mat-3). Results of total IgG against KLH of all patients 
are shown in table 2.
Humoral response against KLH in serum
H um oral responses against K L H  (total 
IgG) were detected in serum  o f  m ost pa­
tients (9 out o f  10) vaccinated w ith m ature 
D Cs given i.v. and i.d. (table 2). A fter a 
single vaccination w ith K LH -pulsed DCs, 
IgG  antibodies reactive w ith K L H  were 
readily detectable by ELISA  (figure 3). A f­
ter subsequent vaccinations w ith m ature 
DCs, the IgG  antibody titers increased and 
rem ained elevated after vaccinations with 
the protein K L H  at days 56, 84 and 112 
(figure 3). In  contrast, in serum  o f  all the 
patients vaccinated w ith im m ature K LH - 
pulsed DCs, IgG  antibodies reactive with 
K L H  rem ained absent (figure 3, table 2) 
even after 3 D C  vaccinations. To exclude 
the possibility that these patients were re­
fractory to K LH , 2 patients received a sub­
sequent single vaccination w ith K L H  p ro ­
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tein. H igh titers o f  IgG  against K L H  
could be obtained dem onstrating that their 
im m une system was no t affected (figure 3). 
Sera containing K L H  antibodies after vac­
cination w ith m ature D Cs were further 
analyzed for subtypes o f  IgG  (IgG1, IgG 2 
and IgG4).
We did no t observe anti-K LH  antibodies 
o f  the IgG 4 subclass in any o f  the pa­
tients. In  four patients we observed equal 
am ounts o f  IgG1 and IgG2, whereas in 5 
patients the levels o f  IgG 2 were signifi­
cantly higher com pared to the levels o f  
IgG1, indicating the presence o f  IFN-y 
and hence a Th1 response (figure 3)36;37. 
Together, bo th  antibody and proliferative 
responses against K L H  dem onstrate the 
superiority o f  m ature D Cs in inducing 
Th1 responses.
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DTH reac&ons
N o D T H  skin reactions against im m ature 
D Cs either unpulsed or pulsed w ith K LH  
a n d /o r  peptides were observed in patients 
vaccinated 3 times w ith im m ature DCs 
(table 2). In  contrast, in all patients vacci­
nated (i.v./i.d.) w ith m ature DCs, positive 
D T H  reactions w ith indurations up to 12 
m m  were observed against m ature DCs 
pulsed w ith K L H  a n d /o r  peptides, and 
also in 8 out o f  9 patients against unpulsed 
m ature D Cs (table 2). M oreover, in one 
patient vaccinated w ith m ature DCs, a 
D T H  w ith unpulsed im m ature D Cs in­
duced induration as well (data n o t shown). 
These data imply that vaccination w ith m a­
ture bu t n o t w ith im m ature D Cs provoke a 
D T H  response.
Detec&on of tumor pep&de-specific T 
cells in peripheral blood and DTH
To determ ine the presence o f  antigen- 
specific T  cells in peripheral blood, ELIS- 
P O T  m easuring  IF N -y -p ro d u c tio n  by 
C D 8+ T  cells in response to the vacci­
nated tum or-derived peptides and tetram er 
staining were used.
In  some o f  the analyzed samples (in 1 out 
o f  4 tested patients vaccinated w ith im m a­
ture DCs, 1 out o f  5 patients vaccinated 
w ith m ature DCs) a small increase in reac­
tivity against the vaccinated peptides was 
observed after vaccination, either by EL- 
ISPO T or by tetram er staining (data no t 
shown). Furtherm ore, this increase was 
n o t consistent after subsequent vaccina­
tions. From  these experiments we con­
cluded that in peripheral b lood no signifi­
cant elevation o f  peptide-reactive T  cells 
could be found.
Short-term  T  cell cultures (2 to 4 weeks) 
from  biopsies o f  positive D T H  reactions 
o f  seven patients vaccinated w ith m ature 
D Cs provided the opportunity  to test T
cell reactivity o f  the D TH -infiltrated T  
cells w ithout restimulation in vitro.
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Figure 4. Antigen-specific lysis of tumor cells 
by DTH-infiltrating T cells. In a chromium re­
lease assay the lysis of HLA-A2.1 positive BLM 
cells transfected either with G250 (negative con­
trol antigen), gp100 or tyrosinase by T cells (pa­
tient Mat-3) derived from a biopsy of a positive 
DTH site (DCs loaded with KLH and peptides 
[gp100:154, 280 and tyrosinase]) is shown.
N o T  cell outgrow th was observed from  
biopsies o f  D T H  reactions against u n ­
pulsed DCs. From  4 out o f  7 patients suf­
ficient T  cells were available after short 
time culture (i.e. 2—3 weeks) to perform  
cytotoxicity assays. T  cells derived from  a 
D T H  biopsy o f  patient Mat-3 dem on­
stra ted  specific lysis o f  gp100- and 
tyrosinase-BLM  transfectants specifically 
(figure 4). D T H  biopsy-derived T  cells 
from  the o ther 3 patients did n o t show 
specific lysis (data n o t shown). In  5 /7  pa­
tients tetram er staining against the vacci­
nated peptides was perform ed on D T H  
biopsy-derived T  cells. Since cultures from  
these biopsies consisted predom inantly o f 
T  cells as determ ined by flow cytometry 
(data no t shown), we perform ed single te t­
ram er staining. D TH -infiltrated T  cells 
from  one o f  these 7 patients (Mat-10) 
stained positively w ith tetram er gp100:154 
(2.5%) and gp100:280 (3%), and negatively 
w ith tyrosinase (figure 5).
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Clinical outcome and correlation with 
immune responses
O f the im m ature D C  group, 7 patients 
com pleted the D C  vaccinations and 2 pa­
tients com pleted b o th  parts o f  the p ro to ­
col (Imm-1 and Imm-6). O ne o f  the 9 pa­
tients vaccinated with im m ature D Cs was 
no t evaluable for clinical response because 
o f  deteriorating perform ance status. All 
patients had either disease progression or 
stable disease w ith < 4 m onth  duration as 
best response (table 2). The m edian overall 
survival was 7 m onths (range 1.5-19 
m onths).
O f  the m ature D C  group, all patients 
com pleted the D C  vaccinations and 5 pa­
tients com pleted bo th  parts o f  the p ro to ­
col (Mat-1, M at-3, M at-4, Mat-9 and Mat- 
10). Three patients were eligible for m ain­
tenance therapy (Mat-3, Mat-4, Mat-10), 
two o f  them  received two additional D C 
vaccination cycles w ith a 6 m onths interval 
(Mat-3, Mat-10).
O f  the 10 patients vaccinated w ith m ature 
DCs, one patient was no t evaluable for 
clinical response because o f  deteriorating 
perform ance status, 4 patients had disease 
progression. Stable disease was observed 
in 3 patients w ith a duration o f  4.5, 7.5 
and 22 m onths, respectively (table 2). O ne 
patient (Mat-9) had a mixed response: 4 
cutaneous metastases decreased in size 
(30%-50%), however one cutaneous m e­
tastasis increased w ith 35%. T he m edian 
overall survival was 11 m onths (range 2- > 
40 m onths).
In  one patient (Mat-3) w ith stage M1c 
m elanom a vaccinated w ith m ature DCs, a 
partial response was observed in a distant 
lym ph node metastasis w ith concom itant 
norm alisation o f  serum  LD H . This m eta­
static site was subsequently resected. U pon 
pathological exam ination the resected le­
sion showed areas o f  necrosis and an 
abundant infiltrate o f  C D 8+  T  cells in the
tum or, w hich was still gp100 positive, but 
dem onstrated a decreased expression o f 
tyrosinase as com pared to  a cutaneous 
m elanom a lesion which was resected prior 
to  D C  vaccination (data no t shown). This 
patient is now  in com plete rem ission for 
m ore than three years.
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Figure 5. Tetramer analysis by flow cytometry 
of T cells derived from a biopsy of a positive 
DTH reaction of patient Mat-10. Depicted is the 
forward scatter on the x-axis (double staining with 
CD8 FITC might interfere with the tetramer 
staining and predominantly T cells grow out of 
these biopsies) and on the y-axis tetramer PE 
staining. Tetramer staining 1 log above the nega­
tive population was considered positive.
In  our study, the clinical outcom e did no t 
correlate w ith the pretreatm ent expression 
o f  gp100 or tyrosinase, neither w ith the 
percentage o f  positive cells, n o r w ith the 
estim ated staining intensity on the mela­
nom a metastases (data no t shown). 
A lthough the num ber o f  patients in this 
study is limited and does no t allow statisti­
cal analysis it is intriguing that the best 
clinical outcom e was observed in the two 
patients in w hom  tum or-specific T  cell re­
sponses o f  D TH -infiltrating lymphocytes 
was dem onstrated. Patient Mat-3 and Mat- 
10 had a progression free survival o f  m ore
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than 40 and 22 m onths, respectively. For 
com parison, in the patients in w hom  no 
specific T  cell reactivity could be observed, 
the median progression free survival was 2 
m onths (range 1.5-7.5).
DISCUSSION
O ur results in m elanom a patients dem on­
strate a clear preference for the use o f  
peptide-pulsed m ature D Cs as opposed to 
im m ature DCs in clinical vaccination stud­
ies. M onocyte-derived D Cs m atured w ith a 
cocktail o f  pro-inflam m atory cytokines 
and P G E 2 in vitro were superior in the in­
duction o f  bo th  hum oral responses and 
proliferative responses against K L H  in 
vivo. Analysis o f  KLH-specific T  cells 
showed the production o f  the Th1 cyto­
kine IFN-Y but n o t o f  the Th2 cytokine 
IL-4, and anti-K LH  antibodies were o f  the 
IgG 2 isotype which is also indicative for a 
Th1 response36,37.
D espite the previously observed lack o f  
IL-12 production and subsequent Th1 de­
velopm ent o f  PG E 2-m atured  D Cs in vi­
tro3,8, we conclude that vaccination with 
these fully m atured D Cs polarize T  cells 
towards IFN-Y production in patients.
The absence o f  T- and B cell responses to 
K L H  after vaccination w ith K LH -pulsed 
im m ature D Cs m ight be partly explained 
by our recent observation that im m ature 
D Cs are n o t able to efficiently migrate to 
the T  cell areas o f  lym ph nodes15. Since 
lym ph nodes are the prim ary site o f  inter­
action betw een B cells, T  cells and DCs, 
D Cs should migrate into the T  cell areas 
o f  secondary lym ph nodes. M igration and 
subsequent induction o f  an im m une re­
sponse o f  the m ature D Cs m ight be partly
attributed to the use o f  P G E 2 in our m atu­
ration cocktail.
Recently, P G E 2 was described as a key fac­
tor in regulating the m igratory capacity o f 
D C s39,40 (and our own unpublished re­
sults). In  addition to the lack o f  migration 
o f  im m ature DCs, the inability o f  these 
D Cs to induce an im m une response m ight 
also be due to the low production o f  D C- 
CK1 (CCL18), a chem okine which prefer­
entially attracts b o th  naive T  and B 
cells41,42.
We previously dem onstrated that DC-CK1 
production by im m ature D Cs is signifi­
cantly lower w hen com pared to m ature 
D C s25,41-43. O ur observation that injection 
o f  antigen-pulsed im m ature D Cs does no t 
lead to significant im mune responses con­
firms and extends findings o f  Jonuleit et 
al. w ho showed that im m ature D Cs failed 
to induce peptide-specific cytotoxic T  
cells44. Furtherm ore, the inability o f  im m a­
ture D Cs to give rise to an im m une re­
sponse also indicates th a t m onocyte- 
derived D Cs do n o t m ature after injection 
in vivo. Thus, for active im m unization in 
cancer patients it appears to be critical that 
D Cs are m atured in vitro before injection. 
Recently it became clear that im m ature 
D Cs are no t simply ignored by the im ­
m une system but that antigen-pulsed im ­
m ature DCs may blunt the capacity o f  the 
corresponding antigen-specific T  cells to 
m ount lytic activity in vitro45. In  addition, 
it has been shown that repetitive stimula­
tion w ith im m ature D Cs may lead to toler­
ance by inducing IL-10-producing regula­
tory T  cells46. In  mice D Cs can, under 
steady state conditions, induce T  cell toler­
ance and thereby m aintain peripheral tol­
erance to self-antigens47.
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P atien ts N u m b e r  o f  in je c te d  D C s (106 o f  ce lls ) D T H  a A n ti-K L H C lin ica l PFS
r esp o n se R e sp o n se
im m a tu re V acc. 1 ( i .v ./s .c .) V acc. 2 ( i .v ./s .c .) V acc. 3 ( i .v ./s .c .) T  c e ll b A b c
Imm-1 9/3 5/3 8/4 - + - PD 1
Imm-2 20/5 - - n.d. - - PD 0.5
Imm-3 14/4 12/3 21/5 - + - PD 3
Imm-4 25/6 7/2 - n.d. - - n.e. 1.5
Imm-5 8/6 7/5 2/5 - - - PD 3
Imm-6 30/8 27/5 30/5 - - - PD 4
Im m atu re ( i.v ./i .d .) ( i.v ./i .d .) ( i .v ./i .d .)
Imm-7 18/5 14/3 9/9 - - - PD 2
Imm-8 33/10 16/3 13/13 - + - PD 1
Imm-9 45/15 25/10 52/15 - + - PD 4
m atu re ( i.v ./i .d .) ( i.v ./i .d .) ( i .v ./i .d .)
Mat-1 31/5 30/8 55/7 + ++ + SD 7.5
Mat-2 45/15 34/6 50/13 n.d. + - n.e. 2
Mat-3 30/7 30/8 30/10 ++ + + + + PRd >40e
Mat-4 50/15 17/5 30/15 + + + + + + - SD 4.5e
Mat-5 33/15 19/12 27/15 ++ + + + + PD 2
Mat-6 70/25 50/17 60/30 + + + + + + + PD 1.5
Mat-7 12/10 12/12 10/10 + + + + + PD 1.5
Mat-8 15/7 26/9 13/13 + + + PD 1.5
Mat-9 30/14 18/8 20/10 + + + + + MxR 6
Mat-10 36/12 15/8 24/12 + + + + + SD 22e
Table 2. Immune and clinical responses after vaccination with immature and mature DCs. PFS:
progression-free survival (months); PD: progressive disease; SD: stable disease; MxR: mixed response; 
n.e. not evaluated; n.d. not done. aDTH was considered positive as at least 2 out of the 4 DTH sites 
had a positive induration (+ induration >2<5; ++ induration >5<10; +++ induration 10). b+ standard 
index (SI) >2<10; ++ SI >10<20; +++ SI20. cantibody titer, + designates >1 in 400. dcomplete re­
sponse after excision of regressing tumor ereceived maintenance treatment with DC vaccinations.
Recent findings in hum ans also show cir­
culating resident T  cell populations with 
po ten t regulatory properties in the periph­
eral b lood48. W hether regulatory T  cells 
were induced by our vaccination w ith im ­
m ature D Cs remains to be investigated.
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The superiority o f  m ature D Cs to induce 
an im m une response was underscored by 
the observation that positive D T H  reac­
tions were only observed w hen the DCs 
were m atured in vitro. In  addition to D T H  
reactions to  pep tide/K L H -pulsed  m ature 
DCs, D T H  reactions were also observed in
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response to non-pulsed m ature DCs. Simi­
lar findings have been reported  by others 
and can m ost likely be attributed to the 
production o f  large am ounts o f  chemoki- 
nes and cytokines by the m ature DCs 
them selves11,25,43. O f  note, cultures from  
biopsies o f  positive D T H  reactions to u n ­
pulsed DCs did n o t give rise to T  cells. 
A lthough significant differences were ob­
served between vaccination w ith m ature 
and im m ature D Cs w ith respect to im m u­
nological response against K LH , the num ­
ber o f  patients in our study is too small for 
a definite conclusion on  the difference in 
clinical outcom e between these vaccina­
tions. Furtherm ore, 6 /9  patients vacci­
nated w ith im m ature D Cs received their 
vaccine i.v./s.c. whereas all patients vacci­
nated w ith m ature D Cs were treated 
i.v./i.d.. A lthough the route o f  adm inistra­
tion may play a role in the nature o f  the 
response, this seems less likely in our study 
since the observed im m une responses in 
the three patients vaccinated i.v./i.d. with 
im m ature D Cs did no t differ from  the pa­
tients vaccinated i.v./s.c.. Nevertheless, our 
results indicate im proved clinical efficacy 
o f  peptide-pulsed m ature D Cs com pared 
to im m ature DCs. Only in patients vacci­
nated w ith m ature D Cs an objective clini­
cal response could be observed. A partial 
response was observed in a patient (Mat-3) 
w ith a distant lym ph node metastasis with 
a concom itant norm alization o f  serum  
LD H . A fter resection o f  the responding 
lesion, she currently is in ongoing remis­
sion for > 40 m onths. A nother patient 
(Mat-10) achieved disease stabilization o f  
22 m onths in irresectable bulky retroperi­
toneal lym ph node metastases upon  vacci­
nation w ith m ature DCs.
Prediction o f  clinical efficacy by im m uno­
logical markers remains a challenge. Sev­
eral clinical vaccination studies in cancer 
patients have reported  T  cell responses in
the peripheral b lood bu t usually in a m i­
nority o f  patients, or only after prolonged 
restimulation w ith antigen in culture49-53. 
In  our study we could n o t detect signifi­
cant and consistent anti-tum or T  cell reac­
tivity in peripheral b lood cells. This m ight 
be due to the fact that cells were tested 
w ithout restimulation to prevent in vitro 
m anipulation. Furtherm ore, the lack o f 
antigen-specific T  cells m ight be explained 
by the difference in the type o f  tum or an­
tigens used, as the response to gp100 and 
tyrosinase in healthy individuals is m uch 
lower than to, for example, M elan-A / 
MART-152,53.
We investigated the D T H  reactivity as a 
tool to m onitor the efficacy o f  our vaccine 
and its clinical outcome. O ur results show 
that D TH -infiltrated T  lymphocytes after 
short term  culture w ithout antigenic res­
tim ulation show peptide-specific reactivity 
as determ ined by M H C-tetram er positive 
T  cells and cytotoxic reactivity to the vac­
c in a ted  tu m o r an tigens. In trigu ing ly , 
antigen-specific T  cell responses were de­
tected in the two patients w ith the best 
clinical outcom e (Mat-3, Mat-10). In  these 
patients gp100-specific T  cells were de­
tected by M H C-tetram er staining in cul­
tured T  cells from  the biopsy o f  a D T H  
reaction (Mat-10) and M H C-tetram er posi­
tive cells by im m unofluorescent staining 
on frozen biopsy sections (Mat-3, m anu­
script in preparation). M oreover, after a 
short time culture in vitro, these T  cells 
were able to kill tum or cells expressing the 
antigens used for vaccination. T he pres­
ence o f  antigen-specific T  cells in the 
D T H  suggests that a systemic response 
was induced. Furtherm ore, the fact that 
this was only observed in clinical respond­
ing patients suggests that the evaluation o f 
T  cell reactivity in positive D T H  sites may 
be a powerful tool in the m onitoring o f
35
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clinical T  cell-directed vaccination studies 
in cancer patients.
In  conclusion, we here dem onstrate that 
m aturation o f  D Cs before injection is piv­
otal to induce antigen-specific immune re­
sponses in m elanom a patients. M oreover, 
clinical responses were only observed in 
patients vaccinated w ith m ature DCs. Re­
markably, T  cells isolated from  positive 
D T H  sites o f  the patients w ith the best 
clinical outcom e were specific for the anti­
gens used for vaccination. This suggests 
that T  cells isolated from  positive D T H  
sites m ight be very helpful in m onitoring 
vaccination therapy bu t this m ethod re­
mains to be confirm ed in larger clinical 
studies.
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The success of cellular therapies will depend in part on accurate delivery of cells to 
target organs. In dendritic cell therapy, in particular, delivery and subsequent mi­
gration of cells to regional lymph nodes is essential for effective stimulation of the 
immune system. We show here that in vivo magnetic resonance tracking of mag­
netically labeled cells is feasible in humans for detecting very low numbers of den­
dritic cells in conjunction with detailed anatomical information.
Autologous dendritic cells were labeled with a clinical superparamagnetic iron ox­
ide formulation or m In-oxine and were co-injected intranodally in melanoma pa­
tients under ultrasound guidance.
In contrast to scintigraphic imaging, magnetic resonance imaging (MRI) allowed as­
sessment of the accuracy of dendritic cell delivery and of inter- and intra-nodal cell 
migration patterns. MRI cell tracking using iron oxides appears clinically safe and 
well suited to monitor cellular therapy in humans.
Cellular therapies using stem cells and im­
mune cells are being increasingly applied in 
clinical trials. Accurate delivery o f cells to 
target organs can make the difference be­
tween failure or success. Because o f their 
pivotal role in initiating an immune re­
sponse, dendritic cells are o f widespread 
interest as a means o f enhancing the en­
dogenous immune response against tumor 
cells. Tumor antigen-loaded dendritic cell 
vaccines have been introduced in the clinic 
and have proven feasible and nontoxic, 
and both immunological and clinical re­
sponses have been observed1. However, 
effective immune induction is limited to a
minority o f patients. One possible expla­
nation o f this is insufficient delivery o f 
dendritic cells to the target organs. For ef­
fective immunotherapy, dendritic cells 
must migrate throughout the vascular and 
lymphatic system to present their antigens 
to T  cells located within lymph nodes. In 
independent studies, dendritic cells have 
been administered by different routes: in- 
tradermally, subcutaneously, intravenously 
or using combinations o f these routes. Al­
ternatively, dendritic cells can be injected 
directly into the lymph node2.
Thus far it has not been clear which route 
o f administration is optimal. The design o f
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optimal dendritic cell therapy would there­
fore be facilitated by technologies for 
monitoring dendritic cell trafficking. 
Dendritic cells have previously been la­
beled with radionuclides for scintigraphic 
imaging, which is the only clinical cellular 
imaging modality approved by the US 
Food and D rug Administration (FDA)3-5. 
A major drawback o f scintigraphy, how­
ever, is the lack o f anatomical detail; it al­
lows only gross anatomical determination 
o f migration between lymph nodes with­
out the ability to assess the intranodal dis­
tribution pattern o f dendritic cells within 
each lymph node. Furthermore, accurate 
cell delivery, which may be essential for 
subsequent migration into nearby lymph 
nodes, cannot be properly evaluated owing 
to scintigraphy’s lack o f spatial resolution. 
In contrast, MRI is well suited to obtain 
th ree -d im ensiona l, w holebody, high-
resolution images and is widely used in 
clinical practice.
The m ost sensitive existing markers to la­
bel cells for magnetic resonance detection 
are (ultrasmall) superparamagnetic iron ox­
ide ((U)SPIO) particles6. Initially applied as 
a m arker for cells o f  the reticu lo­
endothelial system, including the liver7 and 
lymph nodes8, these contrast agents are 
now either FDA-approved as a liver agent 
(SPIO; Feridex-USA; Endorem-Europe) 
or in late-phase clinical trials as a lymph 
node agent (USPIO; Combidex-USA; 
Sinerem-Europe)9. They are nontoxic and 
biodegradable10. Recently, SPIO particles 
have been applied as a magnetic label to 
detect cells after local grafting11-14 or sys­
temic injection15-18, including dendritic 
cells labeled with a nonclinical-grade SPIO 
preparation through a two-step m ono­
clonal antibody approach19.
Figure 1. Study pro­
tocol. (a) Monocytes 
are obtained by cyto- 
pheresis from stage- 
III  m elanom a pa­
tients. (b) They are 
cultured and labeled 
with SPIO particles 
and m In. (c,d) The 
cells are then injected 
intranodally into a 
(either cervical, ingui­
nal or axillary) lymph 
node basin that is to 
be resected and their 
b io d is tr ib u tio n  is
monitored in vivo by 
scintigraphy (c) and 
MRI at 3 Tesla (d). 
(e—g) The lym ph 
node basis is resected 
and separate lymph 
nodes are visualized 
with high resolution 
MRI at 7 Tesla and 
histology (g).
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These studies have all been perform ed in 
animal models. Translation o f these tech­
niques from animal models to humans is 
not straightforward because SPIO-labeling 
raises safety concerns associated with the 
use in patients o f adjunct compounds, 
such as transfection agents.
In this study, we obviated these concerns 
by taking advantage o f the fact that imma­
ture dendritic cells naturally endocytose 
clinically applied, FDA-approved SPIO- 
labels in substantial amounts. We found 
that cells could be labeled with high effi­
ciency without affecting their function. We 
then investigated the biodistribution o f 
SPIO-labeled dendritic cells applied as 
cancer vaccines in melanoma patients us­
ing MRI. In vitro-generated dendritic cells 
loaded with tumor-derived antigenic pep­
tides were administered to stage-III mela­
noma patients as outlined in figure 13;20. 
Dendritic cells were labeled with m In- 
oxine and SPIO (Endorem) separately and 
coinjected in a lymph node in the lymph 
node basin to be resected. This provided a 
unique opportunity not only to obtain 
magnetic resonance scans at 3 Tesla (T) 
before surgery, but also to generate high­
resolution magnetic resonance images at 7 
T o f individual resected lymph nodes and 
to correlate the results with scintigraphy 
and (immuno)histopathology (figure 1). 
We show that magnetic resonance tracking 
o f magnetically labeled cells is a clinically 
safe procedure that, because o f its high 
resolution and excellent soft tissue con­
trast, appears ideally suited to m onitor 
novel experimental cell therapies in pa­
tients.
Figure 2. Phenotypical and functional charac­
terization of SPIOlabeled dendritic cells. (a)
FACS analysis of the expression of major histo­
compatibility complex class II (HLA-DR/DP) 
and costimulatory (CD80 and CD86) molecules, 
dendritic cell maturation marker CD83 and che- 
mokine receptor CCR7. (b) Migratory capacity of 
dendritic cells determined by the percentage of 
dendritic cells labeled with or without SPIO or 
m In that migrate on a fibronectin surface in a 
random in vitro migration assay. (c) Interferon-g 
production by gp100: 154-162-specific T-cell line 
cocultured with unlabeled, gp100: 154-162-loaded 
dendritic cell, SPIO-labeled, gp100: 154-162- 
loaded dendritic cells or unlabeled dendritic cells 
loaded with an irrelevant peptide.
RESULTS 
In vivo MRI and scintigraphy of den­
dritic cells
We loaded dendritic cells with SPIO parti­
cles by co-culturing immature dendritic 
cells with 200 m g/m l SPIO, as immature 
but not mature dendritic cells are highly 
phagocytic21. Several tests were conducted 
to determine whether the labeling proce­
dure affected the cells’ viability or func­
tion. First, we confirmed that all cells had 
taken up a substantial amount o f SPIO by 
the end o f the culture period (figure 1b). 
Second, the phenotypes o f SPIO-labeled 
and unlabeled cells appeared similar (figure 
2a). Third, the random  migration on 
fibronectin-coated wells3 showed that 
SPIO-labeled dendritic cells migrated as 
well as unlabeled- or 111In-labeled cells
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(figure 2b). Finally, SPIO-labeling o f den­
dritic cells loaded with the melanoma- 
specific peptide gp100: 154-162 was found 
not to affect the peptide-specific produc­
tion o f interferon-y by a gp100: 154-162- 
specific T-cell line22 (figure 2c), indicating 
that the antigen-presentation function o f 
dendritic cells remained unaffected after 
labeling. Together these results demon­
strate that SPIO labeling does not affect 
the cells’ phenotype or function.
Eight stage-III melanoma patients received 
an intranodal injection under ultrasound 
guidance o f a mixture o f 111In- and SPIO- 
labeled dendritic cells (ratio 1:1) 2 days be­
fore radical dissection o f regional lymph 
nodes. Patients were imaged before and 2 
days after the injection by both scintig­
raphic imaging and MRI to m onitor deliv­
ery o f the dendritic cells and their subse­
quent migration to nearby lymph nodes.
Scintigraphic imaging confirmed and ex­
tended previous findings that although a 
significant percentage o f dendritic cells 
remained at the injection site, some did 
migrate to nearby lymph nodes. In four o f 
eight patients, 1% to 40% o f total 111In 
activity was found in regional lymph nodes 
draining the injected lymph node, indicat­
ing migration o f 111In-labeled dendritic 
cells (figure 3d, table 1 and supplementary 
figure 1). The scintigraphic images were 
compared with in vivo magnetic resonance 
images obtained on a 3-T magnetic reso­
nance system (figure 3). Comparison o f 
gradient echo images before and after cell 
injection (figure 3a,c; patient 1) showed 
that the injected SPIO-labeled dendritic 
cells resulted in a significant decrease in 
signal intensity at the injection site. After 
injection, turbo spin echo (SE) images, 
which are relatively insensitive to SPIO- 
induced magnetic susceptibility effects, 
were also obtained (figure 3b).
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Patient Injection site Injection cor­ Number of LNs Number of LNs Number of
rectly in LN visualized on in visualized on ex LNs visu­
vivo scintigra- vivo scintigra- alized on
phy® phya MRa
1 inguinal LN yes 2 (4%) 4 (40%) 4
2 inguinal LN yes 1 (0%) 2 (1%) 3
3 right inguinal LN yes 4 (4.2%) 5 (n.d.) 5
left inguinal LN yes 2 (1.7%) n.d. 2
4 cervical LN partlyb 2 (17%) 2 (n.d.) 2
5 axillary LN no 1 (0%) 1 (0%) 0c
6 axilary LN partlyb 1 (0%) 1 (0%) 1
7 inguinal LN no 1 (0%) 1 (0%) 0c
8 inguinal LN no 1 (0%) 1 (0%) 0c
Table 1. Comparing scintigraphic and MR imaging for monitoring of cell migration. aIncluding the 
injected LN, between brackets the total percentage of m In-activity at the site(s) distant from the injec­
tion depot is given (only for scintigraphy). bPart of the cells were injected in the LN, mostly in the peri­
nodal tissue. cSPIO was detected only outside the LN.
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Figure 3. In vivo 
sc int igraphic  and 
MRI. (a—c) Monitor­
ing of the delivery of 
dendritic cells labeled 
with SPIO and m In 
by MRI before and 
after intranodal injec­
tion in patient 1. (a)
Gradient echo trans­
versal magnetic reso­
nance image before 
vaccination showing a 
right inguinal lymph 
node with a hyperin­
tense signal area (1).
(b) SE (technique 
much less sensitive for 
S P IO ) tra n s v e r s e  
magnetic resonance 
image obtained from 
the same lymph node 
after vaccination. (c)
Gradient echo trans­
verse magnetic reso­
nance images after 
vaccination in same 
position as b showing 
a decreased signal in­
tensity of lymph node 
1. (d—n) Monitoring 
of in vivo migration 
of SPIO and 111In- 
labeled dendritic cells 
with MRI and scintig­
raphy after injection in 
a right inguinal lymph 
node in patient 3. (d)
In vivo scintigraphy 2 
d after vaccination 
showing migration of 
the dendritic cells from
the injection lymph node (1) to three following lymph nodes (2—4). (e—n) Five image pairs of a coronal 
gradient echo and SE image 2 days after vaccination showing migration of the dendritic cells from the 
injection lymph node 1 (e and f) to four following lymph nodes (g—n). Open arrows indicate lymph 
nodes that do not contain SPIO, on the SE images these nodes are dark-gray; on gradient echo images 
they are white. Closed arrows indicate lymph nodes that are positive for SPIO in the gradient echo 
magnetic resonance image. On gradient echo images SPIO-containing lymph nodes have a decreased 
signal intensity compared to SE images. The concentration of SPIO in lymph node 1 was very high, 
resulting even in a decreased signal intensity in the SE image. The lymph node that was identified by 
the scintigraphy as the injection lymph node (lymph node 1 in d) actually consisted of two distinct 
lymph nodes as evidenced by MRI (lymph nodes 1 and 5).
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By comparing the iron-insensitive mag­
netic resonance spin echo sequence with 
ironsensitive gradient echo sequences, one 
can reliably detect the presence of iron in 
a lymph node9. In SE images, lymph nodes 
generally appear as dark-gray structures. In 
gradient echo images, they are white 
(compare open arrows in figure 3e,f; k,l 
and m,n; patient 3); a large decrease in sig­
nal intensity at the sites of the lymph 
nodes indicated the presence of SPIO- 
labeled cells (closed arrows in figure 3). 
111In- and SPIO-labeled cells co-localized 
in the same areas, proving that the loca­
tions detected by MRI indeed represent 
injected and migrated dendritic cells (fig­
ure 3e—n). All lymph nodes that showed 
111In activity were also positive in MRI. 
However, because MRI has a higher spatial 
resolution, the MRI images revealed more 
lymph nodes containing migrated dendritic 
cells as compared with the scintigraphic 
images (table 1). In addition, scintigraphic 
imaging saturates the image such that mul­
tiple adjacent lymph nodes may appear as 
one. An example is shown in figure 3. In 
patient 3, four positive lymph nodes were 
identified by scintigraphy. However, the 
magnetic resonance images revealed five 
lymph nodes, as the hot spot of lymph 
node 1 actually consisted of two separate 
lymph nodes, with the second one lying
close to the injection node (figure 3d,g,h 
and supplementary video 1 online).
From  the scintigraphy of the resected 
lymph node basin from  patient 1, we could 
calculate that 2% o f 7.5x106 dendritic cells 
migrated to draining lymph node number 
4 (see supplementary figure 1). This par­
ticular node was also visible by MRI, indi­
cating that as few as 1.5x105 migrated cells 
could readily be visualized. The node had a 
volume o f 2.3x7.6x3.5 m m  (90 voxels in 
one slice). Assuming that the distribution 
o f SPIO-positive cells in the lymph node 
was homogeneous, as a rough estimate 
~2x103 cells/voxel could be visualized. 
Because the distribution is inhomogene- 
ous, the actual value may be larger.
Notably, the additional anatomical infor­
mation provided by the magnetic reso­
nance images could confirm that the in­
jected dendritic cells were truly localized 
within the lymph node. In addition, MRI 
demonstrated that in three patients the 
dendritic cells were actually delivered not 
into the lymph node but in the perinodular 
fat (figure 4a,b). Notably, in all three pa­
tients no dendritic cell migration to drain­
ing lymph nodes was observed (table 1). 
Furthermore, in two patients, dendritic 
cells were injected only partly in the target 
lymph node and migration o f dendritic 
cells was registered in only one o f them.
Figure 4. Monitoring of the accu­
racy of delivery of SPIO-labeled 
cells using MRI. (a) MRI before 
vaccination; the inguinal lymph 
node to be injected is indicated with 
a black arrow (b) MRI after injec­
tion showing that the dendritic cells 
were not accurately delivered into 
the inguinal lymph node (black ar­
row) but in the vicinity, in the sub­
cutaneous fat (white arrow).
The total number o f SPIO-positive den- dritic cells imaged by magnetic resonance
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was significantly correlated with the suc­
cess o f the intranodal injection (see sup­
plementary figure 2, P<0.05). Thus, in 
contrast to MRI, which allows verification 
that hotspots are actually lymph nodes, 
scintigraphy cannot distinguish between 
correct and incorrect intranodal injections, 
leading to erroneous classification o f in­
jection sites as lymph nodes.
Analysis o f the number o f cases in which 
one technique was more accurate in imag­
ing true dendritic cell-positive lymph 
nodes showed that MRI was significantly 
better than scintigraphy (P < 0.05). Thus, 
the detailed anatomical information (com­
bination o f high spatial resolution and ex­
cellent soft tissue contrast) o f MRI is a 
clear advantage compared with scintig­
raphic imaging, allowing both verification 
o f accurate delivery and monitoring o f 
subsequent migration o f SPIO-labeled 
cells.
Ex vivo MRI and histology of resected 
lymph nodes
As the melanoma patients were scheduled 
for regional lymph node dissection, a 
unique opportunity existed to investigate 
the biodistribution o f the injected den­
dritic cells in more detail in individual re­
sected lymph nodes by high-resolution 
MRI at 7T (figure 5a,c). All lymph nodes 
that contained 111In-positive dendritic cells 
as determined by a gamma probe were 
also positive for SPIO-labeled cells, vali­
dating the ability o f MRI to detect and lo­
calize low numbers o f injected and mi­
grated SPIO-labeled cells. As expected 
when SPIO-labeled cells are present, the 
gradient echo images o f these nodes 
showed much larger areas in the lymph
nodes that are hypointense as compared 
with the SE images (see supplementary 
Videos 2 and 3 online).
Localization o f SPIO-labeled dendritic 
cells in the lymph nodes was further con­
firmed by histology after Prussian blue 
staining o f lymph node sections (figure 
5b,d). There was an excellent correlation 
between the hypointense areas o f images 
obtained by ex vivo MRI and the areas 
containing large num bers o f  SPIO - 
positive cells as visualized by histochemis­
try. Even low numbers o f SPIO-labeled 
dendritic cells distributed over a larger area 
were readily detected by MRI (encircled 
areas in figure 5b,d). These ex vivo MRI 
and histology findings thus confirm that in 
vivo MRI is a sensitive and accurate tech­
nique for monitoring the biodistribution o f 
SPIO-labeled cells.
Further histological evaluation o f the 
lymph nodes beyond the injected node 
that were detected with autoradiography 
and MRI showed iron-containing dendritic 
cells in the paracortex. Large numbers o f 
iron-containing cells were present in the 
sinuses o f the lymph node.
These findings indicate that injected den­
dritic cells entered the lymph nodes via 
their natural route through the afferent 
lymph vessels and sinuses (figure 5e). A 
significant proportion o f the cells pene­
trated deep into the T-cell areas (figure 5f) 
throughout the lymph nodes, whereas no 
cells were found in the B-cell areas. SPIO- 
labeled dendritic cells in T-cell areas were 
often found to be surrounded by rosetting 
lymphocytes (figure 5g). The presence o f 
rosettes o f slightly enlarged T cells around 
SPIO-positive dendritic cells is indicative 
o f T-cell activation, a requirement for ef­
fective dendritic cell vaccines.
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f g h
Figure 5. Ex vivo magnetic resonance images and correla&on with histology. (a-d) SE magnetic 
resonance image of the injected lymph node (a) and a nearby lymph node (c) obtained after resection 
from patient 1. SPIO-labeled dendritic cells were visualized by Prussian Blue staining in sections from 
the injected lymph node (b) and the nearby lymph node (d) at levels comparable to the magnetic reso­
nance images. Areas with (dispersed) SPIO-labeled dendritic cells as detected at higher magnifications 
are encircled and correlated with the magnetic resonance images. The blue area in b that is visible even 
at low magnification represents the injection site. (e-h) Magnifications of specific regions of d. SPIO- 
labeled cells were detected in the sinus (e) and in T-cell areas (f) of the lymph node. (g) T cells form 
rosettes around vaccinated dendritic cells (a representative picture is shown). SPIO-labeled cells are 
negative for the macrophage marker CD68. (h) SPIO-labeled cells were positive for the dendritic cell 
marker S100. Blue represents SPIO-particles, brown indicates specific immunostaining.
The SPIO-labeled cells were negative for 
the macrophage marker CD68 (figure 5g), 
indicating that SPIO-positive cells were 
indeed injected dendritic cells and not 
macrophages that had phagocytosed SPIO 
particles released from dead cells. Moreo­
ver, SPIO-containing cells were also posi­
tive for the dendritic cell-markers S100 
(figure 5h) and CD83 (data not shown). 
Thus, SPIO-labeling does not prevent mi­
gration o f injected dendritic cells to the T- 
cell area in the lymph node in vivo, and 
injected dendritic cells that migrate into 
the T-cell areas have productive interac­
tions with resident T  cells.
DISCUSSION
In this study, we followed the migration o f 
autologous ex vivo-cultured mature den­
dritic cells after intranodal administration 
in eight stage-III m elanom a patients 
scheduled for regional lymph node dissec­
tion. To the best o f our knowledge, there 
is no previous report o f effective tracking 
o f ex vivo-labeled therapeutic cells in hu­
mans by noninvasive MRI. By co-injecting 
equal numbers o f 111In- and SPIO-labeled 
cells, we demonstrated that MRI is at least 
as sensitive as scintigraphic imaging for 
detecting dendritic cell migration in vivo. 
Moreover, MRI is significantly better than 
scintigraphic imaging in that delivery o f 
the dendritic cell vaccine to the intended
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location can be verified and cells can be 
tracked more accurately.
We labeled dendritic cells in the immature 
state, following which they were allowed to 
mature, as immature but not mature den­
dritic cells are highly phagocytic21. This 
obviated the use and clinical approval o f 
transfection agents, which are now widely 
applied for efficient intracellular magnetic 
labeling o f nonphagocytic cells in animal 
models23.
The phenotypical and functional proper­
ties o f the SPIO-labeled cells were unal­
tered as compared with unlabeled cells. 
Moreover, SPIO-labeled cells that had mi­
grated into lymphoid tissue still expressed 
the maturation marker CD83, indicating 
that migrating dendritic cells remained ma­
ture and did not return to an immature 
state.
A major advantage o f MRI over scintig­
raphic imaging is the high-resolution ana­
tomical background contrast, which allows 
precise anatomical localization o f SPIO- 
labeled cells at the actual injection site and 
after migration. A major advantage o f 
scintigraphic imaging, however, is the pos­
sibility to quantify the amount o f cells that 
have migrated from the injection site. 
Preferably, both techniques should be 
combined to obtain both quantitative and 
qualitative information on migration o f 
therapeutically administered cells. Alterna­
tive in vivo approaches for noninvasive 
visualization o f adoptively transferred 
cells, such as bioluminescent imaging or 
positron emission tomography, have no 
endogenous background contrast, lack the 
resolution to delineate fine anatomical de­
tails o f tissues and organs or cannot be 
used clinically (bioluminescent imaging). 
The combination o f both SPIO and radi­
onuclide labeling allows both quantifica­
tion (scintigraphy) and detailed anatomical 
localization (MRI) o f migrated cells.
With these techniques we were able to de­
tect as few as 1.5x105 cells in vivo, which is 
in concordance with a previous study in a 
preclinical porcine model using MRI to 
visualize injected iron fluorophore parti­
cle-labeled mesenchymal stem cells24 and 
which is far below the therapeutic range o f 
~20x106 cells necessary for successful car­
diac infarct engraftment13. Furthermore, 
the combination o f labeling techniques 
offers new possibilities to image differen­
tially labeled subsets o f cells simultane­
ously in vivo after their injection at one 
and the same site (for example, dendritic 
cell subsets or dendritic cells in different 
activation or maturation stages). This is 
particularly relevant for further optimiza­
tion o f cell-based anti-cancer therapies. 
Subsequent autoradiography, (immuno)his- 
tology and Prussian blue staining o f tissue 
sections from resected lymph nodes to 
visualize individual 111In-labeled and 
SPIO-labeled cells would then offer a fur­
ther means o f validation to track mixed 
cell populations at the single-cell level. 
Interestingly, we found that in only ~50%  
of the cases were dendritic cells correctly 
injected into the lymph node, despite ultra­
sound guidance o f the injection needle by 
a highly experienced radiologist. Subse­
quent migration could be observed only 
when dendritic cells were correctly injected 
into the lymph node, demonstrating the 
importance for cellular therapy o f mag­
netic resonance verification o f accurate 
delivery. Inadequate delivery may explain 
why only a limited proportion o f patients 
is responding in ongoing clinical trials o f 
dendritic cell vaccines.
We found that MRI was significantly more 
accurate than scintigraphy for visualizing 
true dendritic cell-positive lymph nodes. 
These findings illustrate the power o f ad­
ditional anatomical information, which can 
also be o f value for other fields o f bio­
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medical research. For example, the impor­
tance o f magnetic resonance tracking o f 
cell delivery has been recognized for bone 
marrow stem cell injections into infarcted 
myocardium o f large animal models13,24.
MRI proved valuable for monitoring not 
only the accuracy o f the injection but also 
the migratory capacity o f antigen-loaded 
dendritic cells, as remote lymph nodes 
containing SPIO-labeled cells could be 
visualized individually. In contrast to scin­
tigraphy, where a hot spot may represent 
one or more lymph nodes, MRI can detect 
all truly positive lymph nodes separately 
owing to its high spatial resolution and 
lack o f saturation o f images. In two pa­
tients, individual lymph nodes were missed 
by scintigraphy because they were located 
in the same vertical plane as the injection 
node. With MRI these lymph nodes could 
be detected separately, allowing correct 
evaluation o f the migratory capacity o f 
SPIO-labeled cells in vivo. That these 
lymph nodes were SPIO positive was con­
firmed by ex vivo MRI and histology. 
High-resolution MRI o f these targeted 
lymph nodes ex vivo provided detailed in­
formation on the three-dimensional bio­
distribution o f small numbers o f cells and 
their migration into the paracortex o f the 
lymph node, the location o f the T-cell ar­
eas where the dendritic cell-T cell interac­
tion takes place. These findings were con­
firmed by immunohistology after Prussian 
blue staining o f lymph node sections. 
Moreover, rosettes o f slightly enlarged T 
cells around injected dendritic cells were 
present in several patients, demonstrating a 
functional interplay between SPIO-labeled 
dendritic cells and T cells. Thus, SPIO- 
labeling o f dendritic cells did not affect 
the migratory behavior and functionality 
o f the dendritic cells in vivo.
In conclusion, this clinical study demon­
strates the potential o f using MRI for
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tracking therapeutic cells in patients. Our 
approach could be easily extended to other 
clinical applications, including those based 
on monocyte, granulocyte and lymphocyte 
trafficking, monitoring o f cellular trans­
plants and tissue-restoration therapies 
based on stem cells and progenitors. The 
routine imaging protocols we used are 
readily available on common MRI systems. 
Therefore, cellular MRI may pave the way 
for many investigators and clinicians to 
obtain a more in-depth view o f the under­
lying biodynamics o f cellular treatment 
modalities.
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METHODS
Patients
This study included melanoma patients enrolled 
in an ongoing protocol in which the in vivo im­
mune responses of a dendritic cell vaccine are 
under study (KUN 99-150). Eligibility criteria in­
cluded stage-III melanoma (according to the 2001 
American Joint Committee on Cancer staging sys­
tem25), planned regional lymph node dissection 
for lymph node metastases, HLA-A2.1 pheno­
type, melanoma expressing the melanoma- 
associated antigens gp100 and tyrosinase, and 
World Health Organization performance status 0 
or 1. Prior treatment was allowed, provided that a 
treatment-free period of at least 4 months was 
observed and all related toxicity had resolved. Pa­
tients with brain metastases, serious concomitant 
disease or a history of a second malignancy were 
excluded. The study was approved by our Institu­
tional Review Board, and written informed con­
sent was obtained from all patients. Toxicity was 
assessed using the National Cancer Institute 
Common Toxicity Criteria. In total, 11 stage-III 
melanoma patients were included, of whom 2 
developed clinical overt brain metastases between 
inclusion and start of treatment and could there­
fore not be included in the analysis. O f the other 
nine patients, one had severe claustrophobia pre­
cluding in vivo MRI, although scintigraphy and ex 
vivo MRI could be obtained. Toxicity was similar 
to previous dendritic cell vaccination studies20 and 
consisted of low-grade fever, mild flu-like symp­
toms and irritation at the site of injection after 
the vaccinations in some patients.
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Preparation of SPIO- and 111In-labeled den­
dritic cells
Dendritic cells were generated from adherent pe­
ripheral blood mononuclear cells by culturing in 
the presence of interleukin-4 (500 U/ml) and 
granulocyte-monocyte colony stimulating factor 
(800 U/ml) (both Cellgenix). For SPIO-labeling, 
200 mg Ferumoxide/ml (Endorem, Laboratoire 
Guerbet) was added 3 days after the onset of 
dendritic cell culturing. At day 5, dendritic cells 
were matured with autologous monocyte- 
conditioned medium supplemented with prosta­
glandin E2 (10 mg/ml, Pharmacia & Upjohn) and 
10 ng/ml recombinant tumor necrosis factor-a 
(Cellgenix) for 48h, as described previously26,27. 
Dendritic cells were pulsed with the melanoma 
peptides gp100:154-162, gp100:280-288 tyrosi­
nase 369-376 as described previously3. Mature 
dendritic cells were labeled with m In-oxine (Tyco 
Healthcare) in 0.1 M Tris-HCl (pH 7.0) for 15 
min at 20°C as described previously3,26 resulting in 
5 ^Ci activity per 7.5x106 cells. Cells were washed 
three times with PBS. Radiolabeling efficiency was 
determined by measuring activity in both the cell 
pellet and the washing buffer. Iron labeling effi­
ciency was verified by Prussian blue staining. Vir­
tually all cells endocytosed SPIO particles (figure 
1). Total iron content of SPIO-labeled cells was 
assessed by a Ferrozin-based spectrophotometric 
assay following acid-digestion of labeled cell 
samples11,28. The iron content was 10—30 pg of 
iron per cell. Cell viability was determined by 
Trypan blue staining, showing comparable viabil­
ity (more than 80%) for unlabeled dendritic cells 
and 111In and SPIO-labeled dendritic cells (data 
not shown).
Phenotypic and functional evaluation of den­
dritic cells
Fluorescenceactivated cell sorting (FACS) analysis 
was performed using a Becton Dickinson FACS- 
Calibur. The following fluorochrome-conjugated 
monoclonal antibodies were used: anti-HLA class
I (W6/32), anti-HLA D R/D P (Q5/13), anti- 
CD80 (all Becton Dickinson), anti-CD83 (Beck­
man Coulter), anti-CD86 (Pharmingen), and anti- 
Chemokine Receptor 7 (kind gift of Martin Lipp). 
Random in vitro migration was tested as de­
scribed previously3. Peptide-specific T-cell stimu­
latory capacity was tested by co-culturing den­
dritic cells with or without SPIO that were loaded 
with the gp100:154-162 peptide or an irrelevant 
peptide with a gp100:154-162 specific T cell line 
(dendritic cell: T cell ratio, 1:5)22. After 48 h the 
cytokines in the supernatant were analyzed with a
cytometric bead array for human Th1/Th2 cyto­
kines (BD Biosciences).
Treatment schedule
Within 2 weeks before vaccination a first (prein­
jection) baseline magnetic resonance scan was 
performed (see below). At day -7 peripheral blood 
mononuclear cells were obtained by leukapheresis 
for dendritic cell culturing. At day 0 patients re­
ceived a single injection of 111Inlabeled dendritic 
cells (7.5x106) mixed with iron oxide-labeled den­
dritic cells (7.5x106, total volume 200 ml) directly 
into a lymph node of the lymph node region that 
was to be resected, using a 21 G sterile needle (0.8 
50 mm, Microlance, Becton Dickinson). Intrano­
dal injections were performed under ultrasound 
guidance.
One hour after injection the first scintigraphic 
image (see below) was acquired. At day 2, a sec­
ond (post-vaccination) magnetic resonance scan 
was perfomed, followed by a second scintigraphic 
imaging session, followed by regional lymph node 
dissection. After surgery, the resected material was 
again imaged scintigraphically to verify whether 
all tissue containing radioactivity was indeed re­
moved. Radioactive lymph nodes were dissected 
from the surgical specimen under guidance of a 
gamma probe (Europrobe, Eurorad) and then 
fixed in Unifix (Klinipath). O f these separate 
lymph nodes, high-resolution ex vivo magnetic 
resonance images were acquired at the end of day
2 and the beginning of day 3. The lymph nodes 
were sliced and embedded in paraffin at the end 
of day 3 and sections were cut at day 4 and proc­
essed for histology (iron-staining). As the lymph 
nodes were to be resected only 2 days after intra­
nodal vaccination, the induction of an immune 
response might not have been optimal. For this 
reason patients simultaneously received melanoma 
peptide-loaded dendritic cells intranodally in a 
contralateral clinically tumor-free lymph node 
which was not to be resected. Patients received 
three more vaccinations at days 14, 28 and 42.
Scintigraphic imaging
In vivo and ex vivo planar scintigraphic images 
(256x256 matrix, 174 and 247 keV 111In pho­
topeaks with 15% energy window) of the injec­
tion depot and corresponding lymph node basin 
were acquired with a gamma camera (Siemens 
ECAM) equipped with medium energy collima­
tors, at day 0 and day 2). Migration was quantified 
by region-of-interest analysis of the individual 
nodes visualized on the images and expressed as 
the relative fraction of 111In-labeled dendritic cells
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that had migrated from the injection depot to 
following lymph nodes after 2 days.
MRI
Patients were imaged using a 3 T whole body 
magnetic resonance system (Siemens Magnetom 
Trio) with a body array radiofrequency coil for 
signal reception. Magnetic resonance images were 
obtained with a gradient echo pulse sequence; the 
signals of three gradient echoes were combined 
into one T2*-weighted image with an average 
echo time of 15 ms (flip angle 36°, repetition time 
(TR) 1,060 ms, total acquisition time ~9 min, 30 
slices, resolution 0.50x0.50x3.50 mm). In addition 
to T2*-weighted images, which are very sensitive 
to SPIO-induced magnetic susceptibility effects, 
SE images at corresponding slice locations were 
also acquired using a short echo time (TE) of 18 
ms (resolution 0.83x0.50x3.50 mm, TR 2.5 s, total 
time ~6.5 min) as a reference control to ensure 
that the decreased signal intensity originated from 
the magnetic field inhomogeneities caused by 
SPIO. To keep radiofrequency power deposition 
within prescribed limits, hyperechoes29 were used 
in SE imaging. Ex vivo MRI of lymph nodes was 
performed using a 7T MR-spectrometer (Surrey 
Medical Imaging Systems) equipped with a 20­
mm diameter radio frequency (RF) coil. The 
lymph nodes were placed in a plastic tube filled 
with Fomblin LC0810 (Ausimont), to reduce sus­
ceptibility artifacts at the tissue-air interface with­
out a background proton signal. Multi-slice 
gradient-echo imaging was performed at two dif­
ferent echo times (TR 1/4 1,500 ms and TE 1/4 
9 and 13 ms, voxel-size 1/4 0.12 0.12 0.5 milli­
meters, acquisition time 13 min). Subsequently 
multi-slice spin-echo imaging was performed at 
corresponding slice locations and voxel size (TR 
= 1,000 ms and TE = 15 and 28 ms, acquisition 
time 8.5 min).
Statistical analysis
Statistical analysis was performed using the Wil- 
coxon rank sum test for nonparametric distribu­
tions for paired and unpaired observations. To 
test the hypothesis that magnetic resonance is 
more accurate than scintigraphy, we coded our 
data for both methods: more lymph nodes visual­
ized by magnetic resonance (MR = +1, scintig- 
rapy = -1); more lymph nodes visualized by scin­
tigraphy (MR = -1, scintigraphy = +1); or equal 
numbers (MR = scintigraphy = 0). When a hot 
spot in scintigraphy was qualified as situated out­
side lymphoid tissue by MRI, this was coded in
favor of MRI (MR = +1, scintigraphy---- 1). P <
0.05 was considered significant.
Iron staining and immunohistochemistry of 
histopathological sections
Sections (5 mm) of the radioactive resected 
lymph nodes were stained with Prussian blue to 
detect SPIO-labeled cells. Slides were stained with 
2% potassium hexacyanoferrate (II)-trihydrate in 
0.2 M HCl for 15 min and counterstained with
0 .0 5 . nuclear fast red in 5% aluminum sulphate. 
Immunohistochemistry was performed using an­
tibodies against CD68 (KP1, DAKO), S100 
(DAKO) and CD83 (Beckman Coulter). Bound 
antibody was visualized using powervision (Im­
munologic). Subsequently the slides were stained 
using Prussian blue and nuclear fast red.
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Supplementary figure 1. Monitoring of in vivo migration of SPIO and 111In-labeled DCs with MR 
imaging and scintigraphy after intranodal injection in patent 1. (a) GE transverse MR images be­
fore vaccination showing a right inguinal LN with a high signal intensity, which is presented in Figure 
3a-c (arrow 1). (b) In vivo scintigraphy 2 days after vaccination showing two positive LNs. (c, f) GE 
transversal MR images before vaccination, (d, g) SE transverse MR images after vaccination show LN 
2-4 with dark-gray signal intensity. (e, h) On GE transverse MR images after vaccination all these LNs 
show decreased signal intensity. (e) Ex vivo scintigrapy of the resected LN basin verified the MR find­
ings. From this scintigraphy the percentage of migrated cells could be calculated (LN 1: 60%; LN2: 
32%, LN3: 2%; LN4: 6% of injected DCs).
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Supplementary figure 2. Number 
of LN positive for labeled DC im­
aged with MR and scintigraphy 48 
hours after intranodal vaccina­
tion. Every symbol in the graph 
represents one patient. Based on 
the results of the MR imaging pa­
tients could be separated into three 
different groups. In the first group 
of patients the radiologist failed to 
inject the labeled cells correctly in 
the lymphoid tissue (missed), in the 
second group the labeled cells were 
only partly delivered into the target 
LN (partly) and in the third group 
injection was successful (correct).
No such distinction could be made 
with scintigraphy where every hot­
spot is classified as being a LN. In the last column, the open symbols represent the patients that were 
categorized in group one (missed) by MR imaging. The total number of positive LNs imaged by MR in 
group three (correct) was significantly higher than the total number of LNs in group one and two (Wil- 
coxon rank sum test).
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Dendritic cell (DC)-based immunotherapy is explored worldwide in cancer pa­
tients. Several strategies have been employed to load DCs with antigen, including 
peptide-loading. To increase immunogenicity of peptides, MHC class I binding af­
finity and stability of peptide-MHC complexes at the cell surface can be improved 
by modification of the amino acid sequence.
In this study, we compare the capacity of DCs loaded with wild-type or modified 
gp100 peptides with higher binding affinities to induce an immune and clinical re­
sponse in advanced melanoma patients. Metastatic HLA-A2.1+ melanoma patients 
were vaccinated with mature DCs loaded with keyhole limpet hemocyanin (KLH) 
together with tyrosinase peptide and either wild-type (15 patients) or modified (12 
patients) gp100 peptides.
All vaccinated patients showed a pronounced proliferative T-cell or humoral re­
sponse against KLH. Gp100-specific T cell responses were monitored in peripheral 
blood by tetramer analysis and in post-treatment biopsies of delayed type hyper­
sensitivity (DTH) skin tests by tetramer and functional analysis. Functional T cell 
responses against the vaccine antigens were found in 2 of 15 patients vaccinated 
with wild-type gp100-loaded DCs, versus 1 of 12 patients vaccinated with modified 
peptide-loaded DCs. These 3 patients also had the best clinical response, with 
long-term ( >8 years) complete responses in two patients.
We conclude that vaccination with peptide-loaded DCs can result in long-term 
clinical responses in a minority of metastatic melanoma patients, and that the use 
of modified as compared to wild-type gp100 peptides for DCs loading does not re­
sult in relevant enhanced immune responses.
Dendritic cells (DCs) are well known for ing tumor antigen-loaded DCs as a thera- 
their unique capacity to induce activation peutic vaccine in cancer patients (reviewed 
o f naïve tumor-specific T cells1. They play in ref. 2). We and other laboratories gained 
a critical role in determining the quantity ample experience with monocyte-derived 
and quality o f the immune response to the DCs in clinical immunization protocols3-9. 
antigen. For this reason, a growing number Objective clinical responses and immune 
o f clinical trials have been performed us- responses without significant toxicity have
59
been observed after vaccination with 
tumor-antigen loaded DCs3,4,9. Although 
the clinical outcome o f vaccination studies 
with antigen-loaded DCs are encouraging, 
DC vaccination is at an early stage, and 
several parameters need to be optimized10. 
Several strategies have been employed to 
load DCs with antigen. The availability of 
class I-restricted peptides derived from 
tumor-associated antigens, such as gp100, 
tyrosinase, MAGE, and NY-ESO-1, led to 
the use of peptide-pulsed DCs in anti­
tumor vaccination trials11. However, natu­
ral epitopes are often poorly immuno­
genic. MHC class I binding affinity and 
stability of peptide-MHC complexes at the 
cell surface contributes to the immunogen- 
icity o f a cytotoxic T  lymphocyte (CTL) 
epitope. The sequence at amino acid resi­
dues that are crucial for the interaction 
with HLA or with the specific T cell re­
ceptor (TCR) can be modified in order to 
increase the affinity for MHC class I and 
enhance the immunogenicity o f peptides. 
In addition, modified peptides may in­
crease the repertoire o f CTLs reactive with 
the tumor antigens. For example, we have 
described the altered HLA-A2.1-binding 
gp100:154 epitopes, which have an im­
proved immunogenicity and elicit wild­
type epitope-reactive CTL12. These modi­
fied peptides can subsequently be used for 
the preparation of more effective DC vac­
cines.
Here we compare the capacity o f DCs 
loaded with wild-type gp100 peptides 
(gp100:154 KTWGQYw Qv ; gp100:280 
YLEPGPVTA) or modified gp100 pep­
tid es (g p 1 0 0 :1 5 4  KTW GQ YW A V; 
gp100:280 YLEPGPVTV), to induce an 
immune and clinical response in advanced 
m elanom a patients. The m odified  
gp100:154 peptide with alanine substitu­
tion at position 8 was selected from a 
panel o f modified gp100:154 peptides
based on enhanced MHC class I binding 
and superior immunogenicity compared to 
wild-type peptides in vitro and in vivo in 
HLA-A2.1 transgenic mice12. The modi­
fied gp100:280 peptide with valine re­
placement at position 9 was selected based 
on high binding affinity to HLA-A2.1 and 
enhanced in vitro CTL induction in pe­
ripheral blood lymphocytes (PBLs) of 
HLA-A2.1 + melanoma patients13. CTLs 
raised against both modified gp100:154 
and modified gp100:280 recognized wild­
type gp100 12;13. In this study, metastatic 
HLA-A2.1 + melanoma patients were vac­
cinated with mature DCs loaded with key­
hole limpet hemocyanin (KLH) together 
with tyrosinase peptide and either wild­
type or modified gp100 peptides and im­
mune and clinical responses were moni­
tored.
MATERIALS AND METHODS
Patient criteria
Inclusion criteria were: histologic evidence of 
metastatic melanoma, progressive disease, meas­
urable disease parameters, focal or diffuse expres­
sion of gp100 (mandatory) and tyrosinase (op­
tionally) in at least one metastasis as determined 
by immunohistochemistry, HLA-A2.1 phenotype, 
WHO performance status 0 or 1, and written in­
formed consent. Patients were staged according 
to the 2001 AJCC staging system14. Patients with 
clinical signs of brain metastases, serious con­
comitant disease or a history of second malig­
nancy were excluded. Prior treatment was allowed, 
provided a treatment-free period of at least four 
months was observed and all related toxicity had 
resolved. Approval from the local regulatory 
committee was obtained.
Clinical protocol and immunization schedule
In eligible patients a leukapheresis was performed 
from which DCs were generated. Patients re­
ceived treatment with either wildtype peptides- 
pulsed DCs (wildtype group) or modified 
peptides-pulsed DCs (modified group). The first 
ten patients were included in the wildtype group, 
the next group of patients in the modified group. 
The first vaccination cycle consisted of two parts.
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In the first part, antigen-pulsed DCs were admin­
istered 3 times at bi-weekly intervals, intrave­
nously (i.v.) and intradermally (i.d.). In the second 
part, patients without tumor progression received 
3 monthly i.d. vaccinations with peptides alone 
(100 g) and KLH (2 g) as maintenance treatment 
for further T cell expansion. Prior to each vacci­
nation 80 ml of blood was collected for immuno­
logical monitoring. A clinical response was de­
fined as stable disease of at least 4 months or any 
partial or complete response. Stable disease and 
partial response were defined according to RE­
CIST criteria15. Toxicity was assessed according to 
NCI common toxicity criteria. Progression free 
survival was calculated from the day of the first 
vaccination. Patients were evaluated for response 
after completing the first and second part of the 
protocol and every three months thereafter. Pa­
tients who remained free of disease progression 
were eligible for 2 maintenance cycles, each at six 
months interval and each consisting of 3 bi­
weekly intranodal vaccinations in a clinically 
tumor-free, usually inguinal lymph node region 
under ultrasound guidance with mature DCs, 
pulsed with gp100-, and tyrosinase peptides and 
KLH. Patients who received DCs pulsed with 
wild-type gp100 peptides in the first cycle re­
ceived modified peptide-pulsed DCs in the first 
maintenance cycle and wild-type peptide-pulsed 
DCs in the second maintenance cycle. Patients 
who received DCs pulsed with modified gp100 
peptides in the first cycle received wild-type 
peptide-pulsed DCs in the first maintenance cycle 
and modified peptide-pulsed DCs in the second 
maintenance cycle (figure 1).
DCs: Preparation and characterization
DCs were generated from peripheral blood 
mononuclear cells (PBMC) as described previ­
ously1^ 17. After leukapheresis, PBMC were used 
for the generation of monocyte-conditioned me­
dium (MCM) and plastic-adherent monocytes 
were cultured in X-VIVO 15 medium (BioWhit- 
taker, Walkersville, Maryland) supplemented with 
2% pooled human serum (Bloodbank Rivieren­
land, Nijmegen, The Netherlands), IL-4 (500 U/ 
ml) and granulocyte macrophage colony stimulat­
ing factor (GM-CSF, 800 U/ml) (both from 
Schering-Plough, International, Kenilworth, New 
Jersey). After the addition of KLH (10 g/ml; Cal- 
biochem, San Diego, CA) on day 3-4, autologous 
MCM with prostaglandin E 2 (PGE2, 10 g/ml, 
Pharmacia & Upjohn, Puurs, Belgium) and 10 
ng/ml recombinant TNF- (kindly provided by Dr. 
Adolf Bender, Vienna, Austria) were added on
day 7 (30%, v/v). This procedure resulted in ma­
ture DCs on day 9 as demonstrated by high ex­
pression levels of MHC class I and II, CD80, 
CD83 and CD86 and absence of CD1416.
Cryopreservaton of PBMCs and DCs
PBMCs and DCs were frozen using a cryo 1°C 
freezing container (Nalgene, Rochester, NY, USA) 
which was put in -80°C for 24 hours, in freezing 
medium consisting of 50% XVIVO-15 (5% HS), 
40% human serum albumin and 10% DMSO (fi­
nal concentration, Sigma). Cells were frozen in 1 
ml per vial containing a maximum of 40x106 
cells16. Cells were thawed in a 37°C water bath 
after which the cells were washed once in cold 
medium and once in medium of room tempera­
ture before further use. The recovery of viable 
mature DCs was 65±10%16.
Peptide pulsing
DCs were pulsed with HLA-A2.1-restricted wild­
type peptides, gp100:154-167, gp100:280-288 or 
modified peptides (gp100:154-167 QA, gp100: 
280-288 AV) and wild-type tyrosinase 369-376. 
Pulsing was done directly after harvesting or after 
thawing18-20. On the day of vaccination, we added 
peptides (50 g/ml) for 90 min and kept DCs at 
37°C/5% CO2. Thereafter, fresh peptides (25 g / 
ml) were added and DCs were kept at room tem­
perature for 60 min. After peptide loading, DCs 
were washed twice in 0.9% sodium chloride and 
resuspended in 0.2 ml and 1 ml for i.d and i.v. in­
jections, respectively4.
Antibodies and immunostaining
To characterize and compare the phenotype of 
the DC populations, flow cytometry was per­
formed using either FITC-conjugated or PE- 
conjugated mAbs. The following FITC- 
conjugated mAbs were used: anti-HLA class I 
(W6/32), and anti-HLA DR/DP (Q5/13); and 
PE-conjugated mAbs: anti-CD80 (Becton Dickin­
son, Mountain View, CA), anti-CD14, anti-CD83 
(both Beckman Coulter, Mijdrecht, The Nether­
lands), and anti-CD86 (Pharmingen, San Diego, 
CA). For immunohistochemistry the following 
mAb were used: HMB-45 (Dako, Glostrup, 
Denmark) against gp100 and T311 (Novocastra, 
Newcastle, UK) against tyrosinase.
Delayed type hypersensitivity
One to two weeks after each of the three cycles 
of DC vaccinations a delayed type hypersensitiv­
ity (DTH) skin test was performed6. Briefly, un­
pulsed DCs, DCs pulsed with peptides (tyrosinase
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and/or wildtype gp100:154 plus wildtype 
gp100:280), DCs pulsed with KLH, and DCs 
pulsed with peptides plus KLH (2x105 DCs each) 
were injected i.d. in the skin of the back of the 
patients at four different sites. The diameter (in 
millimeters) of induration was measured after 48 
hours, each time by the same investigator 
(M.J.P.G.), and an induration of more than 2 mm 
was considered positive. From positive DTH sites, 
punch biopsies (6 mm) were obtained under local 
anesthesia. Biopsies were cut in half, one part for 
immunohistochemistry and the other part was cut 
in small pieces and cultured in RPMI/7%HS sup­
plemented with IL-2 (100 U/ml). Every 7 days, 
half of the medium was replaced by fresh IL-2- 
containg RPMI/7%HS. After 2 to 4 weeks of cul­
turing, T cells were tested for antigen recognition 
in a cytotoxicity assay or tested for tetramer bind­
ing.
Humoral response to KLH
Antibodies against KLH were measured in the 
serum of vaccinated patients by ELISA as previ­
ously described30. Briefly, 96-well plates were 
coated overnight at 4oC with the protein KLH (25 
g/ml) in phosphate buffered saline (0.1 ml/well). 
After washing the plates, different concentrations 
of patient serum (range 1 in 100 to 1 in 500,000) 
were added for 1 hour at room temperature. After 
extensive washing, specific Ab (total IgG, IgG1, 
IgG2, and IgG4) labeled with horseradish peroxi­
dase were allowed to bind for 1 hour at room 
temperature. Peroxidase activity was revealed us­
ing 3,3’ 5,5-tetramethyl-benzidine as substrate and 
measured in a microtiter plate reader at 450 nm. A 
positive signal at a 1 in 400 dilution of the pa­
tients’ serum was considered positive.
Proliferative response and cytokine production 
to KLH
Cellular responses against KLH were measured in 
a proliferation assay. Briefly, 1x105 PBMC, iso­
lated from blood samples taken before each vac­
cination, were plated per well of a 96-well tissue 
culture micro plate either in the presence of KLH 
or without. After 16 hours of culture, super- 
natants (50 ^l) were taken and IL-2, IL-4, IL-5, 
IL-10, TN Fa, and interferon (IFN)y were meas­
ured by a cytometric bead array (Th1/Th2 Cyto­
kine CBA 1; BD Pharmingen, San Diego, CA) 
according to the manufacturer’s instructions. Af­
ter 4 days of culture, 1 ^Ci/well of tritiated 
thymidine was added, incorporation of tritiated 
thymidine was measured in a beta-counter. A pro­
liferation index >2 was considered positive.
MHC tetramer staining
Tetrameric-MHC complexes were kindly provided 
by dr. R Luiten and dr. H. Spits from the Nether­
lands Cancer Institute (Amsterdam, The Nether­
lands)21. Each tetramer was validated by staining 
against a CTL line specific for HLA-A2 in asso­
ciation with the peptide of interest.
PBMC (1x105 cells in 10 ^l) were incubated with 
PE-labeled tetrameric-MHC complexes for 1 
hour at RT. After washing the samples were ana­
lyzed by flow cytometry.
Antigen recognition
Antigen recognition was determined by the pro­
duction of cytokines and cytotoxic activity of 
DTH-derived cells in response to T2 cells pulsed 
with the indicated peptides or BLM (a melanoma 
cell line expressing HLA-A2.1 but without en­
dogenous expression of gp100 and tyrosinase), 
transfected with control antigen G250, with 
gp100 or tyrosin ase , or an allogeneic 
H LA -A 2.1-positive, gp100-positive, and 
tyrosinase-positive tumor cell line (MEL624). Cy­
totoxic activity was measured using the chromium 
release assay22. Cytokine production was meas­
ured in supernatants after 16 hours of coculture 
by the cytometric bead array (Th1/Th2 Cytokine 
CBA; BD Pharmingen).
Analysis of T cell frequencies in peripheral 
blood
The presence of tumor antigen-specific CD8+ T 
cells was analyzed using mixed lymphocyte- 
peptide cultures as described previously23. Briefly, 
PBMC isolated before and after DC vaccination 
were thawed, divided over three groups, and in­
cubated for 1 h at room temperature in Iscove’s 
medium (Life Technologies, Carlsbad, CA, USA) 
with 1% HS and 10 M of tyrosinase:369 peptide 
(YMDGTMSQV), wild-type gp100:154 peptide 
(KTWGQYWQV), or wild-type gp100:280 pep­
tide (YLEPGPVVTA). Next, these pulsed cells 
were washed, pooled, and distributed at 2x105 
cells/0.2 ml in round-bottom microwells in Is- 
cove’s with 10% HS, L-arginine (116 mg/L), L- 
asparagine (36 mg/L), L-glutamine (216 mg/L), 
IL-2 (20 U/ml), IL-4 (1.5 ng/ml), and IL-7 (10 
ng/ml). On day 7, 50% of the medium was re­
placed by fresh medium containing IL-2 and wild­
type gp100:154 peptide. Wild-type gp100:280 
peptide was added to the cultures at day 8 and 
tyrosinase: 369 peptide at day 9. Tetramer label­
ling was performed on day 14 as described previ­
ously23.
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Statistical analysis
Data were analyzed statistically by means of 
analysis of variance and Student-Newman-Keuls 
test, or by means of Mann Whitney U nonpara- 
metric statistics. Statistical significance was de­
fined as p<0.05.
RESULTS 
Patient characteristics
Twenty-seven patients were included in the 
study. In the first DC vaccination cycle, 15 
patients received wild-type peptide-pulsed 
DCs (supplementary figure 1, partly previ­
ously reported in ref. 4), and 12 received 
modified peptide-pulsed DCs. The clinical 
characteristics are presented in table 1. 
Median age in the wild-type group was 54 
years (22-73), in the modified group 48 
years (30-70). All patients had perform­
ance status 0, according to WHO criteria. 
Serum lactate dehydrogenase (LDH) was 
elevated in 4 patients in the wild-type 
group and in 4 patients in the modified 
group. According to AJCC criteria 9 pa­
tients had stage M1c, 4 M1b and 2 M1a in 
the wild-type group and 7 M1c and 4 M1b 
in the modified group, respectively. In the 
modified group 1 patient with stage IIIC 
disease was incorrectly included.
Characteristics and number of injected 
DCs
Patients vaccinated with wild-type peptide- 
pulsed DCs received an average o f 27x106 
DCs intravenously (i.v.) and 11x106 DCs 
intradermally (i.d.) per vaccination during 
the first cycle. Patients vaccinated with 
modified peptide-pulsed DCs received an 
average o f 22x106 DCs i.v. and 12x106 
DCs i.d. (table 2). After maturation, DCs 
o f all patients showed a mature phenotype 
with high HLA-ABC, H LA -D R/D P,
HLA-DQ, CD80, CD83, and CD86 ex­
pression (supplementary figure 1). There 
was no difference in the amount of in­
jected DCs (p=0.3 for i.v. injected DCs, 
p=0.7 for i.d. injected DCs) or maturation 
status (p=0.2 to p=0.4), except for CD80 
(p=0.02) and CD83 (p=0.01) that were 
expressed at lower levels in DCs pulsed 
with wild-type peptide.
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Figure 1. Computer Tomography scanning im­
ages of the abdomen of patient mod-4.
The images show multiple liver metastases (upper 
image, arrows), which regressed after the first cy­
cle of DC vaccinations and showed complete re­
mission after the peptide vaccinations (lower im­
age).
Clinical outcome and toxicity
Toxicity was limited to grade I-II fever, fa­
tigue, flue-like symptoms and injection site 
reactions, which always resolved within 2 
days after vaccination.
63
Chapter 4
patien t1 a g e /s e x A JC C -stage localization  m etasta ses L D H respon se P F S  (m)
W ild-type group
wt-1 73/m IV-M1b Lung, skin - PD -
wt-2 56/m IV-M1b Lung - PD -
wt-3 50/f IV-M1c Sc, gut - SD 4.5
wt-4 66/m IV-M1a bulky LN - SD 13
wt-5 35/f IV-M1c Kidney, spleen, LN + SD 4.5
wt-6 54/m IV-M1c Sc, gut - PD -
wt-7 22/m IV-M1c Sc, testicle - SD 4
wt-8 59/m IV-M1c Bulky LN, sc + PD -
wt-9 33/f IV-M1a LN - SD2 >124
wt-10 63/m IV-M1b LN, lung - PD -
wt-11 72/m IV-M1c Liver + SD 8
wt-12 52/m IV-M1a Sc - PD -
wt-13 34/m IV-M1b Lung, LN - PD -
wt-14 56/m IV-M1c Liver - SD 6
wt-15 51/m IV-M1c Lung, sc + PD -
M od ified  group 
mod-1 48 /f IIIC LN, in-transits PD
mod-2 55/f IV-M1c Sc, LN, soft tissue + PD -
mod-3 43/m IV-M1c Sc, LN, soft tissue + PD -
mod-4 31/f IV-M1c Liver - CR >100
mod-5 38/f IV-M1c Lung, liver, sc, LN + PD -
mod-6 64/m IV-M1b Lung - PD -
mod-7 48 /f IV-M1c Skin, liver, LN + PD -
mod-8 47 /f IV-M1b Skin, lung - PD -
mod-9
mod-10
30/m
70/m
IV-M1c
IV-M1c LN, skin, lung, adrenal
PD
PD
-
mod-11 32/f IV-M1b Lung, sc - PD -
mod-12 56/m IV-M1b Lung - SD 4
Table 1. Patient characteristics. 1 Abbreviations: m, male; f, female; sc, subcutaneous; LN, lymph 
nodes; PD, progressive disease; SD, stable disease; CR, complete remission. 2Partial remission of a dis­
tant LN metastasis, CR after surgery for >10 years
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In the wild-type group one patient (wt-9) 
had a 27% reduction in diameter o f a dis­
tant lymph node metastasis, which was re­
sected after the first maintenance vaccina­
tion cycle. This patient completed treat­
ment according to protocol, and is free of 
disease at 10 years of follow up. Six pa­
tients in the wild-type group had stable dis­
ease for at least 4 months (4; 4.5; 4.5; 6; 8 
and 13 months).
In the modified group one patient (mod-4) 
had a complete response o f multiple histo­
logically proven liver metastases after the 
first vaccination cycle (figure 1). This pa­
tient also completed protocol treatment 
and is currently free o f disease at 8 years of 
follow up. One patient had disease stabilisa­
tion o f 4 months duration.
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Figure 2. KLH-specific proliferation of PBMCs 
before and after DC vaccination.
Patients were vaccinated with DCs loaded KLH 
together with tyrosinase peptide and either wild­
type (filled circles) or modified (open circles) 
gp100 peptides. KLH-specific proliferation was 
measured in PBMCs isolated before the first vac­
cination and after one, two, or three vaccinations. 
Proliferative response to KLH is given as prolifera­
tion index (proliferation +KLH/proliferation — 
KLH).
Proliferation and cytokine production 
of PBMCs upon stimulation with KLH
To investigate whether DCs loaded with 
modified or wild-type gp100 peptides 
have similar capacity to activate the pa­
tient’s immune system in general, humoral 
and cellular responses to the control pro­
tein KLH were measured in the periph­
eral blood o f patients after each cycle of 
vaccination. Most patients mounted a po­
tent proliferative and antibody response 
against KLH (table 2). KLH-specific IgG 
antibodies were induced after vaccination 
in 8 of 14 patients tested (57%) in the 
wild-type group and in 6 o f 11 patients 
tested (55%) in the modified group. 
PBMCs collected after each DC vaccina­
tion were analyzed for the presence of 
KLH-reactive T cells in a proliferation as­
say. In the wild-type group 13 out o f 14 
patients tested showed a cellular response 
to KLH, whereas in the modified group a 
cellular response was induced in all pa­
tients (table 2). The magnitude o f KLH- 
specific proliferation was similar in the 
wild type and modified group (figure 2). 
There were no significant differences be­
tween the groups at any time-point after 
vaccination (p=0.3 before vaccination; 
p=0.6 after vaccination 1; p=0.6 after 
vaccination 2; p=0.2 after vaccination 3). 
Interestingly, the patient that had no pro­
liferative response (patient wt-8) did show 
an antibody response to KLH. Thus, all 
patients developed a response to KLH, 
either cellular or humoral, and there are 
no differences in KLH-specific immune 
responses after vaccination with DCs 
loaded with wild-type or modified gp100 
peptides.
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patien t no. in jected  D C s (x106) (i.v ./i.d .)
Vacc 1 Vacc 2 Vacc 3
proliferative 
respo nse  
ag a in st K L H 1
h um oral re­
sp o n se  (IgG ) 
ag a in st K L H 2
tetram er positive 
C D 8 +  T  cells in 
D T H 3
W ild-type group
wt-1 l2 / l0 l2 / l2 l0 / l0 + + + + -
wt-2 70/2S S 0 /l7 Ó0/30 + + + + -
wt-3 30/l4 lS /S 20 /l0 + + + + nt
wt-4 36/l2 lS /S 24 /l2 + + + + +4a
wt-S S0/lS l7 /S 30 /lS + + + - -
wt-ó lS /7 2Ó/9 l3 / l3 + + -
wt-7 22/4 30/S SS/7 + + + nt
wt-S 4S /lS 34/Ó S0 /l3 - + nt
wt-9 30/7 30/S 30/l0 + + + + +  4b
wt-l0 33/lS l9 / l2 27 /lS + + + + -
wt-11 l3 /6 2 2 / l l lÓ/S + - -
wt-l2 22/l3 - - nt nt nt
wt-13 2 2 / l l lS /S l3 /7 + + + - -
wt-l4 26/l3 24 /l2 2 3 / l l + + + - -
wt-lS 30/lS 20 /l0 20 /l0 + - nt
M odified group
mod-l 20 /l0 lÓ/S 24 /l2 + + + + -
mod-2 26 /l2 23 /l2 2 2 / l l + + + - no
mod-3 27 /l4 3S /l9 3l/lÓ + - -
mod-4 lÓ/S l4 /7 l4 /7 + + + + +4a
mod-S 20/20 2Ó/l3 30 /lS + + + - nt
mod-6 Ó0/2S 2Ó/l3 30 /lS + + + nt
mod-7 l7 /S l2/Ó l0 /S + + + + nt
mod-S 30/l4 2 0 / l l 2 3 / l l + + + - no
mod-9 l l / l l - - nt nt nt
mod-l0 43/22 2 S /l2 2Ó/l2 + + + + -
m od-ll l7 /9 lS /S lS /7 + - -
mod-l2 24 /l2 lS /S l7 /9 + + + + no
ÓÓ
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Table 2. Vaccine-induced antigen-specific im­
mune responses (previous page). Proliferative 
response to KLH is given as proliferation index 
(= proliferation +K L H /—KLH). + 2>prolifera- 
tion index (PI)<10; + +  10>PI<20; + + +  PI>20, 
at least one time point after vaccination. 2Anti- 
body titer, total IgG, + designates >1 in 400 times 
diluted serum. 3Presence of functional tetramer­
positive T cells in DTH is marked as +; 4aAg- 
recognition of DTH derived T cells after stimula­
tion with T2 cells loaded with the gp100 or ty­
rosinase peptides (peptide recognition), BLM 
transfected with the antigens (protein recognition) 
or a gp100 and tyrosinase-expressing tumor cell 
line (tumor recognition) as analyzed by IFNg- 
production; 4bAg-recognition analyzed by cyto­
toxic activity (chromium release assay). Abbrevia­
tions: i.v. intraveneously; i.d. intradermally; no, no 
outgrowth or outgrowth of less than 1x105 DTH 
infiltrating lymphocytes; n.t. not tested
These results indicate that the immuno- 
genicity o f the DCs were comparable for 
both groups and therefore a possible dif­
ference in gp100 T cell reactivity upon 
vaccination between the two groups is un­
likely to be the result o f differences in the 
preparation and administration o f the 
DCs.
Tumor antígen-specific T cell responses 
in post-treatment DTH
To investigate the immune response 
against tumor peptides generated in vacci­
nated patients, DTH challenges were per­
formed with mature DCs loaded with ty­
rosinase and/or wild-type gp100 peptides. 
For patients receiving a second and third 
cycle o f vaccination, the best immuno­
logical response over all received cycles of 
vaccinations was scored. In the group of
patients vaccinated with wild-type peptide- 
loaded DCs, 11 o f 13 patients tested 
(85%) showed indurations up to 22 mm 
against DCs pulsed with KLH  and/or 
peptide. In the group vaccinated with 
modified peptide-loaded DCs, 9 o f 10 pa­
tients tested (90%) showed indurations up 
to 23 mm against DCs pulsed with KLH 
and/or peptide. Biopsies were taken from 
DTH induration sites, which were cul­
tured in low amounts o f IL-2 without the 
addition of antigen. Outgrowth o f DTH- 
infiltrating lymphocytes occurred in all 
the biopsies taken from patients treated 
with wild-type gp100, whereas only 63% 
of the biopsies in the modified group 
showed DTH-infiltrating lymphocytes 
outgrowth. The lack of outgrowth oc­
curred in all different DTH, there was no 
preference for a DTH induced with a cer­
tain peptide. From 9 patients in the wild­
type group sufficient T cells were available 
after short time culture (i.e. 2-4 weeks) to 
perform tetramer staining and functional 
assays (table 2). Biopsies o f two patients 
(wt-4 and wt-9) contained gp100- and 
tyrosinase-tetramer positive CD8+ T cells 
that recognized gp100 or tyrosinase pep­
tide and protein (previously shown in ref. 
4). Tetramer staining and functional assays 
could be performed on DTH-infiltrating 
lymphocytes o f four patients in the modi­
fied group. Only T cells derived from bi­
opsies o f patient mod-4 contained tetra­
mer positive CD8+ T cells (figure 3a). 
These CD8+ T cells recognized gp100 or 
tyrosinase peptides, however, not the 
complete protein (figure 3b).
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Figure 3. Tumor antigen-specific T cell responses in post-treatment DTH. (a) Tetramer analysis by 
flow cytometry of T cells derived from a biopsy of positive DTH reaction (DCs loaded with KLH and 
peptides gp100:154, gp100:280 and tyrosinase) o f patient mod-4. Tetramer staining o f 1 log above the 
negative population was considered positive. (b) IFN production by T cells o f patient mod-4 derived 
from a biopsy of a positive DTH site (DCs loaded with peptides gp100:154, gp100:280 and tyrosinase) 
cocultured with T2 cell pulsed with gp100 peptides or tyrosinase peptides.
Thus, although the majority of patients in 
both the wild-type and modified group 
showed DTH-infiltrating lymphocytes at 
DTH  sites, we could detect specific and
functional CD8+ T cells in only one pa­
tient in the modified group and two pa­
tients in the wild-type group. Interestingly, 
these three patients also showed the best 
clinical outcome, with progression-free 
survival ranging from 13 (wt-4) to >124 
(wt-9) months. In com parison, the 
progression-free survival of the patients 
without specific T cell reactivity in DTH 
sites ranged from 0 to 8 months.
Tumor antigen-specific T cell responses 
in peripheral blood
The presence of gp100- or tyrosinase- 
specific CD8+ T cells in blood was studied 
in 8 patients in the wild-type group by tet­
ramer staining (data not shown). Although 
we detected gp100- and tyrosinase-specific 
CD8+ T cells in patient wt-4 by tetramer 
analysis, these T cells did not recognize 
gp100 or tyrosinase peptides or protein as 
determined by IFN production upon co­
culture with gp100/tyrosinase-loaded tar­
get cells. We could not detect tumor
antigen-specific T cells in blood of the 
other patients tested.
The frequencies of antigen-specific T cells 
in blood are generally very low, and often 
we were unable to detect antigen-specific 
T cells in peripheral blood by direct tetra­
mer staining, while functional tumor 
antigen-specific T cells were present in bi­
opsies taken from DTH challenges6. To 
further examine anti-gp 100 and anti­
tyrosinase CTL responses, we analyzed 
precursor frequencies of tumor antigen- 
specific CD8+ T cells in peripheral blood 
before and after one cycle of three bi­
weekly DC vaccinations23. These studies 
were performed in the three clinically re­
sponding patients with specific T cells in 
the DTH biopsies (wt-4, wt-9, mod-4) and 
in three non-responding patients (wt-5, 
mod-7, mod-12). Before vaccination, 
CTLp frequencies ranged from 1.7/107 to 
1.6/105 of total blood CD8+ T cells (fig­
ure 4). CD8+ T cells directed against 
gp100:154 showed the highest frequencies 
in both clinical responders and non­
responders before vaccination.
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Fig. 4 Frequencies of tumor antigen-specific CD8+ T cells in peripheral blood. CTLp frequencies 
were analyzed in peripheral blood of three DTH-responders (patients mod-4, wt-4, and wt-9) and three 
non-responders (patients mod-7, mod-12, and wt-5) before vaccination and after one cycle of three 
DC vaccinations by in vitro restimulation of PBMCs with antigenic peptides in limiting dilutions fol­
lowed by tetramer analysis. CTLp frequencies could not be tested (NT) in patient wt-5 after vaccination 
due to lack of outgrowth after peptide stimulation.
After DC vaccination, frequencies of 
gp100:154- and tyrosinase-specific CTLs 
increased in all three responders, up to 31­
fold, whereas frequencies of gp100: 280- 
specific CTLs increased only in patients 
mod-4 and wt-4. CTLp frequencies of 
non-responders increased only modestly 
after DC vaccination. Thus, the increase of 
peripheral blood T cel precursor frequen­
cies correlate with the presence of tumor 
antigen-specific T cells in DTH biopsies 
upon vaccination.
DISCUSSION
In this study we compared mature DCs 
loaded with wild-type or modified gp100 
peptides in their ability to induce immuno­
logical and clinical responses in metastatic 
melanoma patients. Although the number 
of patients in our study is limited, we ob­
served no obvious advantage for the use 
of modified versus wild-type peptides in 
either endpoint.
Since both groups of patients were vacci­
nated with DCs that were matured and 
loaded with KLH  in a similar way, no dif­
ferences in KLH  responses were expected. 
Indeed, patients vaccinated with wild-type 
or modified gp100 peptides showed simi­
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lar cellular and humoral responses to the 
control protein KLH. In addition, indura­
tions in DTH challenges were comparable 
in both groups. As reported before, indu­
ration was not predictive for clinical out- 
come6. Outgrowth of DTH biopsies oc­
curred more often in the wild-type group 
than in the modified group. In both the 
wild-type group and the modified group 
DTH challenges were performed with
wild-type gp100 peptides. This may ex­
plain the lack of outgrowth in the modi­
fied group, although lack of outgrowth 
occurred not only in DTH challenges per­
formed with gp100 peptides, but also in 
DTH challenges performed with tyrosi­
nase peptide.
We observed tumor-specific T cells in 
DTH biopsies of only three patients, two 
vaccinated with wild-type peptides and one 
vaccinated with modified peptides. In one 
patient vaccinated with modified peptides 
during the first cycle, the best immuno­
logical response was found after the sec­
ond cycle of DC vaccinations with wild­
type peptide-loaded DCs. Interestingly, the 
best clinical outcome was observed in 
these three patients in whom tumor- 
specific T cell responses o f DTH-
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infiltrating lymphocytes were observed. 
This is in accordance with our previous 
findings that the presence o f tumor- 
specific T cells in DTH biopsies correlates 
with clinical outcome6.
For other modified peptides (gp100:209- 
217 and MART:26-35) it has been de­
scribed that only a minority (~15-25%) of 
T cells raised against modified peptides 
cross-reacts with the wild-type epitope24;25. 
However, for modified gp100:154 and 
gp100:280 we and others have demon­
strated that in vitro and in HLA-A2.1 
transgenic mice that CTLs raised against 
modified peptides recognized wild-type 
peptides12;13. Our CTLp frequency analy­
sis, which was performed with wild-type 
gp100 peptides, showed no differences in 
T cell expansion between the wild-type 
and m odified group in the D TH - 
responders. All three patients showed in­
creased precursor frequencies o f gp100: 
154-specific CTLs. Two o f these patients, 
one vaccinated with wild-type and one 
with modified peptides, showed a compa­
rable increase in gp100:280-specific CTLs 
after one round o f DC vaccinations. This 
suggests that vaccination with modified 
peptide raised CTLs cross-reacting with 
wild-type tumor antigens.
Recently, Speiser et al.26 demonstrated that, 
although vaccination with modified pep­
tides resulted in higher T cell frequencies 
than vaccination with natural wild-type 
peptides, these T cells have lower tumor 
reactivity as demonstrated by lower avidity 
for the natural antigen and decreased T 
cell activation and effector function. This 
is in contrast with previous in vitro and 
mouse studies demonstrating that CTLs 
raised against modified peptides could 
recognize both wild-type and modified 
peptides as well as gp100-expressing mela­
noma cells12;13. However, based on the re­
sults o f Speiser et al, it may be beneficial
to first vaccinate patients with mature DCs 
loaded wild-type peptides, which activates 
CTLs with strong tumor reactivity, fol­
lowed by injection with mature DCs 
loaded with modified peptides in the sec­
ond round of vaccination to improve ex­
pansion o f these CTLs, thus inducing high 
number o f functional tumor antigen- 
specific CTLs.
In conclusion, vaccination with peptide- 
loaded DCs results in clinically meaningful 
responses in a minority o f metastatic 
melanoma patients, however, the use of 
modified as compared to wild-type gp100 
peptides for DC loading does not result in 
relevant enhanced immune responses.
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Vaccination of colorectal cancer patients with CEA-loaded 
dendritic cells: antigen-specific T cell responses in DTH skin tests
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Dendritic cells (DCs) are the professional antigen-presenting cells of the immune 
system. As such they are currently used in clinical vaccination protocols in cancer 
patients. We evaluated the ability of mature DCs pulsed with carcinoembryonic 
antigen (CEA)- peptide to induce CEA-specific T cell responses in patients with re­
sectable liver metastases from colorectal cancer. CEA-specific T cell reactivity was 
monitored in peripheral blood, biopsies of vaccination sites and post-treatment 
DTH skin tests, and when available also in resected abdominal lymph nodes and 
tumor tissue.
Ten patients were vaccinated intradermally and intravenously with CEA-peptide 
pulsed mature DCs three times prior to resection of liver metastases. High num­
bers of CEA-specific T cells were detected in post-treatment DTH biopsies in seven 
out of 10 patients, which produced high amounts of interferon (IFN)-y upon stimu­
lation with CEA-loaded target cells. These responses were not found in biopsies of 
first vaccination sites, indicating a de novo T cell induction or at least a strong po­
tentiation by the vaccine. In addition, CEA-specific T cells were detected in a re­
sected lymph node in one patient, but not in peripheral blood or tumor tissue. 
Thus, vaccination with CEA-peptide loaded mature DCs induced potent CEA- 
specific T cell responses in advanced colorectal cancer patients. In this study, 
antigen-specific T cell responses were readily detected in DTH skin tests, much less 
in abdominal lymph nodes, and not in peripheral blood and tumor tissue.
Although progress has been made in the tential for cancer immunotherapy4. DC
treatment o f metastatic colorectal cancer vaccination has shown to be feasible and
using chemotherapy and targeted thera- safe, and both immunological and clinical
pies, clinical outcome remains poor1. Im- responses have been reported5. Most clini-
munotherapy forms an alternative ap- cal studies using DCs have been per-
proach for the treatment o f colorectal formed in melanoma patients6. Only a few
cancer2,3. Dendritic cells (DCs) are the small studies investigated the immunogen-
professional antigen-presenting cells o f icity of DC vaccines in colorectal cancer
the immune system. They are essential for patients with variable results7-13.
the induction o f antigen-specific T cell The majority of clinical studies in cancer
immunity and as such they have great po- patients have been carried out using imma-
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ture rather than mature DCs. We, as well 
as others, have demonstrated in compara­
tive studies that only mature DCs are able 
to stimulate T cell responses14-16. These 
findings should be considered when inter­
preting recent negative clinical trials com­
paring immature DCs with other vaccina­
tion modalities17,18. Other pivotal ques­
tions, including the optimal DC culture 
method, dose, route o f administration, 
etc., remain unanswered to date. To start 
to address these questions in small cohorts 
of patients, there is a need of validated as­
says that can monitor immunological out­
come, since clinical responses occur in 
only a minority o f patients. Most studies 
so far have focused on the monitoring of 
antigen-specific T cell responses in periph­
eral blood which, however, often requires 
in vitro restimulation due to low precursor 
frequencies. Tumor tissue and lymph 
nodes would be more interesting com­
partments to monitor these responses, but 
these tissues are often not available. We 
recently described a novel method of 
monitoring antigen-specific T cell re­
sponses: a short culture o f biopsies of 
post-treatment delayed type hypersensitiv­
ity (DTH) reaction sites allowed a detailed 
analysis o f tumor antigen-specific CD8+
T cell responses in stage IV melanoma pa­
tients19. We found that the presence of 
vaccine-induced melanoma-specific T cells 
in these biopsies significantly correlated 
with an improved clinical outcome. 
Carcinoembryonic antigen (CEA) is ex­
pressed in almost all colorectal cancers, 
making it an attractive antigen for immu­
notherapy in patients with this tumor type 
20. Here, we investigated the immunogenic- 
ity o f CEA-peptide loaded mature DCs in 
colorectal cancer patients with resectable 
liver metastases. This model provided the 
unique opportunity to rigorously monitor 
and compare immune responses after vac­
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cination in several relevant compartments 
of the body: peripheral blood, lymph 
nodes, tumor tissue and biopsies o f DTH 
skin tests and vaccination sites.
MATERIALS AND METHODS
Study design
This was an open-label, single-institution, single­
arm exploratory study in which monocyte-derived 
mature D Cs loaded with CEA-peptide were ad­
ministered to patients with resectable liver metas­
tases o f colorectal cancer (figure 1A). Approval 
from the local regulatory committee was ob­
tained.
Objectives
The primary end point was to assess the immu- 
nogenicity o f  the vaccine. Secondary end points 
were the toxicity and the feasibility o f  CEA- 
specific vaccination in colorectal cancer patients 
and, specifically, the feasibility o f  using DTH - 
infiltrated lymphocytes in the monitoring o f T  
cell responses in comparison with other relevant 
body compartments.
Patents
Inclusion criteria included: patients with liver me­
tastases from CEA-expressing colorectal cancer 
scheduled for surgical resection, HLA-A0201 
phenotype, Eastern Cooperative Oncology Group 
(ECO G) performance status 0—1, age >18 years, 
no clinical signs o f extra-hepatic metastases, no 
prior chemotherapy, immunotherapy or radio­
therapy within 2 months before planned surgery.
DC preparation
D Cs were generated as described previously15, 21 
with several modifications (figure 1a). Patients 
donated 0.5 l blood, from which a buffycoat was 
made (Sanquin Bloodbank Nijmegen, the Nether­
lands). Peripheral b lood m ononuclear cells 
(PBMCs) were isolated by PureCell (Medicult, 
Denmark) density gradient centrifugation (30 
min, °4C, 2100 rpm), adherent monocytes were 
cultured in Cellgro medium enriched with 500 U / 
ml interleukin (IL)-4 and 800 U /m l granulocyte 
macrophage colony stimulating factor (GM-CSF, 
all CellGenix, Freiburg, Germany). K L H  (10 ^ g /  
ml; Calbiochem, USA) was added at day 3 o f  cul­
ture, and 2 days before harvesting we added the 
maturation cocktail [IL-4 (500 U/m l), GM -CSF 
(800 U/m l), prostaglandin E 2 (PGE2; Pharmacia 
& Upjohn, Puurs, Belgium, 10 ng/m l), tumor ne­
crosis factor alpha (T N F-a, 10 ng/m l), IL-1b (5 
^g/m l) and IL-6 (15 ng/m l; all CellGenix)]. Cells
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were harvested at day 7 and approximately 25% 
o f the cells were put in a syringe for immediate 
vaccination; the remaining cells were frozen for 
the second and third vaccination and the D T H 22. 
From each batch o f patient DCs, a sample was 
used for quality control. Release criteria were as 
previously described5. D Cs were pulsed with the 
wild type CEA-peptide CAP-1 (CEA571—579, 
Y LSG A N L N L, Clinalfa, Switzerland)23 directly
after harvesting or after thawing15,22.
Treatment schedule
Vaccinations were administered three times at day 
0, 7 and 14 (figure 1a). The patients received 5 
x106 D Cs intradermally (i.d.) in the upper leg, 5— 
10 cm from an inguinal lymph node. The remain­
ing cells were given intraveneously (i.v.) as a bolus 
injection at the same time point. I f  the patient 
consented, a biopsy was taken from the first vac­
cination site at day 7. On day 26 a post-treatment 
D T H  test was performed (see below). At day 28, 
surgical resection o f the liver metastases was per­
formed. During the operation an accessible ab­
dominal lymph node was excised and 6 mm 
punch biopsies were taken from the post­
treatment D T H  reaction sites. Before and after 
vaccination PBM Cs were obtained. The same 
schedule o f 3 weekly i.v./i.d. vaccinations fol­
lowed by a post-treatment D T H  was repeated 
twice at intervals o f  6 months in the absence o f 
recurrent disease.
Immunologic monitoring
C D 4+  T  cell responses against K L H  were meas­
ured using a 3H-thymidine incorporation prolif­
eration assay with PBM Cs o f  the patients before 
and after vaccination15. The index was calculated 
as the counts ratio between KLH-stimulated 
PBM C and non-stimulated PBMC. Post-treatment 
D T H  reactions were performed as described pre­
viously19. Briefly, CEA-peptide only (100 ng in 
100 nl), D Cs pulsed with CEApeptide, DCs 
pulsed with K LH  and CEA-peptide, and DCs 
pulsed with K L H  only (0.4—5x105 D Cs each in 
approximately 100—200nl) were injected i.d., 5—10 
cm from an inguinal lymph node at different sites, 
in the upper leg controlateral from the leg in 
which the D C vaccinations were performed. The 
maximum diameter o f induration was measured 
after 48 h. T  cell culture from D T H  biopsies was 
performed in low dose IL-2 (100 U /m l; Pro-
leukin, Chiron, the Netherlands) for approxi­
mately 2 weeks without ex vivo restimulation with 
antigen as described before19.
Resected lymph nodes were disrupted and cell 
suspensions were made by gentle squeezing in a 
sterile open filter chamber (NPBI; Amsterdam, 
the Netherlands) in IM DM  medium (Invitrogen; 
Paisly, UK) supplemented with 5% human serum 
(Sanquin; Nijmegen, the Netherlands). The cell 
suspension (2x106) was plated on a 24-well plate 
(Costar Badhoevedorp, the Netherlands; 5x105 
cells/well), preincubated with sterile anti-CD3 
ascites 16A9. When the cells were seeded, 1 ng 
sterile an ti-C D 28  (Im m unotech, M arseille, 
France) in 1 ml R PM I/7%  human serum was 
added. After 1 day medium was added, containing 
IL-2 (100U/nl), which was repeated every 3 days. 
T  cells were tested after 1—2 weeks o f culture. 
Tumor-infiltrating lymphocytes (TILs) were ob­
tained and cultured according to the same proto­
col as the lymph node cell suspension (see above). 
DTH-derived cells (1x105 cells in 10 nl) or PBM C 
(1x106 cells in 10 nl) were incubated with PE- 
labeled C E A  and cytom egalovirus (CMV) 
tetrameric-MHC complexes (Sanquin; Amster­
dam, the Netherlands) for 60 min at room tem­
perature. In the last 20 min o f this incubation, 
fluorescein isothiocyanate (FITC)-conjugated 
monoclonal antibodies directed against CD 8 
(Becton Dickinson) were added. After washing, 
the samples were analyzed by flow cytometry. For 
peripheral blood at least 1x106 PBM Cs were ana­
lyzed, for DTH-infiltrating T  cells all available 
cells were analyzed. In all analyses C E A  tetramer 
staining was compared with CM V tetramers as a 
negative control.
Production o f  cytokines by the total population 
o f DTH-derived cells was measured in response 
to T2 cells pulsed with CEA-peptide or an irrele­
vant HLA-A2.1 binding peptide (tyrosinase or 
G250). Cytokine production was measured in su- 
pernatants after 16h by cytometric bead array 
(Th1/Th2 Cytokine CBA 1; B D  Pharmingen). 
IFN-y production was considered positive when 
IFN -y levels o f  DTH-infiltrating T  cells were 
more than 10-fold higher after co-incubation with 
C E A -load ed  T 2 cells com pared  with co ­
incubation with T2 cells loaded with irrelevant 
antigen.
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Figure 1. (a) Treatment schedule, (b) KLH-specific proliferation of PBMC before and after 
vaccination. In all patients a clear KLH-specific proliferative response was observed after vaccination. 
One representative patient (patient 1) who received three vaccination cycles is shown.
Patient evaluation
Clinical follow-up consisted o f history, physical 
examination, serum CEA-level, CT scanning o f 
the liver and X-ray o f  the chest at 3-month inter­
vals.
RESULTS 
Patients
Ten patients were included (Table 1). Me­
dian age was 60 years (range 44—78); all pa­
tients had a performance status o f WHO 
0. Baseline serum CEA levels were ab­
normal in seven patients (median 17 [A.g/1, 
range 5.8—36.6). Six patients had synchro­
nous liver métastasés, four had metachro­
nous liver métastasés with intervals o f 9, 
10, 15 and 22 months, respectively, since 
surgery for the primary tumor.
Clinical outcome and toxicity
Toxicity consisted of mild flu-like symp­
toms. One patient (patient 5) had grade 2 
diarrhea after the third vaccination during 
3 days, which subsided following lopera­
mide treatment. O f the 10 vaccinated pa­
tients, one showed evidence of lung mé­
tastasés shortly before surgery (patient 5; 
table 2), upon which the procedure was 
cancelled, DTH biopsies were obtained,
and the patient received chemotherapy. 
The remaining nine patients underwent 
surgery. Three appeared to have irresecta- 
ble disease during surgery (patients 2, 3 
and 10; table 2), surgery was aborted and 
patients received chemotherapy. Radical 
resection was performed in six patients. 
One of these (patient 7; table 2) had a re­
lapse after 3 months. All other patients 
have no evidence of disease after a median 
follow-up of 14 months (range 3—23 
months). To date, four patients have re­
ceived additional vaccination cycles for 
maintaining immune responses (patients 1, 
4, 6 and 8; table 2).
DC vaccine characteristics
In all patients sufficient amounts o f buffy- 
coat monocytederived mature DCs could 
be obtained for three i.d. vaccinations (ta­
ble 1). However, the yield was not always 
sufficient for simultaneous i.v. injections 
(see, for example, patient 1 or 5 in Table 
1). Final DC vaccine products met the cri­
teria o f a mature phenotype5’15. All pa­
tients had a proliferative peripheral blood 
CD4+ T cell response against the control 
protein KLH, as expected for a mature 
DC vaccine15, indicating that the DCs were 
able to induce de novo T cell responses.
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Patient N u m b e r  o f  v accin ated  D C sa
In d uration  (m m )
V accin ation  sites b
In d uration  (m m ) 
Post-treatm ent D T H  sk in  te sts
V ac I V ac II V ac I II I II III C E A -pep D C + K L H D C + C E A D C + C E A +
K L H
5/8 5/0 5/0 0 5 5 0 nd 4 0
1 5/3 5/2 5/0 5 12 25 0 nd 5 9
2 5/14 5/10 5/10 8 15 14 0 10 8 12
3 5/7 5/9 5/10 1 + 15 0 10 5 10
4 3/0 3/0 4/0 11 15 15 13 nd 18 nd
5 5/5 5/0 5/4 + + + 0 10 9 11
6 5/3 5/2 3/0 + + 20 0 nd 5 9
7 5/5 5/5 5/5 + 4 11 0 15 14 15
8 5/10 5/10 5/10 12 12 18 6 9 12 14
9 4/0 5/0 5/0 0 20 25 0 12 10 15
Table 1. Number of DCs injected per vaccination and induration (mm) of vaccination sites and 
post-treatment DTH skin tests aCell numbers are given in 106, intradermally/intraveneously. bIn some 
cases the exact induration was not noted in the chart: if  a palpable induration was found, this is indi­
cated with a + . CEA-pep, CEA-peptide; ND, not done.
The results o f a representative patient who 
received three vaccination cycles are 
shown in figure 1b.
CEA-responses in blood, tumor tissue 
and lymph nodes
In none o f the patients could an increase 
in CEA-specific T cells be detected in un­
stimulated peripheral blood by direct tet­
ramer analysis (table 2). CEA-specific T 
cells were observed in one patient, how­
ever, these cells were also present before 
vaccination
(supplementary figure 1d-e; patient 5). In 
five out o f the nine patients who under­
went resection of the metastases, low 
numbers o f TlLs were obtained. No spe­
cific anti-CEA or antitumor reactivity was 
observed by tetramer analysis and cytokine 
secretion (table 2). In five patients an ab­
dominal lymph node was resected: a coe- 
liac node (patient 1), a mesenteric node 
(patients 2 and 4) and a node o f the hepa­
toduodenal ligament (patients 3 and 6). In
one o f the hepatoduodenal ligament 
nodes, which are considered the tumor- 
draining lymph nodes in case o f liver me- 
tastases24, a clear population o f CEA- 
specific T cells was detected (patient 3, ta­
ble 2, figure 2c). These T cells were able to 
produce IFN-y and IL-2 when co-cultured 
with CEA-peptide loaded T2 target cells 
(figure 2c). In the other four patients, in 
whom a lymph node could be resected, no 
CEA-specific T cell reactivity could be ob­
served (table 2).
Post-treatment DTH: induration
The induration sizes o f the vaccination 
sites and the post-treatment DTH reaction 
skin tests that were performed with CEA- 
peptide alone or DCs loaded with CEA- 
peptide, KLH or both, are listed in table 1. 
Several trends are noteworthy. The first 
vaccination already induced induration in 
eight o f 10 patients, suggesting that in 
these patients some form o f immunity 
against CEA already existed before vacci­
nation.
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Figure 2. Tetramer analysis and CEA- 
specific cytokine production of all pa­
tients that had specific T cells in at least 
one of their DTH-sites. In all cases per­
centages shown in the tetramer analyses 
figures are percentages o f  tetramer posi­
tive cells o f  the C D 8+ T  cell populations. 
In the cytokine secretion figures, white 
bars are IFN-y secretion and black bars 
are IL-2 secretion upon co-culture with 
T2 cells, loaded with CEA  or an irrelevant 
peptide. For all tetramer analyses CMV 
tetramers were used as a control, which 
were all negative (not shown).
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Secondly, in all patients induration size in­
creased after subsequent vaccinations. 
Thirdly, the induration at the third vaccina­
tion site was usually larger compared with 
the induration at the post-treatment DTH 
sites, which were performed with lower 
numbers o f the exact same CEA and 
KLH-loaded DCs (5x106 versus 0.05— 
0.5x106 DCs, respectively). Fourthly, post­
treatment DTH skin tests that were per­
formed with CEA-peptide alone induced 
induration in only two o f 10 patients. 
These results suggest that the (amount of) 
DCs are o f importance for induration to 
occur.
Post-treatment DTH: CEA-specific T cell 
immunity
In seven out o f 10 patients, CEA-specific 
DTH-infiltrated T cells were detected after 
vaccination by tetramer analyses. O f all 
patients that had specific T cells in at least 
one o f their DTH-sites an example is 
shown in figure 2a—h. In table 2 the pres­
ence or absence o f CEA-specific T cells 
after vaccination is given per DTH-site for 
each patient. We found 0.3% (figure 2e) up 
to 98% (figure 2g) o f CD8+ T cells to be 
CEA-specific in these DTH biopsies. 
When these T cells were co-cultured with 
CEA-peptide loaded T2 target cells they 
were able to produce large amounts of 
IFN-y and IL-2 (figure 2a—h), but not IL-4 
or IL-10 (not shown).
In none o f the five patients in whom a bi­
opsy from the first vaccination site was 
performed, CEA-specific T cell reactivity 
was found (table 2; patients 5—7, 9 and 10), 
despite the presence of induration in four 
o f these patients (table 1; patients 5—7 and 
9). This suggests that a possible pre­
existing CEA-specific T cell reactivity did 
not have the potency to result in T cell 
outgrowth from the biopsy. However, in
two o f these patients CEA-specific T cells 
were readily detected in DTH skin tests 
after treatment (patients 5 and 6; table 2, 
supplementary figure 1).
In a patient with a history of CMV- 
infection, we found high numbers of 
CMV-specific T cells in peripheral blood, 
but not in a biopsy of a positive DTH re­
action skin test (supplementary figure 2a- 
b). In this patient, no CEA-specific T cells 
could be detected in peripheral blood, but 
a large population was readily detected in 
the DTH biopsy (supplementary figure 2c- 
d), demonstrating the specificity o f the 
DTH assay.
DISCUSSION
We vaccinated 10 patients with liver metas- 
tases o f colorectal cancer with CEA 
peptide-pulsed mature monocyte-derived 
DCs prior to liver metastasectomy. 
Antigen-specific T cell responses were 
monitored in peripheral blood, T cell cul­
tures from biopsies o f vaccination sites 
and post-treatment DTH skin tests that 
were performed in skin sites remote from 
the injection sites, and when available also 
in abdominal lymph nodes and tumor tis­
sue.
We here demonstrate that (1) mature 
CEA-peptide pulsed DCs induce potent 
CEA-specific T cell responses, (2) vaccina­
tion with buffy-coat derived, monocyte- 
derived DCs is feasible and (3) monitoring 
antigen-specific T cells in post-treatment 
DTH skin tests proved more sensitive 
when compared with blood, abdominal 
lymph nodes and tumor tissue.
Functional CEA-specific T cells in short 
cultures o f posttreatment DTH biopsies 
without in vitro restimulation could be 
demonstrated in 7 out of 10 patients.
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P ost-treatm ent D T H  C lin ical ou tcom e
p atien t 1st vac. C E A -pep D C + K L H D C + C E A D C + C E A + K L H L N  b lood T u m o r (duration)
1a nd nd nd + + - - - NED (21 months)
2 nd nd - + +  b - - - Irresectable
3 nd nd - + - + - - Irresectable
4 nd nd - + + - - - NED (16 months)
5 - + - + nd ne - ne Lung metastases prior to surgery
6 - + - + - - - - NED (12 months)
7 - - - - - ne - - Relapse (3 months)
8c nd - nd + + ne - - NED (10 months)
9 - - - - - ne - - NED (3 months)
10 ne - Irresectable
Table 2. CEA-specific T cell responses after vaccination. The presence o f  CEA-specific T  cells was 
scored positive (+) if  both tetramer analysis and IFNy release after co-incubation with CEA-loaded 
target cells were positive. Data from the first vaccination cycle are given. The criteria for determination 
o f positive immune responses are described in patients and methods. Grey cells denote results o f 
which the details are given in figure 2. a In this patient data from the D T H  o f the second cycle are 
given. The first post-treatment DTH-culture was not evaluable. b 3rd vaccination site. c In this patient 
data from the D T H  o f the second cycle are given. The first post-treatment DTH-culture did not show 
CEA-specificity. Abbreviations: LN , lymph node; nd, not done (no biopsy taken); ne, not evaluable (no 
tissue excised); N ED , no evidence o f disease.
No CEA-specific T cells were present in 
biopsies o f first vaccination sites, indicat­
ing that specific T cell reactivity in the 
post-treatment DTH was induced by the 
vaccine. In previous reports spontaneous 
low-grade CEA-specific responses have 
been found infrequently in metastatic co­
lorectal cancer patients25. The local indura­
tion that we observed after the first vacci­
nation, which we have never observed in 
our melanoma studies using the same DC 
vaccine15, suggests that some form o f pre­
existing immunity against CEA was also 
present in our patients, although appar­
ently this immunity was not strong enough 
to result in T cell outgrowth from this vac­
cination site. We cannot, therefore, be cer­
tain that de novo induction o f anti-CEA 
immunity is caused by the vaccine; how­
ever, it is evident that at least a strong po­
tentiation takes place.
We did not observe a correlation between 
the induration size of DTH reactions and 
CEA-specific T cell reactivity. This con­
firms our previous observations in mela­
noma patients19. Here, we found that 
antigen-specific T cell reactivity can even 
be detected in the absence o f induration in 
a DTH reaction that was performed with 
CEA-peptide only. The absence o f indura­
tion in this DTH reaction could be ex­
plained by a lack o f CD 4+ T cells in the 
absence of DC-produced chemokines and 
cytokines26. Together these data show that 
the DTH reaction is a complex assay. Yet, 
these findings also indicate that for the de­
tection o f antigen-specific T cells in cancer 
immunotherapy it may be beneficial to al­
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ways obtain biopsies o f DTH-reaction 
sites irrespective o f induration size.
We show here that adequate numbers of 
DCs can be cultured from buffy-coat de­
rived monocytes. Compared to leu- 
kapheresis, which is so far the predomi­
nantly used method to obtain DCs for 
clinical vaccination studies, this is a more 
simple and less laborious procedure with 
little burden for the patient, although cell 
yields are lower. Nevertheless we observed 
CEA-specific IFN-y producing T cells af­
ter three i.d. injections of 3x106 DCs only, 
indicating that low numbers of DCs may 
suffice. If the migration efficiency of 
these low numbers o f DCs can be im­
proved, this response may be further en­
hanced27. Therefore, the use o f buffy-coat 
derived DCs may facilitate clinical DC vac­
cination trials. In other studies with CEA- 
peptide pulsed DCs no CEA-specific im­
mune responses were found7 or only in a 
minority o f patients9-10, which may be ex­
plained by differences in DC maturation 
state, the culture protocol, patient selection 
or immunomonitoring methods (periph­
eral blood only). Fong et al.8 investigated 
the immunogenicity o f another type of 
DCs (Flt-3 Ligand expanded blood DCs) 
pulsed with an altered CEA peptide in pa­
tients with CEA-expressing colorectal and 
non-small-cell lung tumors. In this study, a 
correlation was found between clinical re­
sponse and the post-vaccination expansion 
o f CEA-specific T cells in peripheral 
blood. However, in contrast to our study, 
several restimulation steps in vitro were 
necessary for evaluation of the functional­
ity o f these cells. In our study, CEA- 
specific T cells were detected slightly 
above background in peripheral blood of 
only one out o f 10 patients by direct tet­
ramer staining. However, in this patient 
these cells were already present before 
vaccination. From these results it can be
concluded that CEA-specificity could be 
detected in one in 10.000 CD8+ T cells by 
tetramer staining o f peripheral blood 
mononuclear cells. Therefore, the fact that 
we could not find CEA-specific T cells in 
more patients may be due to lower fre­
quencies of these cells in the circulation 
after vaccination. Perhaps a short in vitro 
culture period would have allowed the de­
tection o f lower CEA-specific T cell fre­
quencies. Nevertheless, very low numbers 
of high-affinity T cells that are not detect­
able by means o f direct tetramer-staining 
of peripheral blood may suffice for reject­
ing tumors in cancer patients, as shown by 
others28’29. In another study these authors 
showed higher frequencies o f vaccine- and 
tumor-specific T cells in metastases com­
pared with peripheral blood after MAGE- 
3 vaccination in a melanoma patient30.
In our study we did not detect CEA- 
specific T cell responses in tumor samples. 
This may be explained by the limited 
amount o f available tumor tissue, the 
short interval between vaccination and 
surgical resection or immuno-modulatory 
mechanisms in the tumor microenviron­
ment that may preclude adequate T cell 
infiltration31. Regional lymph nodes at the 
vaccination site may be another relevant 
compartment to monitor antigen-specific 
T cell responses, as has been shown in 
murine studies as well as in human mela­
noma studies17’27’32. In our study an easily 
accessible abdominal lymph node was re­
sected in five patients. In one patient func­
tional CEA-specific T cells were found. In 
most patients no detectable CEA-response 
was found in lymph nodes, although they 
were present in biopsies o f the DTH skin 
tests. This may be because the excised 
lymph nodes were not draining either the 
DC vaccination sites or the tumor24.
The small patient numbers and short 
follow-up o f our series does not allow any
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correlation between immunological results 
and clinical outcome. Given the positive 
correlation between specific T cell reactiv­
ity in DTH biopsies and clinical outcome 
in our previous study with melanoma pa­
tients vaccinated with peptide-pulsed 
DCs19, our current results provide further 
support for the potential o f DTH skin 
testing to monitor specific T cell reactivity 
upon antigen-specific cancer immunother­
apy.
In conclusion, CEA-peptide pulsed mature 
DCs derived from buffy-coats can induce 
potent CEA-specific T cell reactivity in 
advanced colorectal cancer patients. In this 
study, DTH skin testing provided superior 
results in the monitoring of antigenspe- 
cific T cell responses compared with pe­
ripheral blood, abdominal lymph nodes 
and tumor tissue. These results warrant 
further studies with CEA-loaded DC vac­
cines in colorectal cancer.
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Supplementary figure 1.
Tetramer staining and 
cytokine production of 
T cells cultured from a 
DTH reaction site of 
patient 5 showed CEA- 
specific T cells after vac­
cination (b and c) which 
were not detectable be­
fore vaccination (in first 
vaccination site (a); At the same time points tet­
ramer analysis of peripheral blood mononuclear 
cells before (d) and after (e) treatment, revealed 
no increase in CEA-specific T cells after vacci­
nation, although CEA specificity could be de­
tected in as little as 0.01% of T cells. For all tet­
ramer analyses CMV tetramers were used as a 
control, which were all negative (not shown).
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Supplementary figure 2. Evaluation of 
CMV and CEA-specific T cell responses 
in blood and DTH reactions of patient 2 
by tetramer analysis after vaccination, 
demonstrating the specificity of the DTH. 
A clear population of circulating CMV 
specific T cells (a) is not found in the 
DTH performed with CEA-peptide 
loaded DCs (b), whereas no specific T 
cells are detected in peripheral blood (c) 
by direct tetramer-staining, but 18.6% of 
CD 8+ T cells in the DTH are CEA-
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Tumor-derived peptides are used frequently as antigen (Ag ) source in dendritic cell 
(DC) therapy in cancer patients. An alternative is to load DCs with tumor- 
associated Ag (TAA) -encoding RNA. RNA-loading obviates prior knowledge of CTL 
and Th epitopes in the Ag. Multiple epitopes for many HLA alleles (both MHC class 
I and class II) are encoded by the RNA and loading is independent of the patient's 
HLA make-up. Here, we determined the optimal conditions for mRNA- 
electropora+on of monocyte-derived DCs for clinical application in relation to dif­
ferent maturation cocktails.
The data demonstrate that TAA carcinoembryonic antigen, gp100 and tyrosinase 
are expressed already 30 min after electroporation with the encoding mRNA. 
Moreover, gp100-specific CTL are activated by gp100 mRNA-electroporated DCs. 
Importantly, we show here that the presence of polyinosinic-polycy+dylic acid 
[poly(I:C ) ] in the matura+on cocktail prevents effec+ve protein expression of the 
electroporated mRNA as well as subsequent CTL recogni+on. This effect of 
poly(I:C ) correlates with the induc+on of IFN-induced genes and innate an+-viral 
eVector molecules in DCs.
Together these data show that electropora+on of mature DCs with TAA-encoding 
mRNA is attrac+ve for use in DC vaccina+on protocols in cancer pa+ents, but pro­
tein expression should be tested for each matura+on cocktail.
Dendritic cell (DC) vaccination studies 
showed the feasibility and safety o f DC 
vaccinations (reviewed in refs. 1 and 2). 
Clinical and immunological responses have 
been reported in some patients. One im­
portant aspect in DC-based vaccines is the 
maturation o f DCs. The cocktails used 
commonly for DC maturation in clinical 
studies3 fail to induce IL-12p70 produc­
tion in the DCs. For cancer vaccine devel­
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opment DCs producing IL-12p70 are de­
sired because o f the Th type 1 (Th1) and 
CTL inducing capacity4. It has been shown 
that ligation o f particular Toll-like recep­
tors (TLR) is a prerequisite to induce full 
maturation, enabling DCs to produce IL- 
12p705. We and others have recently de­
veloped clinically applicable maturation 
cocktails, containing TLR ligands (TLR-L), 
to generate mature DCs with high migra­
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tory and IL-12 producing capacity6’7. An­
other crucial aspect in DC-based vaccines 
concerns the efficacy of Ag delivery to 
DCs. To date, in most clinical studies DCs 
loaded with tumor lysates or defined tu­
mor peptides have been used for the in­
duction o f anti-tumor immunity8-11. Vari­
ous methods have been designed to intro­
duce whole tumor Ag into DCs, including 
tumor mRNA or synthetic mRNA12-14. 
The advantage o f endogenous expression 
o f whole tumor Ag by the DCs is that T 
cell epitopes do not need to be specified, 
HLA type is not a limiting factor and mul­
tiple epitopes (both CTL and Th epitopes) 
can be presented. DCs transfected with 
mRNA encoding tumor-associated Ag 
(TAA) or with whole tumor mRNA can 
induce potent Ag- and tumor-specific T 
cell responses (reviewed in refs. 15 and 
16). Electroporation o f mRNA is an effi­
cient way of transfection15’16, leading to 
clear expression o f the introduced gene. 
This strategy can be optimized for the 
treatment o f cancer patients using syn­
thetic RNA encoding tumor Ag, by analyz­
ing protein expression levels in the elec­
troporated cells and by testing efficiency of 
protein expression after mRNA electropo­
ration in combination with different, clini­
cal grade, maturation cocktails.
We optimized the electroporation protocol 
for transfection o f synthetic mRNA to ob­
tain a clinical grade mature monocyte- 
derived DC vaccine. This protocol was 
used for the electroporation o f mRNA 
encoding TAA. We found that transfection 
o f TAA carcinoembryonic antigen (CE A ), 
gp100 and tyrosinase leads to expression 
and presentation o f these Ag by clinical 
grade mature monocyte-derived DCs. 
Moreover, we show that the presence o f 
polyinosinic-polycytidylic acid [poly(I:C)], 
a TLR3 and melanoma differentiation-
associated gene 5 (MDA-5) ligand, in the 
maturation cocktail interferes with effec­
tive transgene expression after mRNA 
electroporation o f DCs and that this cor­
relates with the upregulation o f genes in­
volved in an anti-viral response by 
poly(I:C). These results may improve the 
generation o f efficient DC-based vaccines 
for use in cancer patients.
RESULTS 
Expression and presenta+on of TAA af­
ter electropora+on of mRNA differs for 
various tumor Ag
Electroporation is an efficient way to 
transfect DCs with mRNA15’16. Because 
studies comparing mRNA transfection o f 
immature and mature DCs are contradic-
tory14’17’18, we compared the efficiency o f
electroporation o f immature and mature 
DCs with our settings. As shown in figure 
1a the level o f transgene expression was 
higher in mature DCs than in immature 
DCs. We decided to electroporate mature 
DCs with gp100, tyrosinase and CEA as 
TAA, because in our ongoing clinical trials 
peptides derived from these Ag are used to 
load D Cs19-21. First we studied the expres­
sion o f TAA after electroporation o f the 
encoding mRNA. As shown in figure 1b, 4 
h after electroporation, gp100, tyrosinase 
and CEA proteins were clearly detectable 
in the electroporated DCs both by intracel­
lular FACS analysis and by staining of cy- 
tospins. All three TAA were already highly 
expressed 30 min after electroporation 
(figure 1c), but tyrosinase protein levels 
decreased to background levels within 24 h 
after electroporation (figure 1c), whereas 
both gp100 and CEA expression could 
still be measured 96 h after electroporation 
(data not shown).
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Figure 1. E lectropora+on  of DCs with mRNA encoding TAA resu lts in expression  o f the respec+'ve proteins 
and p resen ta+on  o f gp100-derived ep ito p e  to  specific CTL. (a) D C s were incubated with cytokine cocktail 
(mature D Cs) or not (immature D Cs). After 48 h, D C s were electroporated with m RN A  encoding the tN G F-R . 
tN G F-R  expression at the cell surface was determined by FACS analysis 24 h after electroporation. Histograms 
show staining with specific antibody [filled curve (mature D Cs) and thick-lined curve (immature DCs)] or isotype 
control antibody (thin-lined curve) after electroporation by exponential decay pulse. (b) Cytokine cocktail-matured 
D C s (cDCs) were electroporated with m R N A  encoding CEA , gp100 or tyrosinase by exponential decay pulse. 
Intracellular FACS analysis was perform ed 4 h after electroporation. Histogram s showing isotype control anti­
body (thin-lined curves) and specific antibody (filled curves) are presented in the left panels. Cytospins were prepared 4 
h after electroporation and stained with isotype control antibody (middle panels) or specific antibody (right panels). 
(c) cD Cs were electroporated with m RN A  encoding CEA , gp100 or tyrosinase by exponential decay pulse. At 
different time points after electroporation intracellular FACS analysis was performed. Median fluorescence inten­
sity o f  the staining o f  positive cells is shown for one representative experiment o f  three performed. (d) cD Cs 
were electroporated with m R N A  encoding for C E A  (control) or gp100 by exponential decay pulse. At diVerent 
time points after electroporation 2.5x104 TIL1200 cells (gp100-specific C T L  line) were incubated for 24 h with 
titrated amounts o f  electroporated D Cs. IFN y was measured in the supernatants by specific E LISA . D ata shown 
are IFN y production induced by gp100 mRNA-electroporated D C s, corrected for IFN y production induced by 
C E A  mRNA-electroporated D C s (control) and are mean ± S E M  o f  triplicates from one representative experi­
ment o f  four performed. IFN y production induced by C E A  mRNA-electroporated D C s (control) was 52, 174 
and 57 p g/m l for 10,000 D C s and 59, 168 and 23 p g/m l for 1,000 D C s, when added 4, 24 and 48 h after elec­
troporation. Stimulation indices were 16, 6 and 5 for 10,000 D C s and 6, 2 and 3 for 1,000 D C s, when added 4, 
24 and 48 h after electroporation. Stimulation indices for the three experiments that were not shown were 9, 2 
and 35 for 1,000 D C s added 24 h after electroporation.
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The percentage o f cells expressing gp100, 
tyrosinase and CEA was 81, 12 and 76%, 
respectively 24 h after electroporation and 
59, 1 and 71%, respectively 48 h after elec­
troporation.
To examine whether DCs electroporated 
with gp100-encoding mRNA are capable 
o f presenting gp100-derived epitopes to 
specific T cells we used the T cell line 
TIL120022-24, specific for the gp100154 
and gp100457 CTL epitopes presented in 
HLA-A2.119. DCs were electroporated 
with gp100-encoding mRNA and incu­
bated with TIL-1200 cells at different time 
points after electroporation. As shown in 
figure 1d, high IFNy-production was in­
duced in specific CTL by gp100 mRNA- 
electroporated DCs as soon as 4 h after 
electroporation and this capacity to stimu­
late specific CTL was retained for at least 
48 h.
Taken together the data presented here 
show that electroporation o f clinical grade, 
monocyte-derived DCs in the mature state 
leads to expression o f tumor Ag in the 
DCs and efficient presentation o f TAA- 
derived epitopes to specific CTL for a du­
rable time period.
Protein expression after mRNA electro- 
pora+on is dependent on DC matura- 
+on s+muli
To date the most widely applied DC vac­
cines are matured with a defined cocktail 
o f pro-inflammatory cytokines: IL-1^, IL- 
6, T N F a and prostaglandin E2 (PGE2)3 
or with monocyte-conditioned medium 
(MCM) combined with T N F a and PGE2 
(conventional DCs, cDCs)25. We used this 
cytokine mixture to optimize the electro­
poration protocol. Monocyte-derived 
cDCs produce very low to undetectable 
levels o f IL-12p706,26. Recently, maturation 
cocktails containing TLR-L have been de­
veloped that induce the production o f 
IL12p70 by DCs6^ 26.
We tested the efficiency o f transgene ex­
pression after electroporation o f DCs with 
gp100-encoding mRNA after maturation 
with TLR3 and MDA-5 ligand poly(I:C) 
(pIC-DCs), TLR7/8L R848 (R848-DCs) 
and the combination (R +  P-DCs). All 
maturation cocktails were supplemented 
with PG E 2, because this is required to en­
hance migration for clinical application6. 
All DCs (cDCs, pIC-DCs, R848-DCs and 
R+PDCs) were phenotypically mature as 
determined by FACS analysis (data not 
shown and ref. 6). However, poly(I:C) 
and/or R848 induced much higher levels 
of IL-12 than cytokine mixture (data not 
shown and ref. 6).
As shown in figure 2a, gp100 expression 
levels after gp100 mRNA electroporation 
were equal for R848-DCs and cDCs. In 
contrast, the presence o f poly(I:C) in the 
maturation cocktail decreased the gp100 
protein expression both at 4 and 24 h after 
electroporation. As shown in figure 2b, the 
capacity to activate gp100-specific T cells 
was also decreased for DCs matured with 
a cocktail containing poly(I:C). Poly(I:C) is 
a synthetic viral dsRNA analog and we 
have shown recently that treatment of 
DCs with poly(I:C) induces a strong 
upregulation of mRNA and protein for 
viral sensors, including the RNA helicases 
retinoic acid-inducible gene I (RIG-I) and 
MDA-5, and effector molecules like the 
double stranded RNA-activated serine/ 
threonine protein kinase (PKR) and 2’-5’- 
oligoadenylate synthetase (2,5-OAS) (ref. 
27 and unpublished data). PKR is known 
to inhibit protein synthesis and 2,5-OAS 
activates RNAse L, that degrades single­
stranded RNA.
Therefore, the mRNA expression levels o f 
these genes induced by the different matu­
ration cocktails were measured.
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Figure 2 Polyinosinic-polycy+dylic acid s+'mula+'on prevents effec+'ve protein expression  after mRNA 
e lectro pora+on  and in creases expression  o f both viral sen sors  and effector m olecules. D C s were matured 
with the conventional cytokine cocktail (T N F a , IL-1^ and IL-6; cD Cs), poly(I:C) (pIC-DCs), R848 (R848-DCs) 
or poly(I:C)/R848 (R +  P-D Cs), all with addition o f  P G E 2. D C s were electroporated with gp100-encoding 
m RN A  48 h later. (a) Histogram s o f  intracellular staining with specific antibody (filled curves) or with isotype con­
trol Ab (thick-lined curves) 4 and 24 h after electroporation. Numbers shown in the figures are median fluorescence 
intensity o f  gp100-staining (after subtracting median fluorescence intensity o f  isotype control staining). (b) 2.5 x 
104 TIL1200 cells were co-incubated with 400 D C s 24 h after electroporation and IFN y was measured in super- 
natants 24 h later by specific E LISA . (c) m RN A  levels o f  M DA-5, 2’5-OAS’ P K R  and RIG-I were determined 
using qPCR at several time points after electroporation (0 h is the time point o f  electroporation). (d) Protein 
expression o f  M DA-5, P K R  and RIG -I was analyzed by western blot assay at different time points after electro­
poration. (e) Four and twenty-four hours after electroporation, D C s were stained with antibodies specific for 
MDA-5 and D C -SIG N , followed by Alexa 568- and Alexa 488-conjugated secondary Ab, respectively, and ana­
lyzed by confocal m icroscopy as described in ’’Materials and methods.”  For D C -SIG N  a cell surface staining was 
perform ed, whereas M DA-5 was stained intracellularly.
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As shown in figure 2c, cocktails containing 
poly(I:C) strongly increased the expression 
o f MDA-5, 2,5-OAS, PKR and RIG-I, 
whereas cytokine cocktail or R848 alone 
did not. Expression levels were upregu- 
lated 48 h after the induction o f matura­
tion (t = 0 h), the time point at which the 
cells were electroporated, and remained 
upregulated compared to cDCs and R848- 
DCs up to at least 24 h after electropora­
tion.
Western blot analysis corroborated our 
findings by qPCR and demonstrated ele­
vated protein levels of RIG-I, PKR and 
MDA-5 following exposure to poly(I:C) 
(figure 2d) at the time o f electroporation 
and up to 24 h later. Furthermore, confo- 
cal microscopy analysis showed an in­
creased expression o f MDA-5 in the cyto­
plasm o f DCs stimulated with a mixture 
containing poly(I:C) (figure 2e).
Collectively, these data show that the pres­
ence o f poly(I:C) in the maturation cock­
tail prevents effective expression o f TAA 
after electroporation o f DCs with mRNA. 
The upregulation o f genes involved in the 
induction o f an antiviral state in the DCs 
and regulating protein expression levels is 
uniquely associated with the presence of 
poly(I:C) in the maturation cocktail and 
might be an explanation for this phe­
nomenon.
DISCUSSION
In this study we show that CEA, gp100 
and tyrosinase proteins are expressed al­
ready 30 min after mRNA electroporation. 
Furthermore, electroporated DCs present 
dominant epitopes derived from the en­
coded tumor Ag to specific CTL. Impor­
tantly, we show that the presence o f 
poly(I:C) in the maturation cocktail pre­
vents efficacious protein expression after 
electroporation o f mRNA encoding TAA
and subsequent CTL recognition. This 
correlates with upregulation by poly(I:C) 
o f genes regulating protein expression lev­
els by inducing degradation o f mRNA and 
inhibition o f protein synthesis. Dendritic 
cell vaccination trials have shown that DC 
vaccines can induce immune responses in 
cancer patients. However, as reviewed in 
ref. 28, many variables need to be opti­
mized and standardized to further improve 
the efficacy o f DC vaccination. One of 
these parameters is the way o f loading the 
DCs with Ag. Electroporation o f mRNA 
is an efficient way o f antigen loading15,16. 
We used synthetic mRNA encoding well- 
characterized TAA as a source to transfect 
DCs. This has the advantage that mRNA 
can be produced in batches for a large 
number o f patients and it allows proper 
immune monitoring and comparison with 
peptide-loaded DCs.
It is now generally accepted that mature 
DCs should be applied for vaccination 
purposes29,30. Currently, ex vivo generated 
monocyte-derived DCs, matured with a 
cocktail containing MCM, T N F a and 
PGE2 or IL-1p, IL-6, T N F a  and PGE2, 
are used commonly in clinical studies. A 
disadvantage o f this maturation cocktail is 
the poor IL-12p70 production by the DCs. 
We recently proposed a novel clinical 
grade maturation protocol in which TLR-L 
poly(I:C) and R848 are combined with 
PG E2 to generate DCs with both high mi­
gratory capacity and IL-12p70 production 
upon T cell encounter6. For peptide load­
ing o f DCs this seems to be a good 
choice. However, we show here that pro­
tein expression after mRNA electropora­
tion o f DCs matured for 48 h by cocktails 
containing poly(I:C) is very ineffective. 
These results are in agreement with re­
cently published data showing that protein 
expression after mRNA electroporation o f
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DCs matured for 24 h with a cocktail 
containing poly(I:C) is very inefficient 7. It 
is therefore necessary to test maturation 
cocktails and loading methods o f DCs in­
dividually to find the optimal combination. 
We propose to mature the DCs with R848 
and PGE2 if electroporation o f mRNA is 
the Ag loading method. The observed in­
terference with effective transgene expres­
sion by the presence o f poly(I:C) in the 
maturation cocktail might be explained by 
the upregulation o f genes involved in the 
innate anti-viral response. Poly(I:C) is a 
synthetic dsRNA and it has been shown 
that dsRNA inhibits protein synthesis in 
cell-free systems prepared from IFN- 
treated cells31. Interferons trigger the de­
velopment o f a defensive response led by 
the enzymes 2,5-OAS and PKR. 2,5-OAS 
is activated by dsRNA and on its turn acti­
vates the latent ribonuclease RNAse L, 
which degrades single-stranded RNA. 
PKR inhibits initiation o f protein synthe­
sis. These two pathways regulate protein 
expression levels32 and hereby impair the 
replication o f viruses. We here show that 
incubation o f DCs with poly(I:C) induces 
expression  o f  these two dsR N A - 
dependent enzymes: PKR and 2,5-OAS. 
These genes and the corresponding pro­
teins are highly expressed at the time of 
electroporation and up to at least 24 h 
thereafter. Highly efficient induction o f 
CTL responses by DCs co-electroporated 
with poly(I:C) and mRNA18 are not in dis­
agreement with our data, but might be ex­
plained by translation o f the mRNA into 
protein before the anti-viral response in­
duced by poly(I:C) is full blown.
The data provided here show that electro­
poration o f DCs with mRNA encoding 
TAA is an efficient way o f Ag loading, 
which is feasible and can be performed 
under cGMP conditions. We propose the 
use o f TLR-L poly(I:C) and R848 in com­
bination with PGE2 as maturation cocktail 
for peptide loading of DCs and omission 
of poly(I:C) from the cocktail for mRNA 
electroporation. Future clinical studies will 
demonstrate the efficacy o f these mRNA- 
loaded DC vaccines in cancer patients.
MATERIALS AND METHODS
See supplementary material.
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SUPPLEMENTARY MATERIALS AND 
METHODS
DC prepara+on from peripheral blood precur­
sors and DC characteriza+on
DCs were generated from PBMC prepared from 
leukapheresis products or from whole blood ob­
tained from healthy donors and patients essen­
tially as described previously1,2. The patient study 
was approved by the local medical ethical com­
mittee. No differences were observed in quality of 
the DCs and electroporation efficiency between 
buffy coat- and leukapheresis material-derived 
DCs and between healthy donor- and patient- 
derived DCs. Therefore we did not specify the 
source of PBMC used in each experiment. 
Plastic-adherent monocytes from leukapheresis or 
whole blood were cultured in X-VIVO 15™ me­
dium (BioWhittaker, Walkersville, Maryland) sup­
plemented with 2% pooled human serum (HS) 
(Sanquin, Nijmegen, The Netherlands), IL-4 (500 
U/ml) and GM-CSF (800 U/ml) (both from 
CellGenix, Freiburg, Germany). On day 7, cells 
were either kept in the immature state or matured 
with 10 ng/ml recombinant TN Fa, 5 ng/ml IL- 
1b and 15 ng/ml IL-6 (all CellGenix) (conven­
tional DCs, cDCs); 20 ^g/ml poly(I:C) (Sigma 
Chemicals Co., St. Louis, MO) (pICDCs); 3 ^g/ 
ml R848 (PharmaTech, Shanghai, China) (R848- 
DCs); or 20 ^g/ml poly(I:C) and 3 g/ml R848 
(R+P-DCs). To all the before mentioned matura­
tion cocktails 10 ^g/ml PGE2 (Pharmacia & Up- 
john, Puurs, Belgium) was added. All maturation 
cocktails gave rise to mature DCs on day 9, meet­
ing the release criteria described previously3. After 
maturation more than 80% of the DCs expressed 
high levels of CD80 and CD86, analyzed by 
FACS analysis as described below. Immature DCs 
were also harvested on day 9 and expressed low 
levels of CD80 and CD86. Both immature and 
mature DC preparations contained more than 
80% DCs.
Culture of gp100-specific CTL
TIL1200, a gp100-specific CTL line has been de­
scribed4,5, and was cultured in RPMI-1640 (Gibco 
BRL, Carlsbad, CA), containing 7% human serum 
and 1000 U/ml IL-2 (Cetus Corp., Emeryville, 
CA). The TIL1200 line recognizes two gp100- 
derived epitopes: gp100154 (aa 154-162, 
KTWGQYWQV)6 and gp100457 (aa 457-466, 
LLDGTATLRL)4.
Plasmids and in vitro mRNA transcription
Plasmids pGEM4Z-5’UT-CEA-3’UT-A64 and 
pGEM4Z-5’UT-tNGFR-3’UT-A64 were a kind 
gift from E. Gilboa (Duke University, Durham) 
[7] and pGEM4Z-5’UT-hgp100-3’UT-A64 was 
provided by Kris Thielemans (Free University 
Brussels, Belgium). pGEM4Z-5’UT-tyrosinase- 
3’UT-A64 was constructed by digestion of 
pGEM4Z-5’UT-tNGFR-3’UT-A64 with Bglll 
a n d  X b a l  a n d  d i g e s t i o n  o f  
pcDNAl.amp/tyrosinase with BamHI and Xbal 
and insertion of the tyrosinase into the cut 
pGEM4Z. Plasmids were linearized with Spel 
(pGEM4Z-5’UT-CEA-3’ UT-A64) or Notl en­
zyme (pG E M 4Z -5 ’U T -tN G FR -3 ’UT-A64, 
p G E M 4 Z - 5 ’ U T - h g p 1 0 0 - 3 ’ UT-A64  and 
pGEM4Z-5’UT-tyrosinase-3’UT-A64), purified 
with phenol/chloroform extraction and ethanol 
precipitation, and used as DNA templates. tNGF- 
R mRNA was obtained by in vitro transcription 
with T7 RNA polymerase (mMESSAGE mMA- 
CHINE kit, Ambion, Austin, TX) according to 
the manufacturer’s instructions. The transcribed 
RNA was recovered after DNasel (Ambion) di­
gestion with phenol/chloroform extraction and 
ethanol precipitation.
TAA-encoding mRNA (gp100, tyrosinase and 
CEA) was obtained from CureVac GmbH (Tübi­
ngen, Germany). RNA quality was verified by 
agarose gel electrophoresis, RNA concentration 
was measured spectrophotometrically, and RNA 
was stored at -40°C in small aliquots.
Electroporation of DCs
Immature or mature DCs were washed twice in 
PBS and once in OptiMEM® without phenol red 
(Invitrogen, Breda, The Netherlands). 20 ^g RNA 
was transferred to a 4-mm cuvette (BioRad, 
Veenendaal, The Netherlands) and 10 x 106 cells 
were added in 200 ^l OptiMEM® and incubated 
for 3 min before being pulsed in a Genepulser 
Xcell (Bio-Rad). Two methods of pulsing were 
applied and compared for electroporation of 
DCs: exponential decay pulse and square wave 
pulse. With exponential decay pulsation the volt­
age across the electrodes rises rapidly to the peak 
voltage and declines over time, whereas with 
square wave pulsation the pulse has approximately 
the same voltage at the end as at the beginning of 
the pulse. Electroporation settings were optimized 
for each pulse method by varying voltage and ca­
pacitance settings (exponential decay pulse) or 
voltage and pulse time settings (square wave 
pulse) using immature DCs and analyzing expres­
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sion of the transgene and survival. We found that 
electroporation of 10 x 106 cells in 200 ^l pulsed 
at 300 V, 150 ^ F (exponential decay pulse) or 400 
V, 0.6 ms (square wave pulse) resulted in the high­
est electroporation efficiency (data not shown). 
Immediately after electroporation, the cells were 
transferred to warm (37°C) X-VIVO 15™ with­
out phenol red (Cambrex Bio Science, Verviers, 
Belgium) supplemented with 5% HS and left for 
at least 30 min at 37°C, before further manipula­
tions were performed. Electroporation efficiency 
was analyzed by intracellular staining and FACS 
analysis for each separate TAA.
Flow cytometric analysis (FACS analysis)
To characterize and compare the phenotype of 
the DC populations, flow cytometry was per­
formed. The following mAb or appropriate iso­
type controls were used: anti-HLA class I (W6/ 
32), anti-HLA DR/DP (Q5/13) (both ascites), 
anti-CD80 (BD Biosciences, Mountain View, CA), 
anti-CD14, anti-CD83 (both Beckman Coulter, 
Mijdrecht, The Netherlands), anti-CD86 (BD 
PharMingen, San Diego, CA), anti-CCR7 (kind 
gift of Martin Lipp, Max Planck Institute, Berlin, 
Germany) and anti-tNGF-R (mAb 20.4 (IgG1), 
used as concentrated hybridoma supernatant). All 
stainings with primary antibodies were followed 
by staining with FITC-labeled goat-anti-mouse 
(Zymed, San Francisco, CA).
For intracellular staining of the TAA the follow­
ing mAb were used: NKI/beteb (IgG2b) (purified 
antibody) against gp100, T311 (IgG2a) (Cell 
Marque Corp., Rocklin, CA) against tyrosinase 
and Col-1 (IgG2a) (Lab Vision Corp., Fremont, 
CA) against CEA. For intracellular staining cells 
were fixed for 4 min. on ice in 4% (w/v) para­
formaldehyde (Merck, Darmstadt, Germany) in 
PBS, permeabilized in PBS/2% bovine serum 
albumin (BSA)/0.02% azide/0.5% saponin 
(Sigma-Aldrich) (PBA/saponin), and stained with 
mAb diluted in PBA/saponin/2% HS, followed 
by staining with allophycocyanin-labeled goat- 
anti-mouse (BD PharMingen). Flow cytometry 
was performed with FACSCalibur™ flow cytome- 
ter equipped with CellQuest software (BD Biosci­
ences).
Cytospins and staining
Immunohistochemistry was performed on cyto- 
spins by incubation with the same antibodies as 
described above for intracellular staining, followed 
by incubation with biotinylated horse-anti-mouse 
(Vector, Burlingame, CA) and staining with 
Power-DAB (Immunologic, Duiven, The Nether­
lands). Cells were analyzed on a Leica DM LB 
microscope using Leica IM500 software (Leica, 
Wetzlar, Germany).
Induc+on and determina+on of IFNg produc- 
+on by gp100-specific CTL
T cell stimulatory capacity was tested by cocultur- 
ing 400 (figure 5C), 103 or 104 (figure 4B) DCs 
after electroporation with gp100-encoding or 
control mRNA with a gp100-specific T cell line 
(2,5 x 104 TIL1200 cells)8. After 24 h supernatants 
were tested for IFNg content using a standard 
sandwich ELISA. Coating Ab: mouse-IgG1-anti- 
hIFNg (clone 2G1; Pierce, Rockford, IL), detec­
tion Ab: biotinylated mouse-IgG1-anti-hIFNg 
(clone B133.5; Pierce). Streptavidin-HRP and 
TMB were used as enzyme and substrate, respec­
tively.
RNA isola+on
Total RNA was isolated from DC cultures using 
TRIZOL reagent (Invitrogen Life Technologies) 
according to the manufacturer’s instructions, with 
minor modifications. RNA quantity and purity 
were determined using a NanoDrop® ND1000 
Spectrophotometer (Isogen Life Science, IJssel- 
stein, The Netherlands). The reverse transcription 
reaction was performed using Moloney Murine 
Leukemia virus reverse transcriptase (Invitrogen 
Life Technologies) according to the manufac­
turer’s instructions. For each sample a “ - RT” 
control was included in which the reverse tran­
scriptase was replaced by ultrapure milli-Q (Invi- 
trogen Life Technologies). The cDNA was stored 
at -20°C until further use.
Quan+ta+ve PCR
Quantitative analysis of gene expression in DCs 
was performed using SYBR Green-based qPCR. 
The qPCR reactions were performed in a 20 ^l 
volume containing 10 ^l SYBR Green mix (Ap­
plied Biosystems), 1.2 ^l forward/reverse primer 
(300 nM endconcentration), 3.6 ^l milli-Q and 4 
^l cDNA dilution. Reactions were performed on 
an ABI 7000 Sequence Detection System (Ap­
plied Biosystems). Analysis was performed using 
7000 system software (version 1.2X, Applied Bio­
systems). Primer sequences are available upon 
request and were designed using the freely acces­
sible Primer Bank program9.
Western blot
Equal amounts of protein were separated by 
12.5% sodium dodecyl sulfatepolyacrylamide gel 
electrophoresis and electroblotted onto nitrocellu­
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lose membranes (Bio-Rad), followed by probing 
with the indicated antibodies. Anti-RIG-I and 
anti-protein kinase R (anti-PKR) antibodies were 
purchased from ProSci Incorporated and Becton 
Dickinson Transduction Laboratories, respec­
tively. Rabbit polyclonal anti-MDA-5 was a kind 
gift of Paul Fisher (Departments of Pathology, 
Neurosurgery and Urology, Columbia University, 
College of Physicians and Surgeons, New York, 
USA) and production of this antibody was de­
scribed previously10. RIG-I, PKR and MDA-5 
antibodies were used in 1:1,000, 1:500 and 
1:10,000 dilutions, respectively. After washes, 
membranes were incubated with IRDye anti­
mouse or anti-rabbit immunoglobulin G (IgG) 
(1:15,000) (Li-Cor Biosciences). Imaging was 
done using the Odyssey System.
Confocal Microscopy
DCs were harvested, washed and allowed to ad­
here to poly-L-lysinecoated coverslips in serum­
free medium for 1 h at 37°C. Cells were fixed 
with 1% paraformaldehyde and blocked in PBS/ 
2% HS/2% BSA (blocking buffer, BB) supple­
mented with 50 mM NH4Cl. For cell surface 
staining, cells were incubated with mouse anti­
human DC-SIGN (AZN-D1, 5 ng/ml, Beckman 
Coulter) in BB, washed and incubated with 
isotype-specific Alexa-labeled goat anti-mouse 
IgG1 in BB (Alexa 568, Molecular Probes). For 
intracellular staining, cells were fixed using 1% 
paraformaldehyde, permeabilized using 0.1% 
saponin in BB supplemented with 50 mM 
NH4Cl, and incubated with polyclonal anti- 
MDA-5 followed by incubation with goat anti­
rabbit IgG-Alexa 488 (Molecular Probes) in BB. 
After final washes, cells were sealed using Mowiol 
(Merck) and analyzed by confocal microscopy 
(Olympus Fluoview, FV1000).
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Dendritic cells (DCs) are the professional antigen-presenting cells of the immune 
system. We have demonstrated that vaccination of autologous ex vivo cultured 
DCs results in the induction of tumor-specific immune responses in cancer pa­
tients, which correlates with clinical response. Optimization of antigen-loading is 
one of the possibilities to further improve the efficacy of DC vaccination. Theoreti­
cally, transfection of DCs with RNA encoding a tumor-specific antigen may induce a 
broader immune response as compared to the most widely used technique of 
pep0de pulsing.
In this clinical study, we compared RNA transfection with peptide pulsing as an an­
tigen loading strategy for DC vaccination. Patients with resectable liver metastases 
of colorectal cancer were vaccinated intravenously and intradermally 3 times 
weekly with either carcinoembryogenic antigen (CEA) derived HLA-A2 binding- 
peptide loaded or CEA-mRNA electroporated DCs prior to surgical resection of the 
metastases. All DCs were loaded with keyhole limpet hemocyanin (KLH) as a con­
trol protein. Evaluation of vaccine-induced immune reactivity consisted of T prolif­
erative responses and B cell antibody responses against KLH in peripheral blood. 
CEA reactivity was determined in T cell cultures of biopsies of post-treatment de­
layed type hypersensi0vity skin tests.
Sixteen patients were included. All patients showed T cell responses against KLH 
upon vaccination. CEA peptide-specific T cells were detected in 8 out of 11 patients 
in the peptide group, but in none of the 5 patients in the RNA group.
In our study, DC CEA-mRNA transfection was not superior to DC CEA-peptide puls­
ing in the induction of a tumor-specific immune response in colorectal cancer pa­
tients.
Introduction
Dendritic cells (DCs) are the most potent 
antigen presenting cells, and are capable of 
inducing an effective anti-tumor immune 
response1. Currently they are employed in 
clinical immunization protocols in cancer
patients and objective clinical and immu­
nological responses have been observed2. 
However, a lot of crucial questions regard­
ing the optimal preparation and admini­
stration of DC vaccines for clinical use 
remain unanswered to date3. One o f these
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questions concerns the optimal method of 
antigen-loading. In the vast majority of 
studies, tumor antigenic peptides have 
been used2. This has the advantage that 
the monitoring o f the immune response is 
focused on a limited and predefined num­
ber o f epitopes. However, pulsing DCs 
with peptides limits the response to identi­
fied epitopes and therefore limits the 
treated patient group to certain specific 
HLA-types. In addition, peptide-pulsing 
does not account for post-translational 
modifications o f the tumor antigens. 
These limitations may not exist for the ex­
pression o f tumor antigens by DCs 
through RNA transfection, which has been 
shown effective in vitro and in vivo46. 
Moreover, RNA transfection may lead to a 
more prolonged presentation of the anti­
gen as compared to peptide-loading which 
appears to be short-lived7. The feasibility, 
safety, and potential efficacy o f non-virally 
RNA-transfected DCs has been shown in 
clinical studies with cancer patients8-12. On 
the other hand, RNA transfection has po­
tential drawbacks including a variable anti­
gen expression and a low yield o f viable 
cells after transfection, especially when us­
ing the technique of RNA electroporation 
10. The true benefit o f using RNA trans­
fection over peptide loading should be de­
rived from clinical trials. A clinical com­
parison o f RNA-transfected DCs with 
peptide-pulsed DCs, however, has not 
been reported. Here, we compare the im- 
munogenicity o f an RNA-based DC vac­
cine versus a peptide-based DC vaccine in 
colorectal cancer patients. We included pa­
tients with resectable colorectal cancer 
liver metastases for the following reason. 
Vaccine therapy is likely to have greater 
efficacy in patients with low tumor volume 
compared to patients with widespread 
bulky metastases in whom immune sup­
pression is often present. Patients with re­
sected liver metastases have a high risk for 
relapse and may therefore potentially bene­
fit from adjuvant treatment, such as vac­
cine therapy. Therefore we opted to test 
the immunogenicity o f our method in this 
specific subgroup o f patients.
PATIENTS AND METHODS
Study design
This was an open-label, single-institution, explora­
tory study in which monocyte-derived DCs 
loaded with CEA-peptide or electroporated with 
CEA-encoding mRNA were administered to pa­
tients with resectable liver metastases of colorec­
tal cancer. It was planned that the first 10 patients 
would receive DCs pulsed with CEA peptides, 
and another 10 patients would receive DCs trans­
fected with mRNA. Approval from the local regu­
latory committee was obtained. Trial registration: 
NCT00228189 (ClinicalTrials.gov).
Objectives
The primary endpoint was to compare the immu- 
nogenicity of CEA peptide-loaded DCs with DCs 
electroporated with CEA-mRNA. Secondary 
endpoints were the toxicity and the feasiblity of 
CEA-specific vaccination in colorectal cancer pa­
tients.
Patients
Inclusion criteria included: patients with liver me- 
tastases from CEA-expressing colorectal cancer 
scheduled for surgical resection, HLA-A0201 
phenotype, Eastern Cooperative Oncology Group 
(ECOG) performance status 0—1, age >18 years, 
no clinical signs of extra-hepatic metastases, no 
prior chemotherapy, immunotherapy or radio­
therapy within 2 months before planned surgery.
DC preparation
DCs were generated either from buffy coats or 
from leukapheresis products. Monocytes were 
enriched from buffy coats as follows: patients do­
nated 0.5 l blood, from which a buffy-coat was 
made (Sanquin Bloodbank Nijmegen, the Nether­
lands). Peripheral blood mononuclear cells 
(PBMCs) were isolated by PureCell® (Medicult, 
Denmark) density gradient centrifugation (20 
min, 20°C, 2100 rpm) and monocytes were en­
riched by adherence to plastic. Monocytes were 
enriched from leukapheresis products by counter­
flow elutriation using Elutra-cell separator (Gam-
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bro BCT, Inc.) and single-use, functionally sealed 
disposable Elutra sets, as described before14 and 
according to the manufacturer’s instructions. 
Monocytes were cultured in Cellgro® medium 
supplemented with interleukin (IL)-4 (500 units/ 
ml) and granulocyte macrophage colony- 
stimulating factor (GM-CSF; 800 units/ml; all 
Cellgenix). KLH (10 ng/ml; Calbiochem, USA) 
was added at day 3 of culture, and 2 days before 
harvesting we added the maturation cocktail con­
sisting of prostaglandin E 2 (PGE2; Pharmacia & 
Upjohn, Puurs, Belgium, 10 ng/ml), tumor necro­
sis factor alpha (TNFa, 10 ng/ml), IL-1 (5 ng/ 
ml) and IL-6 (15 ng/ml; all CellGenix). Release 
criteria were as previously described3: more than 
80% of the DCs expressed high levels of CD80 
and CD86. Mature DCs were electroporated with 
mRNA encoding CEA directly after harvesting as 
described below or pulsed with wild-type CEA- 
peptide CAP-1 (CEA571-579, YLSGA NLNL, 
Clinalfa, Switzerland)13’15 directly after harvesting 
or after thawing16’17.
Electroporation of DC
Mature DCs were washed twice in PBS and once 
in OptiMEM without phenol red (Invitrogen). 
Twenty micrograms of mRNA were transferred 
to a 4-mm cuvette (Bio-Rad) and 12x106 cells 
were added in 200 ^l OptiMEM and incubated 
for 3 min before being pulsed in a Genepulser 
Xcell (Biorad) by an exponential decay pulse of 
300 V, 150 ^F, as described before10. Electropora­
tion was done under good manufacturing practice 
conditions. For the first vaccination, 2 to 3 ali­
quots of 12x106 DCs were electroporated with 
CEA-encoding mRNA. Electroporation effi­
ciency was analyzed by flow cytometry. DCs for 
the first vaccination were injected 4 h after elec­
troporation. DCs for subsequent vaccinations 
were frozen 2 h after electroporation, thawed at 
the day of vaccination, and incubated for an addi­
tional 2 h at 37°C before injection.
Treatment schedule
Vaccinations were administered three times at day 
0, 7 and 14. The patients received 5 x 106 DCs 
intradermally (i.d.) in the upper leg, 5—10 cm from 
an inguinal lymph node. The remaining cells were 
given intraveneously (i.v.) as a bolus injection at 
the same time point. On day 26 a post-treatment 
DTH test was performed (see below). At day 28, 
6 mm punch biopsies were taken from the post­
treatment DTH reaction sites. Before and after 
vaccination PBMCs were obtained.
The same schedule of 3 weekly i.v./i.d. vaccina­
tions followed by a post-treatment DTH was re­
peated twice at intervals of 6 months in the ab­
sence of recurrent disease. Serum CEA levels 
were measured before and after completion of 
the vaccination protocol.
Immunologic monitoring
CD4+ T cell responses against KLH were meas­
ured using a 3H-thymidine incorporation prolif­
eration assay with PBMCs of the patients before 
and after vaccination17. The index was calculated 
as the counts ratio between KLH-stimulated 
PBMC and non-stimulated PBMC. Antibodies 
against KLH were measured in the serum of vac­
cinated patients by enzyme-linked immuno­
sorbent assays (ELISA) as previously de­
scribed17’18.
Post-treatment DTH reactions were performed as 
described previously19. Briefly, CEA-peptide only 
(100 ng in 100 ^l), DCs pulsed with CEA- 
peptide, DCs pulsed with KLH and CEA-peptide, 
and DCs pulsed with KLH only (0.4—5 x 105 
DCs each in approximately 100—200 ^l) were in­
jected i.d., 5—10 cm from an inguinal lymph node 
at different sites, in the upper leg controlateral 
from the leg in which the DC vaccinations were 
performed. The maximum diameter of induration 
was measured after 48 h. T cell culture from DTH 
biopsies was performed in low dose IL-2 (100 U/ 
ml; Proleukin®, Chiron, the Netherlands) for ap­
proximately 2 weeks without ex vivo restimulation 
with antigen as described before19. After 2 to 4 
weeks of culturing, T cells were tested for antigen 
recognition or tested for tetramer binding. 
DTH-derived cells (1 x 105 cells in 10 ^l) were 
incubated with PE-labeled CEA and cytomega­
lovirus (CMV) tetrameric-MHC complexes (San- 
quin; Amsterdam, the Netherlands) for 60 min at 
room temperature. In the last 20 min of this in­
cubation, fluorescein isothiocyanate (FITC)- 
conjugated monoclonal antibodies directed 
against CD8 (Becton Dickinson) were added. Af­
ter washing, the samples were analyzed by flow 
cytometry. In all analyses CEA tetramer staining 
was compared with CMV tetramers as a negative 
control.
Production of cytokines by the total population 
of DTH-derived cells was measured in response 
to T2 cells pulsed with CEA-peptide or an irrele­
vant HLA-A2.1 binding peptide (tyrosinase or 
G250) or in response to PBMCs electroporated 
with CEA mRNA. Cytokine production was 
measured in supernatants after 16 h by cytometric 
bead array (Th1/Th2 Cytokine CBA 1; BD
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Pharmingen). IFN-y production was considered 
positive when IFN-y levels of DTH-infiltrating T 
cells were more than 10-fold higher after co­
incubation with CEA-loaded T2 cells compared 
with co-incubation with T2 cells loaded with ir­
relevant antigen.
Patient evaluation
Clinical follow-up consisted of history, physical 
examination, serum CEA-level, CT scanning of 
the liver and X-ray of the chest at 3-month inter­
vals.
Statistical analysis
Data were analyzed statistically by means of 
analysis of variance and Student-Newman-Keuls 
test, or by means of Mann Whitney U nonpara- 
metric statistics. Statistical significance was de­
fined as p<0.05.
RESULTS 
Patients
Sixteen patients were included in the study. 
In the period 2004-2005 eleven patients 
received peptide-pulsed DCs (previously 
reported in ref. 13). One extra patient was 
included as planned in case a patient 
proved not to be evaluable. Due to a slow 
accrual o f only 5 patients in the second
phase o f the study, as well as the results in 
these patients, the study was prematurely 
closed. Baseline characteristics between 
patients receiving peptide-pulsed DCs and 
RNA-loaded DCs were comparable (data 
not shown).
Clinical outcome and toxicity
Four out o f 11 patients in the peptide­
group and 1 out o f 5 patients in the RNA- 
group had irresectable disease at surgery. 
In the peptide-group, one patient (pep-5) 
was diagnosed with lung metastases before 
surgery and one patient died o f post­
operative complications not related to the 
vaccination treatment (pep-9). No toxicity 
other than grade 1 flue-like symptoms, fe­
ver and injection site reactions were ob­
served in both groups. Specifically, no di­
arrhea or other signs o f autoimmune coli­
tis were observed. Seven patients treated 
with peptidepulsed DCs and two patients 
treated with mRNA-loaded DCs showed a 
transient and modest rise in serum CEA 
level upon vaccination, defined as an in­
crease of 15% compared with baseline33.
Figure 1. DC characteristics. (a) Expression of HLA-ABC, HLA-DR/DP, HLA-DQ, CD80, CD83, 
CD86 and CCR7 was measured by flow cytometry on mature DCs for the first iv/id vaccination. Re­
sults are shown as mean SEM of the percentage of cells expressing the maturation markers of peptide- 
loaded DCs (grey bars) and mRNA-electroporated DCs (black bars). (b) CEA protein expression was 
measured by flow cytometry 2 h after electroporation with mRNA. Results are shown as the percentage 
of cells expressing CEA protein for each individual patient.
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In the patients who underwent a radical 
resection o f metastases the median 
progression-free survival after treatment 
with peptide-pulsed DCs and mRNA- 
loaded DCs was 18 months (range 1-77 
months) and 26 months (range 13-41 
months), respectively.
DC vaccine characteristics
In all patients sufficient amounts o f 
monocyte-derived mature DCs could be 
obtained for three i.d. vaccinations (see 
Table 1). However, the yield was not al­
ways sufficient for simultaneous i.v injec­
tions. Patients vaccinated with CEA 
peptide-pulsed DCs received an average of 
4x106 DCs i.v. and 5x106 DCs i.d. per vac­
cination during the first cycle. Patients 
vaccinated with RNA-electroporated DCs 
received an average of 11x106 DCs i.v and 
5x106 DCs i.d. (Table 1). Final DC vaccine 
products met the criteria o f a mature phe- 
notype3;17 with high HLA-ABC, HLA- 
DR/DP, HLA-DQ, CD80, CD83, CD86 
and CCR7 expression (Figure 1a). There 
was no difference in the maturation status 
(p=0.09 to p=0.88) or amount o f i.d. in­
jected DCs. However, patients in the pep­
tide group received less i.v. injected DCs 
(p<0.001). All patients had a proliferative 
peripheral blood CD4+ T cell response 
against the control protein KLH (Table 1), 
as expected for mature DC vaccine17, indi­
cating that the DCs were able to induce de 
novo T cell responses.
On average, 66% o f the DCs electropo­
rated with mRNA expressed CEA protein 
2 h after electroporation (range 44-89%; 
Figure 1b).
KLH-specific immune responses
To investigate whether peptide-loaded 
DCs or mRNA-electroporated DCs have 
similar capacity to activate the patient’s
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immune system in general, humoral and 
cellular responses to the control protein 
KLH  were measured in the peripheral 
blood of patients. PBMCs collected after 
each DC vaccination were analyzed for the 
presence o f KLH-reactive T cells in a pro­
liferation assay. In both the peptide group 
and the RNA group all patients tested 
showed a cellular response to KLH. KLH- 
specific IgG antibodies were induced after 
vaccination in 8 o f 10 patients tested 
(80%) in the peptide group and in 2 of 5 
patients tested (40%) in the RNA group. 
Thus, all patients developed a response to 
KLH, either cellular or humoral. However, 
more patients vaccinated with peptide- 
loaded DCs developed a humoral response 
to KLH. These results indicate that there 
may have been differences in the immuno- 
genicity o f DCs in both groups. Neverthe­
less, all patients had a proliferative T cell 
response against KLH, indicating that the 
DCs were able to induce de novo T cell 
responses in all patients.
Post-treatment DTH: CEA specific T cell 
immunity
To investigate the immune response 
against tumor peptides generated in vacci­
nated patients, DTH challenges were per­
formed with mature DCs loaded with 
CEA peptide or CEA mRNA. Biopsies 
were taken from DTH induration sites, 
which were cultured in low amounts of 
IL-2 without the addition o f antigen. In 
eight out of 11 patients, CEA-specific 
DTH-infiltrated T cells were detected by 
tetramer analysis after vaccination. We 
found that 0.3% up to 98% o f CD8+ T 
cells was CEA-specific in DTH biopsies of 
patients vaccinated with HLA-A2 binding 
peptide-loaded DCs (table 1; partially pre­
viously reported in ref. 13).
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Figure 2. KLH responses. (a) KLH-specific pro­
liferation of PBMCs before and after one, two 
and three DC vaccinations of patient RNA-1. 
Proliferative response to KLH is given as prolif­
eration index (proliferation +KLH/proliferation 
-KLH). (b) Humoral responses against KLH in 
the serum of patient RNA-5. Serum was obtained 
before (dotted line) and after three vaccinations 
(solid line). Results of the anti-KLH immune re­
sponses of all patients are shown in table 1.
When these T cells were co-cultured with 
CEA-peptide loaded T2 target cells they 
were able to produce large amounts of 
IFNy and IL-2, but not IL-4 or IL-10 (ta­
ble 1 and ref. 13). An example o f specific 
T cells in a DTH site is shown in figure 3a. 
In table 1 the presence or absence of 
CEA-specific T cells at DTH sites is pre­
sented for each patient. In none of the pa­
tients vaccinated with mRNA- electropo­
rated DCs CEA-specific T cell reactivity 
was found in DTH-biopsies (figure 3b and
table 1), despite the presence o f skin indu­
ration in these patients (data not shown).
DISCUSSION
Colorectal cancer is an immunogenic type 
of cancer. Tumor-associated antigens have 
been identified, tumor-specific T cells have 
been isolated from patients and small 
proof-of-concept studies have shown that 
immunotherapeutic strategies can induce 
immunological and clinical responses20-24. 
CEA is a tumor-associated antigen that is 
expressed by alm ost all colorectal 
cancers25;26. Hence, it is an attractive anti­
gen to use in clinical immunization proto­
cols. However, because CEA is also ex­
pressed in normal tissues, and it is also 
shed from the surface of tumor cells, a 
high threshold o f tolerance must be over- 
come27. Previously, it has been demon­
strated that DCs loaded with CEA-peptide 
can induce robust immune responses in 
colorectal cancer patients13;20;28-31. Theo­
retically, using CEA-mRNA instead of 
peptides to load the DCs, may result in the 
induction of a much broader, more robust 
T cell repertoire, since more epitopes are 
expressed and posttranslational modifica­
tions can occur.
For this reason, we compared CEA- 
peptide loaded DCs with CEA mRNA- 
electroporated DCs as vaccine in colorec­
tal cancer patients. Previously, we have 
shown that with this technique clinical- 
grade DCs can be efficiently transfected 
with tumor antigens, resulting in pro­
longed antigen-presentation and efficient 
T cell activation10. In all patients in the 
mRNA-group, CEA-expression was high 
upon electroporation o f the DCs. The two 
DC vaccines were phenotypically identical. 
In addition, T cell reactivity against the 
control protein KLH  was comparable in 
the two groups after vaccination, indicat­
ing that the T cell-stimulatory potential o f
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patient in jected  D C  (x106) (i.v ./i.d .) proliferative
respo n se
again st
K L H 1
hum oral re­
sp o n se  (IgG ) 
ag a in st K L H 2
tetram er 
positive 
CD8+ T  cells 
in D T H
IF N -
prod u cin g  
CD 8+ T  cells 
in D T H 3
Vacc 1 Vacc 2 Vacc 3
pep-1 4/5 0/5 4/5 + - + +
pep-2 2/5 4/5 0/5 +  +  + + + +
pep-3 14/5 10/5 10/5 +  +  + + + +
pep-4 7/5 9/5 4/5 +  +  + +  2a + +
pep-5 0/3 0/3 0/3 + + + + + +
pep-6 5/5 0/6 4/5 + + +  2a + +
pep-7 3/5 2/5 0/3 +  +  + + - -
pep-8 5/5 5/5 5/5 nt + + +
pep-9 9/5 7/5 9/5 + + + + - -
pep-10 0/4 0/5 0/5 + nt - -
pep-11 5/5 3/5 1/5 + + + - + nt
RNA-1 10/5 7/5 12/5 + + + + - -
RNA-2 13/5 17/5 11/5 + + + - - -
RNA-3 10/5 12/5 11/5 + + + - - -
RNA-4 10/5 10/5 7/5 + - - -
RNA-5 10/5 17/5 9/5 + + + - -
Table 1. Vaccine-induced antigen-specific immune responses. Proliferative response to KLH is 
considered positive when the proliferation index (PI; proliferation +KLH/proliferation —KLH) is >2, 
at least at one time point after vaccination. + 2>PI<10; + +  10>PI<20; + + +  PI>20, at least at one 
time point after vaccination. 2Antibody titer, total IgG, + designates >1 in 400 times diluted serum at 
least at one time point after vaccination. 2aSera of first cycle not available, antibody titers measured af­
ter second cycle of DC vaccinations. 3Ag-recognition of DTH derived T cells after stimulation with T2 
cells loaded with CEA peptides (peptide group and mRNA group) or PBMCs electroporated with CEA 
mRNA (RNA group) as analyzed by IFNy-production. n.t. not tested
the two DC vaccines were comparable. 
However, in 8 out o f 11 patients who were 
vaccinated with peptide-pulsed DCs we 
found CEA peptide-specific T cell reactiv­
ity in DTH skin tests upon vaccination, 
whereas we could not detect CEA peptide- 
specificity in the 5 patients who were vac­
cinated with mRNA-electroporated DCs.
Monitoring immune responses in patients 
who are vaccinated with mRNA- trans­
fected DCs poses a difficulty because the 
precise epitopes are not known. Therefore, 
the absence o f tetramer-positive T cells in 
the DTH tests should be interpreted with 
caution; it is possible that T cells with 
specificity for other epitopes are in fact 
induced.
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Figure 3. Tumor antigen- 
specific T cell responses in 
post-treatment DTH. Tet­
ramer analysis by flow cy­
tometry of T cells derived 
from a biopsy of a DTH re­
action of patient pep-2 (a;
CEA) and RNA-3 (b; DCs 
electroporated with CEA- 
encoding mRNA). Depicted 
is CD8 on the x-axis and 
CEA tetramer staining on 
the y-axis. Tetramer staining 
of 1 log above the negative
population was considered positive. Tumor antigen-specific T cell responses of all patients are shown 
in table 1.
However, in a previous melanoma study, 
using the same DC culture and electropo­
ration protocol but different antigens 
(gp100 and tyrosinase), we were able to 
demonstrate tetramer-specific T cells in 8 
out o f 11 vaccinated patients9. In addition, 
we also used mRNA-electroporated 
PBMCs as stimulator cells in co-culture 
with DTH-infiltrated T cells upon vaccina­
tion for monitoring purposes. Neverthe­
less, we observed no T cell specificity after 
vaccination in the mRNA-group, which 
may depend on the antigen characteristics 
as well as the nominal epitope derived 
from the antigen.
In contrast to studies in melanoma9, these 
results indicate that using CEA-mRNA 
electroporation as a DC antigen loading 
strategy is not superior to peptide loading. 
The reasons for this difference may be 
twofold. First, CEA is not processed 
through the MHC class II pathway 
whereas gp100 is, unless it is coupled to a 
lysosomal targeting signal32. Second, a dif­
ferent T cell repertoire may be present in 
the vaccinated patients.
This study was not designed to allow 
meaningful conclusions on clinical efficacy. 
We did observe a transient increase in se­
rum CEA upon vaccination in several pa­
tients, which may indicate a cytotoxic ef­
fect on CEA-expressing tumor cells33.
CONCLUSION
In our study we could not find a benefit 
for CEA-mRNA electroporation over 
peptide-pulsing as a method for antigen 
loading o f DCs for vaccination in colorec­
tal cancer patients.
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Tumor micro-environments feature immune inhibitory mechanisms that prevent T 
cells from generating effective immune responses. Therapeutic interventions 
aimed at disrupting these inhibitory mechanisms have been shown to result in en­
hanced anti-tumor immunity, but lack direct cytotoxic effects.
Here, we investigated the effect of cancer chemotherapeutics on immune inhibi­
tory pathways. We observed that exposure to platinum-based chemotherapeutics 
markedly reduced expression of the T cell inhibitory molecule Programmed Death 
Receptor-Ligand 2 (PD- L2), for both DCs and tumor cells. This down- regulation of 
PD-L2 results in enhanced antigen-specific proliferation and Th1 cytokine secre­
tion, plus enhanced recognition of tumor cells by T cells. We demonstrated that 
this down-regulation of PD-L2 is controlled by Signal Transducer and Activator of 
Transcription 6 (STAT6). Indeed, patients with STAT6-expressing head and neck 
cancer displayed significantly enhanced recurrence-free survival upon treatment 
with cisplatin-based chemoradiation compared to patients with STAT6-negative 
tumors, demonstrating the clinical relevance of platinum-induced STAT6 modula­
tion.
We conclude that platinum-based anti-cancer drugs can enhance the immuno- 
stimulatory potential of DCs and decrease the immuno-suppressive capability of 
tumor cells. This novel double action of platinum compounds may extend their 
therapeutic application in cancer patients and provides a rationale for their use in 
combination with other immuno-stimulatory compounds.
Recently, it has become evident that che- antigen cross-presentation, T lymphocyte 
motherapeutic drugs not only have a direct expansion and T cell infiltration of tumors 
cytotoxic effect on tumor cells but may by to date unknown molecular mecha- 
also potentiate the immune system via so- nisms3,4. In addition, the cytotoxic drug 
called off-target effects1,2. For example, oxaliplatin was shown to induce an immu- 
direct immune-activating effects o f cancer nogenic type o f cell death in a Toll-like re­
chemotherapy have been observed: treat- ceptor 4/high-mobility group box 1- 
ment with low concentrations o f several dependent manner5,6. However, the effect 
chemotherapeutics resulted in increased of treatment with cancer chemotherapy on
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Figure 1. DCs exposed to platinum- based chemotherapy display enhanced T cell stimulatory ca­
pacity. (a) DCs were cultured in clinically relevant concentrations of chemotherapeutics during 48 
hours of cytokine maturation and subsequently used in a mixed lymphocyte reaction with allogeneic 
peripheral blood mononuclear cells (PBMCs). T cell proliferation was measured by 3H-Thymidine in­
corporation after 5 days. Ctrl= control DCs (non-treated); MTX= methotrexate; Cyta= cytarabine; 
Vinc= vincristine; Irino= irinotecan; Eto= etoposide; Bleo= bleomycine; DTIC= dacarbazine; Gem= 
gemcitabine; 5-FU= 5-fluorouracil; Doxo= doxorubicin; Lena= lenalidomide; Carb= carboplatin (for 
all experiments: * p < 0.05, * *  p < 0.01, * * *  p < 0.001; the mean and standard error of the mean are 
depicted). (b) Same experiment with different platinum-based chemotherapeutics. Ctrl= control DCs 
(non-treated); oxali=oxaliplatin; cis=cisplatin; carb=carboplatin. (c) Concentration-dependent effect of 
platinum exposure on T cell stimulatory potential of DCs. This effect was observed irrespective 
whether the platinum drugs were added during or after DC maturation (data not shown). Concentra­
tions of oxaliplatin were 0.5, 2.0, 3.0 and 4.0 microgram/ml, respectively. (d and e) Secretion of 
interferon-y and IL-2 by T cells in MLR upon exposure to DCs cultured with or without platinum. (f) 
Enhanced T cell stimulatory potential of DCs matured with cytokines or TLR-ligands in the presence 
of platinum chemotherapy in an antigen-specific model. KLH-specific T cells were cocultured with 
KLH-loaded DCs, matured with cytokines or R848 and poly-I:C, in the presence or absence of plati­
num chemotherapy. The exposure to platinum compounds increased the T cell stimulatory capacity of 
cytokine-matured DCs to a level that was almost comparable to that of fully activated, TLR-matured 
DCs. cDC=cytokine-matured DCs; TLR-DC= TLR-ligands matured DCs. Ox= oxaliplatin. (g) En­
hanced interferon-y secretion by T cells in MLR upon exposure to TLR-ligand matured DCs cultured 
with platinum as compared to platinum-untreated DCs.
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immune inhibitory pathways that play a 
crucial role in tumor immune-escape7 is 
unknown.
RESULTS AND DISCUSSION 
The T cell-stimulating potential of DCs is 
enhanced by platinum-based chemo­
therapy
We hypothesized that anti-cancer chemo- 
therapeutics may influence the type o f T 
cell-mediated immune responses induced 
by DCs, by acting on immune inhibitory 
pathways. Therefore, we determined the 
effect o f a large number of clinically rele­
vant concentrations o f chemotherapeutic 
agents on the allogeneic T cell stimulatory 
potential o f monocyte-derived DCs (sup­
plementary table 1).
Surprisingly, DCs exposed to carboplatin 
during their maturation by cytokines in­
duced a significantly higher T cell prolif­
eration compared to all other chemothera­
peutics tested (figure 1a). We also observed 
this similar enhanced immune-stimulating 
activity in a dose-dependent manner for 
the platinum compounds oxaliplatin and 
cisplatin, which are frequently used in the 
clinic (figure 1b and c, supplementary table 
1). T cells that were activated by DCs ex­
posed to platinum compounds produced 
significantly higher levels o f interferon-y 
(IFNy) and interleukin-2 (IL-2) compared 
to untreated DCs (figure 1d and e). 
Notably, this increased T cell-stimulating 
activity of platinum-treated DCs was also 
observed in antigen-specific T cells using 
keyhole limpet hemocyanin (KLH) as a 
model antigen. In this antigen-specific 
context we found a profoundly enhanced 
T cell-stimulatory capacity when DCs were
exposed to platinum compounds (figure 
1f). Moreover, we observed that the T cell 
stimulatory capacity of DCs matured in 
vitro through Toll-like receptors (TLR) in­
stead o f cytokines, was also further en­
hanced by platinum-exposure (figure 1f). 
This demonstrates that the observed effect 
of platinum compounds is independent 
from stimuli used to activate and/or ma­
ture DCs. The observed effect on TLR- 
DCs was not only limited to enhanced T 
cell proliferation but also supported by 
abundant IFN-y production by these T 
cells (figure 1g).
The enhanced im m unogenicity of 
platinum-treated DCs is dependent on 
PD-L2/STAT6
To investigate why platinum-treated DCs 
display enhanced immunogenicity, we de­
termined their phenotype (figure 2a, shows 
effects o f oxaliplatin; similar results were 
obtained with carboplatin and cisplatin, 
not shown).
No significant differences were observed 
in expression o f MHC class I and II or the 
costimulatory molecules CD80 and CD86 
on platinum-treated versus non-treated 
DCs. We also detected no relevant differ­
ences in pro- or anti-inflammatory cyto­
kine production o f DCs matured in the 
presence of platinum compounds in com­
parison with non-treated cytokine- or 
TLR-matured DCs (figure 2b and c, sup­
plementary figure 1).
We therefore concluded that the enhanced 
immunogenicity is not caused by increased 
expression of MHC- or co-stimulatory- 
molecules or by increased pro- inflamma­
tory cytokine secretion upon platinum 
treatment.
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Figure 2. Platinum-based chemotherapeutics down -regulate PD-L2 expression on DCs, resulting 
in enhanced T cell activation in a STAT6- dependent manner. (a) Expression of MHC class I and II, 
co-stimulatory molecules CD80, CD83 and CD86 by DCs exposed to increasing clinically relevant con­
centrations of oxaliplatin during maturation with R848/poly-I:C (isotype grey; indicated antibody 
white). (b and c) Production of pro-inflammatory cytokines T N Fa and IL-8 by DCs exposed to plati­
num chemotherapy during maturation. Supernatants were harvested 24 hours after stimulation. (d and 
e) Expression of T cell inhibitory molecules PD-L1 and PD-L2 (isotype grey; untreated DCs white; 
platinum-treated DCs dark-grey) and B7-H2/H3/H4 and IDO by DCs exposed to platinum chemo­
therapy during maturation. (f) MLR with DCs matured in the presence (black bars) or absence (grey 
bars) of oxaliplatin 5 ng/ml in the presence of blocking antibodies against PD-L1, PD-L2 or control 
immunoglobin (# p < 0.05 compared with IgG control DCs). (g) MLR with DCs that were transfected 
with STAT6 siRNA or control-siRNA and subsequently matured with or without oxaliplatin 5 ng/ml.
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Since DCs can also express several T cell 
inhibitory molecules, including PD-L1 and 
PD-L2, the enhanced T cell stimulatory 
potential upon platinum exposure could 
result from decreased PD-L expression. 
Indeed, treatment with oxaliplatin, cis- 
platin or carboplatin during DC matura­
tion moderately reduced the expression of 
PD-L1, and profoundly reduced the ex­
pression of PD-L2 (figure 2d). Expression 
o f other known inhibitory receptors re­
mained unaltered upon platinum-treatment 
(figure 2e).
Short-circuiting o f the PD-1 — PD-L1/2 
axis by anti- PD-L1 and PD-L2 antibodies 
enhanced the capacity o f mature DCs to 
stimulate T cells to a similar level when 
compared to platinum-treated DCs. How­
ever, the increased allo-stimulatory poten­
tial o f DCs upon platinum treatment is ab­
rogated in the presence of PD-L2 antibod­
ies (figure 2f). This strongly supports the 
notion that down-regulation of PD-L1, 
and particularly PD-L2, is a major cause of 
the enhanced T cell stimulatory capacity of 
platinum-treated DCs.
Since STAT6 is a known regulator of PD- 
L28,9, we subsequently tested the T cell 
stimulatory activity of platinum-treated 
DCs exploiting small interfering RNA 
(siRNA) against STAT6 (figure 2g, sup­
plementary figure 2). Despite the fact that 
inhibition was not complete, STAT6 
knock-down DCs now lacked the previ­
ously observed enhanced T cell response 
upon platinum treatment, which was not 
observed when DCs were transfected with 
control siRNA.
Together, these data show that the en­
hanced immunogenicity o f platinum- 
treated DCs depends on STAT6 inactiva­
tion resulting in PD-L2 down-regulation.
Platinum dephosphorylates STAT6 in 
tumor cells resulting in decreased PD-L2 
and subsequent increased T cell recog­
nition
Since many cancer cells are capable to in­
duce an immunosuppressive microenvi­
ronment and to upregulate PD-Ls in order 
to evade anti-tumor immunity10, we next 
tested if the same platinum compounds 
also affected PD-L expression on tumor 
cells. To mimic an immunosuppressive mi­
croenvironment in vitro, we exposed BLM 
melanoma cells to cytokine combinations 
known to induce PD-L1/2 expression on 
endothelial cells, i.e. IL-4 together with 
IFNy, LPS or T N F a11. Subsequent expo­
sure to platinum compounds clearly re­
versed PD-L2 expression, but not PD-L1 
expression (figure 3a, supplementary figure 
3).
Because PD-L2 is regulated by STAT6 and 
nuclear factor k B  (NFkB)8,9, 12, we measured 
protein levels of STAT6 and phosphory- 
lated (active) STAT6 in BLM tumor cells 
upon co-culture with IL-4 and several 
NFkB activating stimuli (figure 3b, sup­
plementary figure 4). We found that cis- 
platin caused a strong dephosphorylation 
of STAT6. Although several STAT mole­
cules are constitutively expressed in multi­
ple types o f cancer and play an important 
role in the proliferative capacity and anti- 
apoptotic and immune-evasive potential o f 
cancer cells13, a direct STAT-inactivating 
mechanism induced by cytotoxic chemo­
therapy has not been reported before.
To further explore whether chemotherapy- 
induced reversal o f an immunosuppressive 
tumor microenvironment not only reduces 
PD-L2, but also effectively enhances sus­
ceptibility o f tumor cells to cytotoxic T 
cells, we compared the recognition of 
platinum-treated and non-treated gp100
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Figure 3. Platinum-based chemotherapeutics downregulate PD-L2 on tumor cells via STAT6 
dephosphorylation, resulting in enhanced tumor cell recognition by tumor antigen-specifìc T 
cells. (a) PD-L1 and PD-L2 expression by BLM melanoma cells cultured with or without platinum 
chemotherapy for 24 hours (cis= cisplatin 10^g/ml). (b) Western blot of BLM melanoma cells treated 
with or without IL-4, IFNy, LPS, T N Fa and cisplatin 20^g/ml for 8 hours, as indicated. (c) IFNy pro­
duction of gp100-specific T cells upon co-culture with gp100-expressing BLM melanoma cells, pre­
incubated with or without cisplatin 10^g/ml for 24 hours. (d) STAT6 expression by squamous cell car­
cinoma of the head and neck. (e) STAT6-negative tumor with immune infiltrates as internal positive 
control. (f) Kaplan-Meier estimates of recurrence-free survival of patients with (n=35) or without 
(n=21) tumor STAT6 expression (p=0.038). The time to recurrence was analyzed in a cohort of head 
and neck cancer patients that had been treated with cisplatin and radiotherapy in our institute in the 
period of 2003-2007.
antigen expressing melanoma cells by 
gp100-specific T cells 14. As expected, we 
observed that platinum-induced reduction 
o f PD-L2 coincides with enhanced T cell 
recognition as measured by antigen- 
specific IFNy production (figure 3c). To­
gether, these findings indicate that plati­
num compounds not only directly affect 
immune cells, but also modulate an immu­
nosuppressive microenvironment by
dephosphorylating STAT6 in tumors, re­
sulting in down-regulation o f PD-L2 and 
subsequent enhanced tumor cell killing by 
cytotoxic T lymphocytes.
Tumor STAT6 dictates response to 
platinum-based cancer treatment
Finally, to verify the clinical relevance of 
platinum-induced STAT6 modulation in 
tumor cells in cancer patients, we analyzed
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tumor STAT6 expression in a cohort of 
patients with squamous cell carcinoma of 
the head and neck that had been treated in 
our institute with cisplatinum in combina­
tion with radiotherapy (figure 3d and e, 
supplementary table 2). After a median 
follow-up o f 68 months we observed a 
clinically highly relevant and statistically 
significant difference between patients 
with STAT6-negative tumors and STAT6- 
positive tumors with a 3-year recurrence- 
free survival o f 48% and 80%, respectively 
(figure 3f). These data demonstrate the 
significance o f platinum-induced STAT6 
modulation in the tumor microenviron­
ment in cancer patients.
The PD-1/PD-L pathway is of pivotal 
importance in regulating the immune bal­
ance between T cell activation and inhibi­
tion10. High PD-L expression by antigen 
presenting DCs can result in the induction 
o f tolerant or anergic T cells10,15,16. A wide 
variety o f human cancers express PD-Ls, 
which are known to correlate with poor 
prognosis17-20. Antibody blockade of the 
PD-1/PD-L pathway results in enhanced 
tumor-specific T cell expansion and activa- 
tion21,22. Our findings show that treatment 
with platinum compounds down-regulate 
these PD-L inhibitory molecules, which 
not only results in enhanced T cell stimula­
tion by dendritic cells, but at the same time 
enhances the sensitivity o f the tumor for 
lysis by cytotoxic T cells. The importance 
o f our findings is underscored by recent 
evidence that not only pro-inflammatory 
cytokines such as T N F a23, but also IL-4 
and IL-13 are abundantly present in the 
tumor microenvironment and induce 
phosphorylation o f STAT6 in tumor cells, 
resulting in an incompetent Th2 type of 
immune milieu24. We propose that 
platinum-based chemotherapy may revert 
this incompetent Th2 into effective Th1
anti-tumor immunity. These findings may 
contribute to the design o f innovative 
treatment schedules for cancer patients by 
the combination o f platinum compounds 
with known immunotherapeutic ap­
proaches.
METHODS
DC culture
Peripheral blood mononuclear cells were obtained 
from leukapheresis material from melanoma and 
colorectal cancer patients participating in clinical 
DC vaccination studies (Clinical Trials.gov identi­
fication numbers NCT-00243529 and NCT- 
00228189)25’26. Informed consent for experimen­
tal use of the cells was obtained from all patients. 
DCs were generated from adherent peripheral 
blood mononuclear cells by culturing in X-VIVO 
15 medium (Lonza, Verviers, Belgium) supple­
mented with 2% human serum (Sanquin, Amster­
dam, the Netherlands) in the presence of 
interleukin-4 (IL-4, 500 U/ml) and granulocyte- 
monocyte colony stimulating factor (800 U/ml, 
both Strathmann, Hamburg, Germany), as previ­
ously described(27).
For experiments concerning Keyhole Limpet 
Hemocyanine (KLH)-specific immune responses, 
the DCs were loaded on day 3 of the culture with 
KLH (10 ng/ml; Calbiochem, USA).
At day 5, DCs were matured with a cytokine 
cocktail (prostaglandin E2 [Pfizer, New York, 
NY, USA, 10 ng/ml], tumor necrosis factor alpha 
[TNFa, 10 ng/ml], IL-1P [ 5 ng/ml] and IL-6 [15 
ng/ml, all CellGenix, Freiburg, Germany]) or with 
Toll-like receptor 3 and 7 ligands (poly-I:C, 
Sigma-Aldrich, St. Louis, USA 20 ng/ml and 
R848, Axxora, Lausan, Switzerland 3 ng/ml) for 
48 hours. Chemotherapy was added either after 
the maturation or during the maturation, as indi­
cated. Supernatants were harvested after 24 hours 
for cytokine analysis.
Mixed lymphocyte reaction
DCs were plated in sterile 96 well U-bottom 
plates (Corning, New York, USA), 2x104/well in 
RPMI medium (Invitrogen, Carlsbad, USA), sup­
plemented with 5% human serum. Peripheral 
blood mononuclear cells of a healthy voluntary 
donor were freshly isolated by density gradient 
centrifugation and added to the wells, 1x105/well. 
Supernatants were harvested after 48 hours for 
cytokine analysis, as indicated. After 5 days 1 |aCi/
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well of 3H-thymidine was added to the culture for 
8 hours, after which proliferation was stopped by 
storing the culture plate at -20°C. Incorporation 
of 3H-thymidine was measured in a B-counter.
In some experiments blocking antibodies against 
PD-L1 and PD-L2 (both from e-Bioscience, San 
Diego, USA) were added to the culture in a final 
concentration of 10 |ag/ml, as indicated. Normal 
mouse serum was used as isotype control. Anti­
bodies against PD-L1 and PD-L2 were pre­
incubated with the DCs for 30 minutes before 
adding the PBMCs.
Cytokine measurement and flow cytometry
Cytokine production was measured by cytometric 
bead array in the supernatants of the MLR (Th1/ 
Th2 Cytokine CBA 1; BD Pharmingen or Flow- 
cytomix BenderMed, Vienna, Austria) or DC cul­
ture (Inflammation kit CBA; BD Pharmingen or 
Flowcytomix, BenderMed).
Flowcytometry
The following antibodies were used for analysis of 
DC and tumor cell phenotype: HLA-ABC (hybri­
doma W6/32), HLA-DR/DP (hybridoma Q5/ 
13), CD80, CD86, (all Becton-Dickinson, Frank­
lin Lakes, USA), CD83 (Beckman Coulter, Fuller­
ton, USA), PD-L1-PE (eBioscience, San Diego, 
USA), PD-L2-PE, IgG1-PE (both Becton- 
Dickinson).
Tumor cell culture
The human melanoma cell line BLM was cultured 
in DMEM medium (Invitrogen, Breda, the Neth­
erlands) supplemented with penicillin G, strepto­
mycin sulfate, and amphotericin B (Invitrogen) 
and 7% human serum, in a concentration of
0.5x106 cells in T25 flasks or 1x106 cells in T75 
flasks (Corning). Twice weekly the cells were har­
vested and plated again 1:10.
For PD-L expression upon platinum-treatment, 
cells were cultured in the presence of oxaliplatin, 
carboplatin and cisplatin in concentrations as in­
dicated. After 24 hours the cells were washed 
twice with phosphate-buffered solution (PBS), 
upon which trypsine (Invitrogen) was added for 
30 seconds, which was blocked with human 
serum-containing medium. Then the cells were 
harvested and analyzed by flowcytometry.
For (p)STAT6/SHP-1 western blot analysis, cells 
were activated for 30 minutes to 24 hours (as in­
dicated) with IL-4 (300 U/ml, Strathmann) and/ 
or IFNy (400 U/ml, Endogen, Woburn, USA) 
with or without cisplatin 10 ng/ml (added 15 
minutes before the IL-4/IFNy). This was done in
5ml medium in T25 flasks for each condition. 
After 30 minutes of activation the cells were 
washed twice with phosphate-buffered saline 
(PBS), upon which trypsine (Invitrogen) was 
added for 30 seconds which was blocked with the 
human serum-containing medium. Then the cells 
were harvested. For western blot analysis cells 
were washed twice in PBS, centrifuged 1500 rpm 
for 5 minutes, and lysis buffer was added, on ice 
(see below).
In vitro chemotherapy treatment
The chemotherapeutic agents that were used in 
the experiments are indicated in supplementary 
table 1. All drugs were used in clinically meaning­
ful concentrations.
Transfection of siRNA against STAT6
Small interfering RNA (ON-TARGET^/us) for 
the STAT6 gene were obtained from Dharmacon 
(Lafayette, CO). In the case of DC, ~ 1x106 im­
mature monocyte-derived DCs were replated on 
day 3 in a well of a 24-well plate, and transfected 
at day 5 with 2 nM siRNA and 6 nl Dhar- 
maFECT4 transfection reagent, essentially follow­
ing the manufacturer's directions. Knockdown 
efficiency was assessed at the protein level by 
means of Western blot analysis. Cells were stimu­
lated on day 6 with poly-I:C and R848 and 48 hr 
after stimulation these cells were used in mixed 
lymphocyte reactions, as described above.
Preparation of protein lysates and Western 
bloMng
Regardless of celltype, 1x106 cells were lysed in 
100 nl phosphatase-inhibiting lysisbuffer contain­
ing 10 mM Tris/HCl pH 7.8, 5 mM EDTA, 50 
mM NaCl, 1 mM Na3VO4 10 mM pyrophosphate, 
50 mM NaF, 1% Triton X-100, 1mM PMSF, 10 
ng/ml aprotinin, 10 ng/ml leupeptin and 1X 
Roche protease inhibitor cocktail (Roche Diag­
nostics Nederland BV, Almere, the Netherlands). 
Before polyacrylamide gel electroforesis, reducing 
sample buffer (62.5 mM Tris/HCl pH 6.8, 25% 
v/v glycerol, 2% w/v sodium dodecyl sulfate,
0.01% w /v bromophenol blue, 5% v/v/P- 
mercaptoethanol) was added 1:1 to a lysate 
equivalent of ~200,000 cells. Samples were sub­
jected to polyacrylamide gel electrophoresis using 
the MiniProtean system (BioRad, Hercules, CA) 
and further processed for Western blot analysis28. 
After blocking, membranes were incubated with 
one of the following antibodies: mouse mono­
clonal anti-P-actin (1:10,000; Sigma-Aldrich, St. 
Louis, MO), mouse monoclonal anti-pSTAT6
122
chapter 8
(pY641; 1:250; BD Biosciences Pharmigen) or 
rabbit polyclonal anti-STAT6 antibody (S-20; 
1:500; Santa Cruz Biotechnology). After washing, 
the membranes were incubated with polyclonal 
goat anti-rabbit Alexa Fluor-680 (Molecular 
Probes, Eugene, OR) and goat anti-mouse IRD- 
ye800CW (LI-COR Biosciences, Lincoln, NE) as 
a secondary antibody, and analyzed with the LI­
COR Odyssey Imaging system (LI-COR Biosci­
ences, Lincoln, NE). Integrated intensities were 
analyzed using Excel (Microsoft Corp., Redmond, 
WA). Whenever necessary, membranes were 
stripped in 0.2 M glycine/1% w /v sodium dode- 
cyl sulfate, pH 2.5, blocked, and reprobed and 
processed as described above.
Generation of CD8+ gp100- specific T cells
The vectors pGEM4Z-TCRa296 and pGEM4Z- 
TCRP296, a kind gift from Dr. N. Schaft (Univer­
sity Hospital Erlangen, Germany), encode the 
TCR a  and P chains originating from a 
gp100:280-288/HLA-A2-specific CTL clone29. 
Gp100-specific T cells were generated by trans­
ferring the TCR a  and P chain to T cells by elec­
troporation of RNA, resulting in transient expres­
sion of the TCR chains as described previously30. 
Briefly, the DNA vectors were linearized with SpeI 
enzyme and purified by phenol/chloroform ex­
traction and ethanol precipitation, and used as 
DNA templates for in vitro transcription. In vitro 
RNA synthesis was done with T7 RNA po­
lymerase (mMESSAGE mMACHINE T7 kit; 
Ambion, Austin TX, USA) according to manufac­
turer’s instructions. After DNase treatment, RNA 
was purified by phenol/chloroform extraction 
and isopropanol precipitation. RNA concentra­
tion was measured spectrophotometrically and 
RNA was stored at -20°C. RNA quality was veri­
fied by agarose gel electrophoresis.
CD8+ T cells were isolated from PBMC of an 
HLA-A2.1 positive donor. Monocytes were re­
moved via adherence and CD8+ T cells were iso­
lated from the non-adherent cell population by 
positive isolation using FITC-conjugated anti­
human CD8 (BD Biosciences, San Jose, CA, 
USA) and anti-FITC microbeads (Anti-FITC 
Multisort kit, Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to manufacturer’s instruc­
tions.
For RNA electroporation, the CD8+ T cells were 
washed once with PBS and once with OptiMEM 
without phenol red (Invitrogen Gmbh, Karlsruhe, 
Germany). 10-12x106 cells were incubated for 3 
min with 15-20 |ag of RNA in 200 |al OptiMEM 
in a 4-mm cuvette (Biorad). Subsequently, cells
were pulsed in a Genepulser Xcell (Biorad). Pulse 
conditions were square-wave pulse, 500 V, 5 ms. 
Immediately after electroporation, the cells were 
transferred to X-VIVO-15 medium without phe­
nol red (Cambrex, Belgium) supplemented with 
2% human serum. After 4 hrs incubation at 37°C, 
cells were washed and frozen in FCS and 10% 
DMSO in liquid nitrogen. Expression of the 
gp100 TCR in the T cells was verified by flow cy­
tometry using PE-conjugated anti-TCRVpi4 
mAb (Coulter Immunotech, Marseille, France), 
which recognizes the gp100 TCR. Functionality 
of the gp100-specific T cells was shown by 
upregulation of the early activation marker CD69 
after overnight stimulation with gp100:280-288 
peptide loaded HLA-A2+ immature DCs.
Gp100- specific activation of CD8+ T cells
For gp100-specific activation BLM cells and 
BLM-gp100 14 were activated for 20 hours with 
IL-4 (300U/ml, Strathmann) and/or IFN (400U/ 
ml, Endogen, Woburn, USA) with or without cis­
platin 5 ng/ml (added 15 minutes before IL-4/ 
IFNy). After 20 hours of activation BLM-gp100 
or BLM (7x103 per well) were washed and co­
incubated with CD8+ gp100:280-288-specific T 
cells (5x104 per well) in round-bottom 96 well- 
plates. After overnight incubation IFNy produc­
tion was measured using a standard sandwich 
ELISA. Gp100-specific T cells produced no IFN 
ywhen co-cultured with BLM melanoma cells that 
were not transfected with gp100 (not shown). 
Coating Ab: mouse-IgG1-anti-hIFNy (clone 2G1; 
Pierce, Rockford, IL), detection Ab: biotinylated 
mouse-IgG1-anti-hIFNy (clone B133.5; Pierce). 
Streptavidin-HRP and TMB were used as enzyme 
and substrate, respectively.
STAT6 staining of tumor sections
Paraffin-embedded slides of 58 patients with lo­
cally advanced squamous cell carcinoma of the 
head and neck that had been treated with cisplatin 
(weekly 40 mg/m2) in combination with acceler­
ated radiotherapy were stained for STAT6 expres­
sion. Inflammatory cells that stain for STAT6 
were used as internal control. Percentage of tu­
mor cells with cytoplasmic staining, regardless of 
intensity, was estimated. Based on the distribution, 
50% positive cells was chosen as cut-off level: 
tumors were considered STAT6-positive when 
more than 50% of the cells had cytoplasmatic 
staining.
The staining procedure was as follows. Slides were 
deparaffinized by 5-minute incubation in xylol, 
and washed in 100% ethanol, and hydrated in
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PBS. Slides were then incubated in 3% hydrogen 
peroxide for 10 minutes and hydrated in PBS. The 
slides were then placed in preheated to boiling 
temperature Sodium citrate, 0.05%, pH 6, and 
incubated for 10 minutes and rinsed in 1x PBS. 
They were then incubated overnight with the 
primary antibody STAT6 diluted in Normal anti­
body Diluent (Immunologic, Duiven, the Nether­
lands) overnight at room temperature (dilution 
1:80) at 4 °C. The secondary antibody was Pow­
erVision Poly-HRP—Anti M s/Rb/Rt IgG (Immu­
nologic, Duiven, the Netherlands) which was used 
for 30 minutes by RT, followed by DAB (DAB 
plus, Power DAB) substrate for 5 min, and coun­
terstained with hematoxylin and mounted with 
Xylol.
Clinical study
We retrospectively constructed a patient database 
using data obtained in the period of 2003-2007 in 
our institute. Eligible patients had histologically 
proven locally advanced squamous cell carcinoma 
of the head and neck without distant metastases, 
which was treated with weekly cisplatin 40mg/m2 
in combination with a 6-week course of radio­
therapy. Histological tumor material for STAT6- 
staining obtained before treatment had to be 
available. The primary endpoint was recurrence- 
free survival, which was defined as the period be­
tween start of treatment and the occurrence of a 
relapse, not including a second primary or death 
due to other causes. The following characteristics 
were registered in the database: tumor location, 
TNM-stage, age and sex (supplementary table 2). 
We collected data of 58 patients. Tumor and pa­
tient characteristics were evenly distributed be­
tween STAT6-positive and STAT6-negative cases. 
Two patients were excluded: one patient because 
of inadequate tumor material for STAT6-staining, 
one patient because only material was available 
that was obtained after treatment.
Statistica/ analysis
Data were analyzed statistically by means of 
analysis of variance (ANOVA) and Student- 
Newman-Keuls-test. Statistical significance was 
defined as p < 0.05. The recurrence-free survival 
curves were estimated by the Kaplan—Meier 
method and compared by means of the log-rank 
test.
Supplementary Information is linked to the on­
line version of the paper.
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Supplementary figure 1. Cytokine production by monocyted- derived DCs. Cells were maturated by 
R848/Poly-I:C in the presence of clinically relevant concentrations of platinum compounds (numbers 
on X-axis denote jig/ml). Levels are means with SD of 3 independent experiments.
Supplementary figure 2. Knock-down efficiency of DCs transfected with con­
trol or STAT6- siRNA as measured by western blot analysis. The ratio of the in­
tegral intensity of STAT6 protein expression, normalized to the integral intensity of 
actin is shown.
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Supplementary figure 3. 
PD-L2 expression by BLM 
melanoma cell lines. Cells 
were treated with IL-4 
combined with T N F a/
4 IFNy/LPS, with or without 
cisplatin 10 ¡ig/ml (light- 
grey-isotype control, dark- 
grey PD-L2).
10° 101 10* 103 104 10u 101 10z 103 10* 10° 101 10z to3 104FL2-H FL2-H FL2-H
control |g
cisplatin
+ +
—ICO
+ +
—ICO
+
STAT6
pSTAT6
actin
Supplementary figure 4. Western blot 
analysis of BLM melanoma cells. Expres­
sion of total STAT6, phosphorylated STAT6 
and actin was measured 30 minutes, 1 hour, 2 
hours, 8 hours and 24 hours after stimulation 
with IL-4/IFNy and cisplatin 20 ¡ig/ml.
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compound group C *Vymax clinical dose ref. used dose
in vitro
Methotrexate (Emthexate, Pharma- 
chemie, the Netherlands)
folic acid antagonist 363^g/ml 8-12g/m2 -1 350^g/ml
Vincristine (Vincristine, Pharma- 
chemie, the Netherlands)
vinca-alkaloid 0.37^g/ml 0.5mg/m2 -2 0.4^g/ml
Irinothecan (Campto, Pfizer, Bel- 
gmm)
Topo-isomerase I inhibi­
tor
5^g/ml 350mg/m2 -3 5^g/ml
Etoposide (Toposin, Pharmache- 
mie, the Netherlands)
Topo-isomerase II inhibi­
tor
15^g/ml 150mg/m2
(oral)
-4 15^g/ml
Bleomycin (Pharmachemie, the 
Netherlands)
anti-tumor antibiotic 0.19U/ml 30U -5 0.2U/ml
DTIC (Dacarbazin, Medac, Ger­
many)
alkylating agent 150^g/ml 1900mg/m 2
(HD**)
-6 150^g/ml
Cisplatinum (Platosin, Pharmache- 
mie, the Netherlands)
platinum 5 ^g/ml 100mg/m 2 -7 1; 2; 3; 5; 
10 ^g/ml
Oxaliplatin (Eloxatin, Sanofi- 
Synhelabo, the Netherlands)
platinum 2.5-5.5^g/ml 130mg/m 2 -8 0.5; 2; 3; 4; 
5; 7^g/ml
Carboplatin (Carbosin, Pharma- 
chemie, the Netherlands)
platinum 40-80^g/ml 500mg/m2 -9 20; 40; 80; 
120^g/ml
Cyclophosphamide (Endoxan, Bax­
ter, the Netherlands)
nitrogen mustard alky­
lating agent
140^g/ml 4g/m2 (HD) -10 140^g/ml
Gemcitabine (Gemzar, Eli Lilly, the 
Netherlands)
pyrimidine antagonist 23^g/ml 1000mg/m 2 -11 25^g/ml
5-FU (5-Fluorouracil, Teva, the 
Netherlands)
pyrimidine antagonist 500^g/ml 1250mg/m 2 
(capecitabine)
-12 500^g/ml
Doxorubicine (Doxorubin, Phar- 
machemie, the Netherlands)
anthracycline derivate 0.5^g/ml 30mg/m2 -13 0.5 ^g/ml
Lenalidomide (Revlimid, Cellgene Thalidomide analogue 0.5^g/ml 1x25mg -14 0.5^g/ml
-Europe, the Netherlands, )
Supplementary table 1. Characteristics of the chemotherapeutic agents used in the in vitro ex­
periments.
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STAT6+ (n=37) STAT6- (n=21)
median age (range) 55 (32-71) 57 (40-74)
Localization
oral cavity/oropharynx 59% 47%
hypopharynx 41% 53%
T-stage
T1 3% 5%
T2 11% 14%
T3 43% 43%
T4 43% 38%
N-stage
N1 5% 14%
N2 11% 19%
N3 76% 62%
N4 8% 5%
Supplementary table 2. Patient characteristics
SUPPLEMENTARY REFERENCES
1. Bacci, G., Loro, L., Longhi, A., Bertoni, F., Bacchini, P., 
Versari, M., Picci, P, and Serra, M. 2006. No correlation 
between methotrexate serum level and histologic response 
in the pre-operative treatment o f extremity osteosarcoma.
Anticancer Drugs 17:411-415.
2. Sethi, VS., Jackson, D.V, Jr., White, D.R., Richards, F., 
2nd, Stuart, J.J., Muss, H.B., Cooper, M.R., and Spurr, C.L. 
1981. Pharmacokinetics o f vincristine sulfate in adult can­
cer patients. Cancer Res 41:3551-3555.
3. Raymond, E., Fabbro, M., Boige, V, Rixe, O., Frenay, 
M., Vassal, G., Faivre, S., Sicard, E., Germa, C., Rodier, 
J.M., et al. 2003. Multicentre phase II study and pharma­
cokinetic analysis o f irinotecan in chemotherapy-naive 
patients with glioblastoma. Ann Oncol 14:603-614.
4. Chabot, G.G., Armand, J.P, Terret, C., de Forni, M., 
Abigerges, D., Winograd, B., Igwemezie, L., Schacter, L., 
Kaul, S., Ropers, J., et al. 1996. Etoposide bioavailability 
after oral administration o f the prodrug etoposide phos­
phate in cancer patients during a phase I study. J  Clin Oncol 
14:2020-2030.
5. Markasz, L., Stuber, G., Flaberg, E., Jernberg, A.G., 
Eksborg, S., Olah, E., Skribek, H., and Szekely, L. 2006. 
Cytotoxic drug sensitivity o f Epstein-Barr virus trans­
formed lymphoblastoid B-cells. BMC Cancer 6:265.
6. Buesa, J.M., and Urrechaga, E. 1991. Clinical pharma­
cokinetics o f high-dose DTIC. Cancer Chemother Pharmacol 
28:475-479.
7. Gullo, J.J., Litterst, C.L., Maguire, P.J., Sikic, B.I., Hoth, 
D.F, and Woolley, PV 1980. Pharmacokinetics and protein 
binding o f cis-dichlorodiammine platinum (II) adminis­
tered as a one hour or as a twenty hour infusion. Cancer 
Chemother Pharmacol 5:21-26.
8. Gamelin, E., Bouil, A.L., Boisdron-Celle, M., Turcant,
A., Delva, R., Cailleux, A., Krikorian, A., Brienza, S., 
Cvitkovic, E., Robert, J., et al. 1997. Cumulative pharma­
cokinetic study o f oxaliplatin, administered every three 
weeks, combined with 5-fluorouracil in colorectal cancer 
patients. Clin Cancer Res 3:891-899.
9. Gaver, R.C., Colombo, N., Green, M.D., George, A.M., 
Deeb, G., Morris, A.D., Canetta, R.M., Speyer, J.L., Far­
men, R.H., and Muggia, F.M. 1988. The disposition of 
carboplatin in ovarian cancer patients. Cancer Chemother 
Pharmacol 22:263-270.
10. Chen, T.L., Kennedy, M.J., Anderson, L.W, Kiraly, S.B., 
Black, K.C., Colvin, O.M., and Grochow, L.B. 1997. Non­
linear pharmacokinetics o f cyclophosphamide and 4- 
hydroxycyclophosphamide/aldophosphamide in patients 
with metastatic breast cancer receiving high-dose chemo­
therapy followed by autologous bone marrow transplanta­
tion. Drug Metab Dispos 25:544-551.
129
chapter 8
11. Sugiyama, E., Kaniwa, N., Kim, S.R., Kikura-Hanajiri, 
R., Hasegawa, R., Maekawa, K., Saito, Y, Ozawa, S., Sa- 
wada, J., Kamatani, N., et al. 2007. Pharmacokinetics o f 
gemcitabine in Japanese cancer patients: the impact o f a 
cytidine deaminase polymorphism. J  Clin Oncol25:32-42.
12. Gieschke, R., Reigner, B., Blesch, K.S., and Steimer, J.L. 
2002. Population pharmacokinetic analysis o f the major 
metabolites o f capecitabine. J Pharmacokinet Pharmacodyn 
29:25-47.
13. Eksborg, S., Strandler, H.S., Edsmyr, F., Naslund, I., 
and Tahvanainen, P 1985. Pharmacokinetic study o f i.v. 
infusions o f adriamycin. Eur J  Clin Pharmacol28:205-212.
14. Chen, N., Lau, H., Kong, L., Kumar, G., Zeldis, J.B., 
Knight, R., and Laskin, O.L. 2007. Pharmacokinetics o f 
lenalidomide in subjects with various degrees o f renal im­
pairment and in subjects on hemodialysis. J  Clin Pharmacol 
47:1466-1475.
130
Chapter 9
A pilot study on the immunogenicity of dendritic cell 
vaccination during adjuvant oxaliplatin/capecitabine 
chemotherapy in colon cancer patients
Lesterhuis WJ, De Vries IJM, Aarntzen EA, De Boer A, Scharenborg NM, Van de Rakt M, 
Van Spronsen DJ, Preijers FW, Figdor CG, Adema GJ, Punt CJA
British Journal of Cancer 2010, In Press

chapter 9
A pilot study on the immunogenicity of dendritic cell vacci­
nation during adjuvant oxaliplatin/capecitabine chemother­
apy in colon cancer patients
W. Joost Lesterhuis1, I. Jolanda M. de Vries2, Erik A. Aarntzen1, Annemiek de Boer2, 
Nicole M. Scharenborg2, Mandy van de Rakt2, Dick-Johan van Spronsen3, Frank W. 
Preijers4, Carl G. Figdor2, Gosse J. Adema2, Cornelis J.A. Punt1
d e p a r t m e n t s  o f  Medica l  Oncology,  2T u m o r  Immunology,  3La b or a tory  M edic ine ,  Ni jm ege n  Centre  
for  M o le cu la r  Life Sc iences ,  R a d b o u d  University Ni j m ege n  Medica l  Centre .  3D e p a r t m e n t  o f  Internal 
Medic ine ,  Canis ius  Wilhelmina  Hospital  N i jm ege n,  Ni jme gen ,  th e  N et he r la n d s
Dendritic cell (DC) vaccination has been shown to induce anti-tumor immune re­
sponses in cancer patients, but so far its clinical efficacy is limited. Recent evidence 
supports an immunogenic effect of cytotoxic chemotherapy. Preclinical data indi­
cate that the combina4on of chemotherapy and immunotherapy may result in an 
enhanced anti-cancer activity. Most studies have focused on the immunogenic as­
pect of chemotherapy-induced cell death, but only few studies have investigated 
the effect of chemotherapeutic agents on the effector lymphocytes of the immune 
system.
Here we investigated the effect of treatment with oxaliplatin and capecitabine on 
non-specific and specific DC vaccine-induced adaptive immune responses. Stage III 
colon cancer patients receiving standard adjuvant oxaliplatin/capecitabine chemo­
therapy were vaccinated at the same time with keyhole limpet hemocyanin (KLH) 
and carcinoembryonic antigen (CEA)-peptide pulsed DCs.
In 4 out of 7 patients functional CEA-specific T cell responses were found at de­
layed type hypersensitivity (DTH) skin testing. In addition, we observed an en­
hanced non-specific T cell reactivity upon oxaliplatin administration. KLH-specific T 
cell responses remained unaffected by the chemotherapy, whereas B cell re­
sponses were diminished.
The results strongly support further testing of the combined use of specific anti­
tumor vaccination with oxaliplatin-based chemotherapy.
Until recently, the commonly held opinion T cell infiltration o f tumors2, and 5- 
was that chemotherapy and immunother- fluourouracil has been described to 
apy should not be combined because o f upregulate tumor antigen expression on 
the myelosuppressive effect of most cyto- colorectal and breast cancer cells3. Fur- 
toxic agents. However, it has now become thermore, suppressive regulatory T cells 
evident that chemotherapeutics can exhibit are depleted by several chemotherapeutics 
several beneficial effects on the immune also resulting in enhanced T cell reactivi- 
system1. For example, treatment with gem- ty4,5. In addition, treatment with non- 
citabine results in increased antigen cross- myeloablative lymphodepleting chemo- 
presentation, T lymphocyte expansion and therapy results not only in reduced regula-
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tory T cell frequencies, but also provides 
‘space’ in the bone marrow for naive T 
cells to proliferate upon adoptive T cell 
transfusion6. Using this strategy, significant 
clinical results have been obtained in meta­
static melanoma patients7. Pioneering work 
by Zitvogel and colleagues has shown that 
the cytotoxic agents oxaliplatin and doxo­
rubicin induce immunogenic cell death, 
since upon treatment with these agents 
tumor cells transport calreticulin to their 
cell surface. The exposure of calreticulin 
provides a signal that is recognized by 
dendritic cells (DCs) and ultimately results 
in phagocytosis of the tumor cells8. Expo­
sure of tumor cells to oxaliplatin results in 
the release o f High Mobility Group Box 1 
(HMGB1) protein, that activates DCs in a 
Toll-like Receptor-4 (TLR4) dependent 
manner9. The clinical impact o f this im­
mune pathway in colorectal cancer patients 
is emphasized by the recent observation 
that patients carrying the TLR4 loss-of 
function allele Asp299Gly exhibit reduced 
progression-free and overall survival in re­
sponse to oxaliplatin as compared to pa­
tients carrying the normal TLR4 allele10. 
Previous studies in animal models provide 
a rationale for the combination of chemo­
therapy and immunotherapy in colon can­
cer. In a murine model, T cell responses 
against the colon cancer-associated antigen 
thymidylate synthase that were induced by 
a peptide vaccin were not hampered by the 
administration o f 5-Fluorouracil (5-FU). 
The combination o f peptide vaccination 
and 5-FU resulted in a significant delay in 
tumor growth as compared to treatment 
with peptide or 5-FU alone11. Similarly, it 
was shown in a murine colon cancer 
model that the addition o f 5-FU / 
leucovorin or irinotecan to bone marrow- 
derived DC vaccination did not diminish 
the immunogenicity o f the vaccine12. Small 
proof-of-concept clinical trials in cancer
patients indicate that the efficacy o f anti­
cancer vaccines may indeed be enhanced 
by chemotherapy13,14, however additional 
studies on scheduling and appropriate 
combinations are warranted. 
Platinum-based chemotherapy represents a 
cornerstone in the systemic treatment of 
many types of cancer15. Beside their direct 
cytotoxic effects, platinum anti-cancer 
drugs may also exert their clinical effect 
through indirect activation o f the immune 
system via induction o f immunogenic tu­
mor cell death8-10. Most studies however, 
mainly focused on the effect of chemo­
therapy on tumor cells and antigen- 
presenting cells. Little attention has been 
paid to the effect of chemotherapy on the 
effector lymphocytes o f the immune sys­
tem. Although neutropenia is a common 
side effect of chemotherapy in the treat­
ment o f solid tumors, lymphopenia is 
rarely observed. A stimulatory effect of 
chemotherapy on tumor immunogenicity 
without impairing immune effector cell 
function would provide a strong rationale 
to develop novel chemo-immunothera- 
peutic strategies. For this reason, we inves­
tigated whether an oxaliplatin-based che­
motherapy regimen com bined with 
antigen-specific vaccination in cancer pa­
tients can result in tumor antigen-specific 
immune reactivity.
PATIENTS AND METHODS
Study design
This was an open-label, single-institution, single­
arm exploratory study in which patients with 
stage III colon cancer received adjuvant treatment 
with monocyte-derived mature DCs loaded with 
CEA-peptide in combination with standard 
oxaliplatin/capecitabine chemotherapy. Approval 
from the local regulatory committee was ob­
tained.
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Objectives
The primary endpoint was to assess the immuno- 
genicity of the vaccine during oxaliplatin/ 
capecitabine chemotherapy. Secondary endpoints 
were the toxicity and the feasibility of CEA- 
specific vaccination in colon cancer patients, dur­
ing chemotherapy.
Figure 1. Treatment schedule.
Patients
Inclusion criteria included: patients with stage III 
colon cancer, HLA-A0201 phenotype, ECOG 
performance status 0-1, age above 18 years, initia­
tion of adjuvant chemotherapy less than 8 weeks 
since surgery for the primary tumor, no prior 
chemotherapy, adequate bone marrow, kidney and 
hepatic function, and written informed consent. 
Exclusion criteria included: the use of immuno­
suppressive drugs, a history of second malignancy 
and other serious concomitant diseases prevent­
ing the safe administration of study drugs or 
likely to interfere with the study endpoints.
DC preparation
DCs were generated as described previously16,17. 
Peripheral blood mononuclear cells (PBMCs) 
were isolated by PureCell® (Medicult, Denmark) 
density gradient centrifugation (30 min, 4°C, 2100 
rpm), adherent monocytes were cultured in Cell- 
gro® medium enriched with 500 U/ml Inter­
leukin (IL)-4 and 800 U/ml granulocyte macro­
phage colony stimulating factor (GM-CSF, all 
CellGenix, Freiburg, Germany). KLH (10 ng/ml, 
Calbiochem, USA) was added at day 3 of culture 
and 2 days before harvesting we added the matu­
ration cocktail (prostaglandin E 2 [PGE2, Phar­
macia & Upjohn, Puurs, Belgium, 10 ng/ml], tu­
mor necrosis factor alpha [TNFa, 10 ng/ml], IL- 
1P [ 5 ng/ml] and IL-6 [15 ng/ml, all CellGenix]). 
Cells were harvested at day 7 and part of the cells 
were loaded with peptide and put in a syringe for
immediate vaccination; the remaining cells were 
frozen for the second and third vaccination and 
the DTH18. O f each batch of patient DCs a sam­
ple was used for quality control. Release criteria 
were as previously described19.
DCs were pulsed with the wild type CEA-peptide 
CAP-120 (CEA571-579, YLSGANLNL, Clinalfa, 
Switzerland) directly after harvesting or after 
thawing18,21.
Treatment schedule
Patients received 8 cycles of oral capecitabine 
2000 mg/m2 days 1-14 and oxaliplatin 130 mg/m2 
intravenously at day 1. Cycles were repeated every 
3 weeks. Prior to the first cycle patients under­
went a leukapheresis for collection of peripheral 
blood mononuclear cells for the DC culture. At 
day 4, 10 and 17 of the first cycle of chemother­
apy patients received 3 vaccinations intradermally 
(i.d.) and intraveneously (i.v.) (5x106 i.d./10x106 
i.v.) with CEA-peptide loaded dendritic cells (fig­
ure 1). In preclinical models it has been shown 
that i.v. administered DCs provide a better anti­
tumor response against visceral metastases, 
whereas non-visceral metastases respond better to 
i.d. administered DCs22. Because both lymphoge- 
neous and hematogenous spreading occur in co­
lorectal cancer, we chose to combine both routes 
of administration. After completion of the vacci­
nations a DTH skin test was performed on day 
19, followed by biopsies of DTH injection sites 
on day 22. Dexamethasone was not administered 
as anti-emetic prophylaxis during the first cycle.
Immunologic monitoring
-Analysis of peripheral blood immune cell subsets 
Within the CD45+ leukocyte population, PBMCs 
were stained with antibodies against CD14, 
CD19, CD3, CD8, CD4 and CD56 (for distinc­
tion of monocytes, B cells, T cells, CTLs, Thelper 
lymfocytes and N K  cells, respectively). After 
washing, the samples were analyzed by flowcy- 
tometry.
-Monitoring of non-specific T  cell stimulatory capacity 
PBMCs were obtained by density-gradient cen­
trifugation at day 1, 4, 10, 17 and 22. Cells were 
plated in 96-wells U-bottom plates, 2x105/well, in 
RPMI/human serum 5% and Phytohaemaggluti- 
nin (PHA) was added (1 ng/ml). After 24 hours 
supernatant was harvested for cytokine produc­
tion analysis. After 3 days 1 ^.Ci/well of 3H- 
thymidine was added to the culture for 8 hours, 
after which proliferation was stopped by storing 
the culture plate at -20°C. Incorporation of 3H- 
thymidine was measured in a B-counter. The in­
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dex was calculated as the counts ratio between 
PHA-stimulated PBMC and non-stimulated 
PBMCs.
-Monitoring of KLH-speafic CD4 +  T  cell responses 
CD4+ T cell responses against KLH were meas­
ured using a 3H-Thymidine incorporation prolif­
eration assay with PBMCs of the patients at day
1, 4, 10, 17 and 22. The index was calculated as 
the counts ratio between KLH-stimulated PBMCs 
and non-stimulated PBMCs.
-Delayed type hypersensitivity reactions 
Post-treatment DTH reactions were performed as 
described previously23. Briefly, CEA-peptide only 
(100 |ig in 100 fxl), DCs pulsed with CEA- 
peptide, DCs pulsed with KLH and CEA-peptide, 
and DCs pulsed with KLH only (0.4-5x105 DCs 
each in approximately 100-200 jxl) were injected
i.d., 5-10 cm from an inguinal lymph node at dif­
ferent sites, in the back of the patients. The 
maximum diameter o f induration was measured 
after 48 hours. T cell culture from DTH biopsies 
was performed in low dose IL-2 (Proleukin®, 
Chiron, Netherlands 100U/ml) for approximately 
2 weeks without ex vivo restimulation with anti­
gen as described before23.
-MHC Tetramer staining
DTH-derived cells (1x105 cells in 10 jxl) or 
PBMCs (1x106 cells in 10 ^l) were incubated with 
PE-labeled CEA and cytomegalovirus (CMV) 
tetrameric-MHC complexes (Sanquin, Amster­
dam, Netherlands) for 60 minutes, room tempera­
ture. In the last 20 minutes o f this incubation, 
FITC-conjugated monoclonal antibodies directed 
against CD8 (Becton Dickinson) were added. Af­
ter washing, the samples were analyzed by flowcy-
tometry. For peripheral blood at least 1x106 
PBMCs were analyzed, for DTH-infiltrating T 
cells all available cells were analyzed. In all analy­
ses CEA tetramer staining was compared with 
CMV tetramers as a negative control.
-Cytokine secretion
Production o f cytokines by the total population 
of DTH-derived cells was measured in response 
to T2 cells pulsed with CEA-peptide or an irrele­
vant HLA-A2.1 binding peptide (tyrosinase or 
G250). Cytokine production was measured in su- 
pernatants after 16 hours by cytometric bead array 
(Th1/Th2 Cytokine CBA 1; BD Pharmingen). 
IFNy production was considered positive when 
IFNy-levels o f DTH-infiltrating T cells were 
more than tenfold higher after co-incubation with 
CEA-loaded T2 cells compared to co-incubation 
with T2 cells loaded with irrelevant antigen.
RESULTS 
Patients and toxicity
Seven patients were included in this study 
with a median age of 55 years (range 47­
75). All patients had stage III colon cancer. 
Most patients experienced grade I fever 
and flu-like symptoms after vaccination. 
One patient had a grade 2 allergic reaction 
of unknown cause after two vaccinations, 
consisting of generalized exanthema with 
fever and pruritus for which he was treated 
with antihistamines.
Figure 2. Frequencies of PBMC 
subsets during treatment with ox­
aliplatin and capecitabine and DC 
vaccination. Means with standard 
deviation are depicted, (a) total T 
cells (CD3+), (b) T helper cells 
(C D 4+), (c) cytotoxic T cells 
(CD8+), (d) natural killer cells 
(C D 3-/C D 56+), (e) monocytes 
(CD14+) (f) B cells (CD19+).
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Figure 3. Proliferative non-specific T cell response upon PHA-stimulation during treatment with 
oxaliplatin/capecitabine and DC vaccination. (a) In all patients an increase in proliferation was ob­
served during treatment. (b) Also the IFNy-production upon PHA-stimulation increased during treat­
ment (data of 4 tested patients are given; the means with standard deviation are depicted).
The third vaccination was without symp­
toms. Other toxicities (grade 2 nausea/ 
vomiting, one patient; grade 1 diarrhea, 
one patient; grade 3 neurotoxicity, one pa­
tient) were considered to be related to the 
chemotherapy. With a follow-up of 10-35 
months (median 18 months), all patients 
are recurrence-free.
Peripheral blood subsets during treat­
ment
Peripheral blood frequencies o f mononu­
clear cells did not significantly decrease 
during treatm ent with oxalip latin / 
capecitabine (figure 2, supplementary fig­
ure 1). The total number of T cells 
(CD3+), T helper cells (CD4+), cytotoxic 
T cells (CD8+), B cells (CD19+), mono­
cytes (CD14+) and Natural Killer cells 
(CD3-/CD56+) remained stable during 
chemotherapy.
Non-specific immune reactivity during 
oxaliplatin/capecitabine
To test whether treatment with oxaliplatin 
and capecitabine affects overall T cell reac­
tivity that could influence the efficacy of 
DC vaccination, we tested the PHA-
induced T cell proliferative response at dif­
ferent time points during treatment (figure 
3). Surprisingly, we found a striking in­
crease in the proliferative capacity o f pe­
ripheral blood T cells, in most cases di­
rectly after infusion o f the oxaliplatin (fig­
ure 3a). In addition, the IFNy-release upon 
PHA-stimulation increased (figure 3b). 
Since this has not been reported before 
after DC vaccination, and since we also 
observed this in a control group o f pa­
tients that were treated with platinum 
compounds only (supplementary patients 
and methods and supplementary figure 2), 
we conclude that this is a platinum-effect 
and not due to the DC vaccine. When pe­
ripheral blood lymphocytes o f 3 healthy 
donors were stimulated with PHA after 24 
hours of in vitro culture with oxaliplatin, 
we did not observe an enhanced effect of 
the platinum treatment (supplementary 
figure 3).
KLH-specific immune responses during 
oxaliplatin/capecitabine
To test whether de novo antigen-specific T 
and B cell immune responses can be in­
duced during treatment with oxaliplatin 
and capecitabine, we loaded the DCs with
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Figure 4. KLH-specific responses. All patients showed a proliferative CD4+ T cell response against the 
control antigen KLH. (a) A representative patient (patient 7) is shown. (b) However, B cell responses 
against KLH upon vaccination could not be detected in 6 of 7 patients.
the control antigen KLH  and measured 
the proliferative T  cell response and anti­
body response (figure 4, table 1). We ob­
served a robust C D 4+ proliferative re­
sponse against KLH in all patients, compa­
rable to previous studies in colorectal can­
cer and melanoma patients who were vac­
cinated with the same vaccine without 
chemotherapy (figure 4a)17>21>23. However, 
in all but two patients antibody responses 
against KLH were absent (figure 3b). In 
the patients with an antibody response, 
this response was only weak. This is in 
contrast to our previous studies in which 
we could detect a response in almost all 
vaccinated patients21.
CEA-specific immune responses during 
oxaliplatin /capecitabine
We next determined the vaccine-induced 
tumor antigen-specific immune response 
in DTH biopsies as previously pub­
lished23,24. In 4 out o f 7 patients we found 
CEA-specific T cells by means of tetramer 
analysis (figure 5a, table 1). In a previous 
cohort of colorectal cancer patients that 
were treated with the same vaccine without 
chemotherapy we found CEA-specific 
DTH-infiltrating T cells in 5 out of 11 pa­
tients after one vaccination cycle17. Thus, 
the efficacy o f the vaccine does not seem 
to be negatively influenced by chemother­
apy in terms o f the induction o f tumor 
antigen-specific immunity. Furthermore, 
the functionality o f the T cells remained 
unaffected since they produced high 
amounts of IFNy and IL-2 upon co­
culture with CEA-loaded target cells (fig­
ure 5b).
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Figure 5. CEA-specific responses. In 4 out of 7
patients CEA-specific DTH-infiltrating T cells 
were observed after completion of vaccination, 
either by (a) tetramer staining or (b) IFNy and IL-
2 release upon co-culture with CEA-loaded target 
cells. Data from a representative patient (no. 2) 
are shown.
DISCUSSION
Despite ample evidence for chemotherapy 
-induced immunogenic cell death, much 
less is known about the effect o f chemo­
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therapy on the effector lymphocytes o f the 
immune system in vivo in cancer patients. 
Therefore we conducted a clinical pilot 
trial to test the immunogenicity o f a DC 
vaccine in stage III colon cancer patients 
treated with standard adjuvant oxaliplatin 
and capecitabine chemotherapy. We found 
that robust de novo KLH-specific T cell re­
sponses could very well be induced during 
the chemotherapy regime. However, B cell 
responses were hampered when compared 
to previous studies using the same vaccine 
without chemotherapy21,23. No additional 
toxicity was observed, apart from the side 
effects that frequently occur for both 
treatment strategies separately.
In 4 out o f 7 patients we observed a func­
tional CEA-specific T cell response upon 
vaccination with CEA-loaded DCs. Al­
though the number o f patients is limited, 
this is comparable to a previous cohort of 
colorectal cancer patients that were treated 
with the same vaccine without chemother- 
apy17. To date, none o f the treated patients 
have had a relapse. However, given the ad­
juvant nature of the treatment, the short 
follow-up and the limited numbers o f pa­
tients, no conclusion can be drawn on the 
clinical efficacy o f adding DC vaccination 
to standard adjuvant chemotherapy. Other 
studies investigating the combination of 
immunotherapy and chemotherapy have
been performed in colorectal cancer pa­
tients. Kaufman and colleagues vaccinated 
metastatic colorectal cancer patients with a 
CEA-ALVAC vaccine in combination with 
irinotecan, 5-fluorouracil and leucovorin 
and found that the CEA-specific T cell re­
sponse was unaffected by the chemothera­
py14. Similar observations were made, us­
ing the same chemotherapeutics but dif­
ferent vaccines25,26.
Surprisingly, the non-specific T cell prolif­
erative capacity increased upon chemo­
therapy treatment in most patients shortly 
after infusion of the oxaliplatin. Previ­
ously, others have found a similar effect 
for gemcitabine in a murine model2, but 
for platinum-based compounds this has 
not been reported before. Although oxali­
platin has been described to induce an 
immunogenic type o f cancer cell death, 
which could result in DC activation and 
subsequent non-specific T cell activa­
tion9,27, we consider this mechanism less 
likely in our study since the patients were 
treated in an adjuvant setting, that is in the 
absence of macroscopic tumor.
A possible explanation for the increased T 
cell activation may lie in our recent finding 
that platinum compounds dephosphory- 
late Signal Transducer and Activator of Tran­
scription 6 (STAT6)28.
chapter 9
Patient 1 2 3 4 5 6 7
KLH CD4+ response +  +  +  +  +  +  +
KLH antibody response - - - - +  +  -
CEA-tetramers peripheral blood - - - - - - -
CEA-tetramers DTH - +  nt - - - -
CEA-specific IFNy response in DTH +  +  +  - - -  +
Table 1. Antigen-specific immune responses. Summary of all tested KLH and CEA-specific immune 
responses upon vaccination and oxaliplatin/capecitabine treatment. nt: not tested
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This protein is o f crucial importance for 
the induction o f T helper 2 immunity and 
hence for the development o f B cell re­
sponses. Inactivation of STAT6 may result 
in enhanced T helper 1 responsiveness and 
at the same time in decreased B cell activa­
tion, as observed in this study. The fact 
that we did not find this effect when lym­
phocytes o f healthy donors were stimu­
lated with PHA after 24 hours o f culture 
in the presence o f oxaliplatin, suggests 
that this mechanism mainly works through 
antigen-presenting cells and not lympho­
cytes. However, it is questionable whether 
the in vitro conditions properly mimic the 
in vivo situation. More research is needed to 
decipher the exact effects o f platinum 
compounds on immune cells.
Our study is the first to investigate the 
combined use o f specific vaccination with 
oxaliplatin-based chemotherapy. Oxali­
platin appears to be a promising drug to 
include in chemo-immunotherapeutic 
regimens, since it induces an immunogenic 
type o f tumor cell death resulting in en­
hanced DC activation9,10,27. Our findings 
that the immune effector cells remain un­
affected and that T cell proliferative capac­
ity following PHA stimulation even in­
creases upon oxaliplatin treatment further 
support this strategy.
Although DC vaccinations frequently in­
duce immune responses, objective clinical 
remissions are rare29. One possible expla­
nation is that DC vaccination may be more 
effective in residual microscopic disease, 
since it lacks a direct cytotoxic effect that 
is likely required in macroscopic disease. 
On the other hand, also cytotoxic chemo­
therapy does not result in complete tumor 
eradication in the majority o f patients with 
metastatic solid tumors. Therefore the 
combination o f DC vaccination with cyto­
toxic chemotherapy is an attractive strat­
egy. Our data demonstrate the feasibility of 
the combination of these two strategies, 
and provide the rationale for future studies 
that investigate the clinical efficacy of this 
strategy.
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SUPPLEMENTARY DATA 
Supplementary Patients and Methods
Because we found enhanced T cell proliferation 
after oxaliplatin infusion, during DC vaccination, 
we questioned whether this could be caused by 
the DC vaccine or by the oxaliplatin. Further­
more, we questioned whether this could be an 
oxaliplatin-specific or general platinum effect. For 
this reason we obtained PBMCs from 2 patients 
with squamous cell head and neck carcinoma and
1 patient with cervical cancer that were treated 
with weekly cisplatin (40 mg/m2) in combination 
with local radiotherapy and tested non-specific T 
cell proliferative capacity by PHA stimulation. 
Patients gave written informed consent. Blood 
was obtained before and 3-4 days after infusion of 
cisplatin.
PBMCs were obtained by density-gradient cen­
trifugation. Cells were plated in 96-wells U- 
bottom plates, 2x105/well, in RPMI/human se­
rum 5% and Phytohaemagglutinin (PHA) was 
added (1 ^g/ml). After 24 hours supernatant was
harvested for cytokine production analysis. After
3 days 1 ^.Ci/well of 3H-thymidine was added to 
the culture for 8 hours, after which proliferation 
was stopped by storing the culture plate at -20°C. 
Incorporation of 3H-thymidine was measured in 
a B-counter. Production of cytokines was meas­
ured in supernatants after 16 hours by cytometric 
bead array (Th1/Th2 Cytokine CBA 1; BD 
Pharmingen). Data were analyzed statistically by 
means of analysis of variance (ANOVA) and 
Student-Newman-Keuls-test. Statistical signifi­
cance was defined as p < 0.05.
In a similar experiment PBMCs were obtained 
from three healthy voluntary donors by density- 
gradient centrifugation. The monocytic fraction 
was removed by plastic adherence during 1 hour 
at 37°C. Cells were plated in 96-wells U-bottom 
plates, 2x105/well, in RPMI/human serum 5% 
either in the presence or absence of oxaliplatin 
(Eloxatin) at a concentration of 4 ^g/ml. After 24 
hours the cells were washed and PHA was added 
(1 ng/ml). Proliferation was measured according 
to the above-described protocol.
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tom etrical determ ination of 
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Supplementary figure 2. PHA responses in cancer patients treated with platinum compounds. (a)
Proliferative response of PBMCs to phytohaemagglutinin (PHA) of cancer patients before and after 
treatment with cisplatin or oxaliplatin (n=5). Production of (b) IL-1 and (c) T N Fa of PHA-stimulated 
PBMCs of cancer patients before and after treatment with cisplatin (n=3; * p <  0.05, * *  p < 0.01).
Supplementary figure 3. Proliferative responses of periph­
eral blood lymphocytes of three healthy donors to PHA.
The cells were pre-incubated for 24 hours in the presence or 
absence of a clinically relevant concentration of oxaliplatin 
(the means of three experiments with standard deviations are 
given; * *  p <  0.01).
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Dendritic cell vaccines in melanoma: from promise to proof?
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D e p a r t m e n t s  o f  *M edi ca l  O nco logy and  2T u m o u r  Immunology,  Ni jm ege n  Centre  for  M o le cu la r  Life 
Sc ie nces ,  R a d b o u d  Univers ity N i jm ege n  Medica l  Centre ,  PO Box 9 1 0 1 ,  6 5 0 0  HB Ni jme gen ,  The  
N et he r la n d s
Dendritic cells (DCs ) are the directors of the immune system, capable of inducing 
tumour antigen-specific T- and B cell responses. As such, they are currently applied 
in clinical studies in cancer patients. Early small clinical trials showed promising re­
sults, with frequent induction of anti-cancer immune reactivity and clinical re­
sponses. In recent years, additional trials have been carried out in melanoma pa­
tients, and although immunological responses are often reported, objective clinical 
responses remain anecdotal with objective response rates not exceeding 5-10%. 
Thus, DC vaccination research has now entered a stage in between 'proof of prin­
ciple' and 'proof of efficacy' trials. Crucial questions to answer at this moment are 
why the clinical responses remain scarce and what can be done to improve the ef­
ficacy of vaccination. The answers to these questions probably lie in the prepara­
tion and administration of the DC vaccines. Predominantly, cytokine-matured DCs 
are used in clinical studies, while from preclinical studies it is evident that DCs that 
are activated by pathogen-associated molecules are much more potent T cell acti­
vators. For sake of easy accessibility monocyte-derived DCs are often used, but are 
these cells also the most potent type of DCs? Other yet unsettled issues include 
the optimal antigen-loading strategy and route of administration. In addition, trials 
are needed to investigate the value of manipulating tolerizing mechanisms, such as 
depletion of regulatory T cells or blockade of the inhibitory T cell molecule CTLA-4. 
These issues need to be addressed in well-designed comparative clinical studies 
with biological endpoints in order to determine the optimal vaccine characteristics. 
DC vaccination can then be put to the ultimate test of randomized clinical trials. 
Here, we review the immunobiology of DCs with emphasis on the different aspects 
that are most relevant for the induction of anti-tumour responses in vivo. The dif­
ferent variables in preparing and administering DC vaccines are discussed in this 
context and the immunological and clinical results of studies with DC vaccines in 
melanoma patients are summarized.
1 Introduction
Melanoma is one of the more immuno­
genic cancer types and many strategies to 
enhance specific or non-specific immunity 
in melanoma patients have been explored 
in clinical studies1.
Dendritic cells (DCs) are crucial as the 
sentinels of the immune system. It has 
been proposed that when the tumour 
reaches a certain size and causes damage 
to the surrounding tissues with release of 
products by the microenvironment, local
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DCs are activated and subsequently the 
immune system is alerted2. It then depends 
on the size o f the tumour and its immu­
nomodulatory characteristics, whether the 
immune system is able to eradicate the 
cancer. Often malignant growth is a slow 
and silent process that fails to provide a 
‘danger signal’ necessary for the activation 
o f the immune system. The goal o f DC 
vaccination is to mend this inattention of 
the immune system by providing it with ex 
vivo ‘educated’ DCs; appropriately acti­
vated and loaded with tumour antigen. 
The underlying principle is that DCs are 
the most potent antigen presenting cells o f 
the immune system that play a central role 
in the induction-phase of antigen-specific 
immunity. DCs acquire and process anti­
gen and migrate to the lymphoid organs 
where they present the antigen to the spe­
cific arm of the immune system, resulting 
in the induction of primary T- and B cell 
responses. Because o f these unique quali­
ties they represent an interesting tool in 
cancer immunotherapy. The possibility to 
generate DCs in large amounts for clinical 
use has accelerated research in this field, 
and immunological and clinical responses 
have been reported in melanoma patients 
after vaccination with DCs (table 1-2)3-5. 
Several years ago it was already estimated 
that more than thousand cancer patients 
had received some form o f DC-based vac­
cination6. In contrast to other systemic 
therapies in cancer treatmeDCsnt, it is not 
possible to pool these patients in a meta­
analysis. This is due to the enormous di­
versity in terms o f vaccine preparation and 
administration and immunomonitoring. 
Although much progress has been made in 
several o f these areas over the past years, 
there seems still room for significant im­
provement before an optimal DC vaccine 
is to put to the ultimate test of large scale 
clinical studies.
2.1 DC subsets
Two distinct categories o f DCs exist: 
plasmacytoid DCs and conventional or 
‘myeloid’ DCs7. Plasmacytoid DCs are cir­
culating cells with a plasmacytoid mor­
phology that are capable o f producing 
large amounts o f type I interferons upon 
activation by microbial stimuli8. In addi­
tion, they can differentiate into DCs that 
are capable of activating naïve T cells 
against allo-antigens9 and exogenous anti- 
gens10. In the context o f cancer, plasmacy- 
toid DCs have been implicated in the in­
duction o f both immunity and tolerance, 
and their potential role in vaccination 
strategies in cancer patients still has to be 
determined11.
Conventional DCs or ‘myeloid’ DCs12 can 
be further divided into migratory DCs, 
which actively sample the peripheral tis­
sues and migrate to draining lymph nodes 
to present antigens to T cells, and 
lymphoid-tissue-resident DCs which capti­
vate local (foreign and self-) antigens and 
present it to local T cells13. Examples of 
lymphoid-tissue-resident DCs are splenic 
and thymic DCs. Migratory DCs derive 
from both CD34+ precursor cells and 
monocytes. Monocytes can differentiate 
into DCs upon transendothelial migra- 
tion14. The presence of GM-CSF, in addi­
tion to other pro-inflammatory cytokines, 
can differentiate both CD34+ precursor 
cells and monocytes into DCs.
Recently, it was proposed to recognize a 
third distinct group o f conventional DCs, 
‘inflammatory‘ DCs: cells that are not pre­
sent in the steady state, but that appear 
under the influence of inflammation or 
infection13.
2.2 DC subsets in clinical trials
Monocyte-derived DCs have been used in 
most vaccination studies because o f the
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relative ease with which large quantities of 
cells can be obtained. Usually, one leu- 
kapheresis is enough to obtain approxi­
mately 100-150x106 cells. Yields are much 
lower with CD34+ selection and repeated 
leukaphereses are often necessary to ob­
tain enough cells15. The same accounts for 
circulating blood DCs, which can be ob­
tained from peripheral blood after in vivo 
Flt-3L expansion and negative selection ex 
vivo16.
Banchereau and collegues have reported 
impressive immunological and clinical re­
sults using Flt3-Ligand expanded CD34+ 
DCs15. In other studies with CD34+ DCs, 
using different maturation and vaccination 
regimes, clinical responses were observed 
less frequently17,18. The same variable out­
comes are seen in studies with monocyte- 
derived DCs (table 1 and 2, and section on 
clinical results). These differences may well 
be more related to the differences in cul­
ture and maturation protocols, than to the 
differences in DC subsets. Due to the 
fragmented nature o f the available data 
and the absence o f direct comparative 
studies, it is not possible at this moment to 
draw any firm conclusion on the most op­
timal DC subset to be used in clinical tri­
als. In recent years, evidence is accumulat­
ing that considerable cross-talk takes place 
between the different DC subsets7, and 
that perhaps it is beneficial even to com­
bine different subsets o f DCs, as has been 
done in the above mentioned studies15.
3.1 Maturation
The term ‘maturation’ refers to the pheno­
typical and functional reaction o f DCs 
upon encountering danger signals. Matura­
tion can be induced by pro-inflammatory 
cytokines such as IL-1 or IL-6, by interac­
tion with T cells and by interaction with 
pathogens. DCs can detect pathogens 
through pattern recognition receptors such
as Toll-like receptors (TLR)19. The TLR 
family consists of several receptors that 
recognize molecular patterns o f patho­
gens, for example bacterial lipopolysaccha- 
ride (through TLR4) and single stranded 
viral RNA (through TLR7)20.
In the past 10 years, the term ‘mature’ 
DCs has generally been used to describe T 
(helper 1) cell stimulatory DCs. Immature 
DCs were considered to be primarily in­
volved in the recognition and uptake of 
antigen. Upon receiving maturation signals 
these immature DCs would then change 
their chemokine receptor repertoire and 
upregulate their co-stimulatory molecules, 
thus acquiring the phenotype o f mature 
DCs that are capable of migration to the 
lymph nodes and activation of T cells. In 
the absence of maturation signals, DCs 
would not upregulate their co-stimulatory 
molecules and would thus remain anergy- 
or tolerance-inducing antigen-presenting 
cells.
Although this concept may not be entirely 
wrong, recent findings show that this is 
probably an oversimplification (for a com­
prehensive review on this topic see ref. 
21). For instance, in the steady state, that is 
in the absence of ‘danger’, immature DCs 
have been shown to be capable o f circulat­
ing through the tissues and lymphoid or­
gans, encountering and capturing both 
self-antigens and innocuous environmental 
antigens22. It is suggested that through this 
mechanism immature DCs play a critical 
role in the continuous induction o f pe­
ripheral tolerance, thereby preventing both 
auto-immunity and hyperreactivity23. In 
addition, although the expression o f co­
stimulatory molecules is one o f the pheno­
typic markers of mature DCs, the induc­
tion o f a tolerogenic immune response 
depends on the presence o f these mole­
cules as well24. In a chimeric murine model 
it was shown that although cytokine-
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matured DCs demonstrated upregulation 
o f co-stimulatory molecules and induction 
o f T cell proliferation, the activated T cells 
did not fully develop into IFN-producing 
effector cells25. Only when the DCs were 
activated through Toll-like receptors 
(TLRs), also referred to as ‘licensed’ 
DCs26, the induced antigen-specific T cells 
were able to fully develop into effector 
cells. The ‘licensing’ o f DCs is not only 
restricted to pathogen-derived signals, 
since activation by bystanding T helper 
cells may also suffice27’28.
Another level of complexity is added by 
the timing and duration o f the maturation 
signal. For example, murine bone marrow- 
derived DCs that are exposed to lipopoly- 
saccharide for 48 hours have the same ex­
pression o f costimulatory molecules 
CD80, CD86 and CD40 as compared to 
DCs that are exposed to lipopolysaccha- 
ride for 8 hours and also have a compara­
ble migratory capacity and allostimulatory 
potential. However, the former exhibit a 
decreased IL-12 production potential cor­
relating with low antigen-specific T cell re­
sponses after vaccination in mice29,30. In 
addition, both the timing of the activation 
signal and the exposure to antigen are of 
crucial importance for optimal antigen 
presentation: only the simultaneous pres­
ence o f apoptotic cells and TLR ligands to 
DCs resulted in efficient antigen- presenta­
tion and subsequent T cell activation31. 
With respect to the type of TLR ligands, it 
has been shown that combinations o f dif­
ferent TLR ligands can have a synergistic 
effect on the immunogenic potential o f 
DCs in vitro32 and in vivo33. For example, 
a combination of triggering via TLR3 and 
TLR 7 leads to a ten- to hundred-fold 
higher IL-12 production, when compared 
to DCs that have been activated by one of 
the respective TLRs alone32. In concor­
dance with these data, Querec et al. re­
cently showed that broad immunity that 
was induced by a Yellow fever vaccine was 
dependent on triggering multiple TLRs 
simultaneously (notably TLR 2,7,8,9)34. In 
terms o f IL-12 production, it appears that 
monocyte-derived DC activation via TLR3 
and 7 leads to the most potent TH1 T cell 
responses32,35,36. However, migratory ca­
pacity is somewhat hampered in these cells 
as compared to cytokine-matured DCs, 
which can be restored by co-culturing the 
DCs in PG E 236.
If DCs with similar expression of co­
stimulatory molecules can exert entirely 
different functions, what then determines 
the nature o f the induced T cell response? 
The ability of DCs to produce IL-12, 
T N F a and IL-6 is thought to be impor­
tant for the induction o f robust T cell re­
sponses and to bypass suppressor T cell- 
induced tolerance37-39. In addition, several 
factors such as IL-10, vitamin-D3 and cor­
ticosteroids can skew the DCs into a more 
suppressive T cell type o f inducer40. How­
ever, it still remains poorly understood 
which mechanisms truly determine the na­
ture o f the T cell response as instructed by 
the DCs.
Taken together, these findings show that 
the process o f maturation is highly com­
plex and that different maturation stimuli 
do not lead to one common ‘mature DCs’, 
but that there are in fact a lot o f different 
types of mature DCs that exert different 
functions ranging from the induction of 
strong Th1-type responses to the induc­
tion o f tolerance. These data also show 
that the maturation stage o f DCs cannot 
be fully characterized by the expression of 
costimulatory molecules and surface- 
MHC. When reporting clinical DC vacci­
nation trials it is therefore of crucial im­
portance that the phenotypic and func­
tional characteristics o f the DCs are care­
fully described.
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Thus far, T cells have been the primary 
target o f DC vaccination protocols. In the 
last few years more evidence is accumulat­
ing that also DC-induced activation of 
natural killer (NK) cells41 and natural killer 
T (NKT) cells42 can eradicate cancer. N KT 
cells and DCs activate each other com­
munally. DCs activate N KT cells by pres­
entation o f exogenous (microbial) and en­
dogenous glycolipid antigens, thereby in­
ducing IFNy release and CD40-ligand 
upregulation by the N KT cells43,44. Recip­
rocally, N KT cells activate DCs via CD40- 
CD40L interaction. This in turn causes the 
DCs to produce IL-12, which further acti­
vates the N KT cells (reviewed in ref. 42). 
Because glycolipid antigens induce both 
N KT and DC activation in this manner, 
they offer an interesting target in cancer 
immunotherapy. The synthetically pro­
duced, marin sponge-derived glycolipid 
-galactosylceramide (GalCer) has been 
studied in murine and human studies. A 
single injection o f GalCer combined with 
a model antigen induced strong CD4+ and 
CD8+ T cell responses, through activation 
o f DCs in a TLR-independent but N KT 
cell-dependent manner45. The results were 
confirmed using tumour vaccines instead 
o f a model antigen46,47.
Thus far, one phase I dose-escalation 
study with clinical-grade GalCer (KRN 
7000) has been carried out in 24 patients 
with solid tumours, in which no clinical 
responses were observed 48
3.2 Maturation of DCs in clinical trials
In early clinical trials only immature DCs 
were used49,50. Some o f these DCs might 
have been ‘semi-mature’ due to the addi­
tion o f fetal calf serum in the culture me­
dium49,51. Although objective clinical re­
missions were observed in these studies, 
there is now strong evidence that imma­
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ture DCs should no longer be used in 
clinical practice. In a comparative study in 
metastatic melanoma patients cytokine- 
matured, peptide-pulsed DCs were supe­
rior to immature DCs, with no immune 
induction against the control protein key­
hole limpet hemocyanine (KLH) in the lat­
ter arm o f the study, while all patients that 
were vaccinated with cytokine-matured 
DCs showed a strong T cell and B cell re­
sponse against K LH 52. In addition, only in 
patients vaccinated with mature DC, de­
layed type hypersensitivity (DTH) re­
sponses against the vaccine were observed. 
Using immature DC in vaccination proto­
cols in cancer patients might in fact be 
hazardous due to the induction o f toler­
ance instead o f immunity23,53,54.
Several maturation methods have been ap­
plied with maturation being defined by a 
high expression o f mature DC-specific 
surface markers (which is a rather limited 
description as discussed in the previous 
paragraph). Most widely used is a cytokine 
cocktail that includes T N Fa, with any of 
the following cytokines in any combina­
tion: IL-1P, IL-6, prostaglandin-E2, or the 
supernatant o f  activated autologous 
monocytes (Monocytes Conditioned 
Medium)55-59. There is some evidence that 
culturing DCs with IL-15 may lead to a 
type o f mature DCs that induces stronger 
Th1 effector type o f immune responses60, 
however no comparative studies have been 
reported yet. Lastly, CD40-ligation has 
been used as a method o f activation of 
DCs in a clinical setting61,62.
None of these different maturation meth­
ods has shown to be clearly superior, 
which is mainly due to the fact that there 
are no direct comparative studies, neither 
in animal models nor in cancer patients. It 
is important to realize that to date no trial 
has been published in which TLR- 
matured, truly Th1-polarized DCs were
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used in cancer patients. In vitro data are 
promising63, but clinical results with TLR- 
matured DCs are eagerly awaited.
4.1 Antigen-processing and presenta­
tion
Intracellular endogenous antigens are usu­
ally presented in MHC class I, whereas ex­
ogenous antigens are usually presented in 
class II by antigen-presenting cells (figure 
1a)64. O f crucial importance for DC-based 
vaccines in cancer immunotherapy is the 
finding that internalized antigens from ex­
ogenous sources, such as apoptotic or ne­
crotic tumour cells65,66 are also presented 
in MHC class I to cytotoxic T cells, a 
process referred to as cross presentation 
(figure 1a)67,68. Thus, tumour antigens de­
rived from necrotic or apoptotic tumour 
cells can be presented by the DCs to both 
CD4+ (in MHC class II) and CD8+ T 
cells (in MHC class I), which implies that a 
broad effector and memory immune re­
sponse can be induced against tumour an­
tigens.
Apoptosis is a physiological ‘silent’ immu­
nologic event, pertaining millions o f cells 
per second. However, with regard to the 
immunogenicity o f apoptotic cancer cells 
the data are less clear69-73. Recently it was 
s ho wn in a mur i ne  mo d e l  that  
chemotherapy-induced apoptosis results in 
cross-presentation and T cell activation, 
thereby preventing tumour outgrowth in a 
prophylactic setting74. The same authors 
show in another study that apoptotic tu­
mour cells induce immune responses in a 
TLR-4 dependent manner via secretion of 
HMBG175. The importance o f these find­
ings is that apoptosis of cancer cells may 
be an immunologic event without the need 
o f an extra ‘danger signal’, and that this 
can be accomplished by the administration 
o f cytotoxic drugs or radiotherapy.
4.2 Antigen-loading in clinical trials
In most clinical DC vaccination studies 
synthetic MHC class I-binding peptides 
have been used15,17,18,49,52,56,76-86, with class 
II-binding peptides being added in some 
(figure 1b)57,87. There is convincing pre- 
clinical evidence that targeting both cyto­
toxic T cells and T helper cells is o f crucial 
importance for the induction o f a strong 
and sustained anti-tumour T cell response 
88,89. However, no clinical trial has yet been 
performed in which MHC class I antigen- 
loaded DCs are compared to the combina­
tion of both MHC class I and II antigen- 
loaded DCs.
Instead of HLA-binding peptides, whole 
antigenic proteins can be used. The DCs 
processes the protein into peptides, which 
has the advantage that multiple epitopes 
are presented in both MHC class I and II 
and that there is no HLA-restriction. Un­
fortunately, little recombinant proteins are 
clinically grade available90.
Autologous49,91-96 or allogeneic61,97-99 tu­
mour cell lysates have also been applied as 
a source o f antigens. This has several ad­
vantages: the antigen expression by the 
tumour does not need to be defined and a 
wide array of both MHC class I and II 
epitopes are presented including tumour- 
unique antigens. Possible drawbacks in­
clude the presentation of auto-antigens, 
the requirement o f a sufficient volume of 
tumour tissue and difficulties in monitor­
ing tumour-specific T cell responses since 
the antigens relevant to T cell responses 
are not known. Palucka et al. partly cir­
cumvented the latter problem by using 
large peptide libraries to pinpoint the 
dominant T cell responses in advanced 
melanoma patients after vaccination with 
allogeneic tumour lysate-loaded DCs61.
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Figure 1. Antigen presen­
tation and antigen load­
ing. (a) Antigens can be 
p ro cessed  by the DC 
through three major path­
ways. Exogenous antigens 
will be internalized by the 
DC and enter the endocytic 
pathway in which they are 
targeted to lysosome-related 
MHC class II-rich com­
partments. In these com­
partments the antigens are 
degraded and loaded onto 
MHC class II molecules. 
During maturation of the 
DC the M H C -peptide 
complexes are released to 
the surface, thus making the 
cell ready for antigen pres­
entation to CD4+ T helper 
cells (route 1 in the figure). 
Intracellular endogenous 
antigens, such as unstable 
self-proteins or viral pro­
teins, are cleaved into pep­
tides in the proteasome and 
subsequently translocated 
into the lumen of the en- 
doplasmatic reticulum (ER) 
by transporters associated 
with antigen processing 
(TAP), where stable MHC 
class I-peptide complexes 
are assembled. Upon bind­
ing of the peptide, the 
complex is released from 
the endoplasmatic reticulum 
and transferred to the cell 
surface (route 2 in the fig­
ure), where it is presented to 
CD8+ cytotoxic T cells. Lastly, DCs have the unique capacity to present exogenous antigens, such as 
necrotic or apoptotic tumour cells, in MHC class I to cytotoxic T cells, a process referred to as cross 
presentation (route 3 in the figure). (b) Either by transfection with DNA or RNA encoding melanoma 
antigens, or pulsing with tumour lysate, antigenic proteins or peptides melanoma antigens can be 
loaded onto the DCs for antigen presentation.
Transfection o f DCs with RNA concerns thetic RNA encoding specific melanoma- 
a novel antigen-loading technique100, with associated antigens being used103. A bene- 
either tumour-derived RNA101,102 or syn- fit o f this technique lies in the presenta-
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tion o f several MHC class I epitopes and 
sometimes also MHC class II epitopes, 
depending on the presence of an endoso- 
mal targeting sequence104. Also, it may lead 
to a more prolonged presentation o f the 
antigen as compared to peptide-loading 
which appears to be short-lived105. Poten­
tial drawbacks of RNA transfection in­
clude a variable expression and a low yield 
o f viable cells after transfection, especially 
with respect to the most widely used tech­
nique of RNA electroporation. However, 
several studies have shown that this tech­
nique is feasible and results in highly effi­
cient DC-transfection103,106-109. Further­
more, anti-tumour T cell responses and 
clinical responses have been reported in 
patients vaccinated with DCs electropo­
rated with tumour-derived RNA110, 111.
In a study with 33 metastatic melanoma 
patients vaccination with autologous tu­
mour lysate-loaded DCs resulted in a 
slightly higher response rate compared to 
peptide-pulsed DCs, (3 versus no partial 
remissions, respectively)93. Equal immuno- 
genicity was demonstrated for peptide- 
and RNA-pulsed DCs in colorectal cancer 
patients112. However, immature DCs were 
used in both studies. Mature DCs have not 
been used in clinical studies comparing 
different antigen-loading techniques. 
Therefore at this moment the optimal 
method for antigen loading is unknown.
Antigens that target DCs in vivo would 
obviate the need for laborious ex vivo cul­
turing protocols113. Although this appears 
to be feasible through DC-specific mole­
cules such as the C-type lectins DC- 
SIGN 114 and DEC-205115 using model an­
tigens, it will probably take some years be­
fore this can be applied in clinical experi­
ments in cancer patients. In addition, a DC 
maturation stimulus should be applied in 
vivo.
Another approach concerns the targeting 
of intratumoural DCs by delivering danger 
signals in situ, which can be combined 
with chemokine treatment in order to in­
crease the number o f intratumoural DCs 
116. In addition, local tumour-destructing 
therapies can induce antigen-release in 
situ, for example by using radiotherapy 117, 
chemotherapy118 or radiofrequency abla- 
tion119. The immunogenicity o f these 
methods may then be further enhanced by
the local delivery o f DC-activating signals
120,121.
5.1 Migration
DCs are the sentinels o f the immune sys­
tem and therefore need efficient migratory 
capacity. In peripheral tissues they con­
tinuously sample the environment for anti­
gens. After antigen uptake DCs must mi­
grate to the secondary lymphoid organs, in 
particular the lymph nodes for presenta­
tion o f the antigens to the adaptive arm of 
the immune system. The lymph node 
homing chemokine receptor CCR7 is es­
sential for DC migration to the lymph 
nodes122,123. CCR7 guides the DCs towards 
and through the lymphatic vessels to the 
lymph nodes in response to chemotactic 
gradients o f its ligands CCL19 and CCL21 
that are expressed by lymphatic vessels and 
lymph node-residing cells (figure 2a)124. 
Expression o f CCR7 is upregulated upon 
DC maturation, resulting in an enhanced 
migratory capacity of matured DCs as 
compared to immature DCs73. In addition, 
inflammatory signals such as prostaglan­
din- E 2 are needed to further sensitize 
CCR7 to its ligands125,126. These findings 
are of importance for DC-based vaccina­
tion, since they show that it may be bene­
ficial to culture DCs in the presence of 
prostaglandin-E2 in order to get a good 
migratory capacity after vaccination, even 
though prostaglandin-E2 has been de­
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scribed to skew DCs under some circum­
stances towards a Th2 type of immune re-
40sponse40.
Interestingly, in a murine model DC migra­
tion could be increased up to ten-fold after 
pretreatment o f the injection site with 
T N F a or unloaded DCs, due to the 
upregulation o f CCR7-ligand CCL21 in 
lymphatic endothelial cells, resulting in a 
superior magnitude and quality o f the T
cell response123.
5.2 Route of DC administration in 
clinical trials
For the effective induction o f immunity it 
is obligatory for the DCs to interact with T 
cells, which takes place in the peripheral 
lymphoid organs: mainly in the lymph 
nodes but to some extent also in the 
spleen. Recent evidence suggests that also 
the bone marrow may be a site for primary 
immune responses127. As different routes 
lead to different sites o f accumulation of 
the vaccinated DCs, these issues are of 
importance when considering the route of 
delivery o f the DCs (figure 2b). Murine 
models have shown that after intravenous 
injection the majority o f DCs accumulate 
in the spleen and to a lesser extent in the 
lungs, kidneys and liver, while hardly any 
DCs end up in peripheral lymph nodes128.
In vivo studies in cancer patients have 
shown that after intradermal injection ap­
proximately 2-4% o f the DCs migrate to 
draining lymph nodes129. There is now 
convincing evidence from several inde­
pendent human studies that migration af­
ter subcutaneous injection is much lower
compared with intradermal injection84,129- 
131.
Intranodal injection results in a much 
higher amount o f DCs accumulating in 
lymph nodes, not only in the injected 
node, but also in subsequent draining 
nodes129. Migration to these subsequent
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nodes via the physiological pathway 
through lymph vessels can be as much as 
80%. However, the magnitude o f DC mi­
gration that is observed after intranodal 
injection is more variable than after intrad­
ermal vaccination129.
Intranodal injections are usually adminis­
tered under ultrasound guidance. Suppos­
edly, this would result in an assured accu­
rate delivery, which was the reason for 
some studies to prefer this route o f ad- 
ministration54. However, using paramag­
netic beads-labeled DCs that can be 
tracked in patients after injection by MR 
imaging, we recently found that intranodal 
injection is complicated by inaccurate de­
livery: in a considerable proportion o f pa­
tients the DCs were misinjected, in the 
perinodal fat132. Inaccurate injection corre­
lated with absent migration to remote 
lymph nodes. These results explain the 
variability in migratory outcome after in­
tranodal administration and underscore 
the importance of accurate delivery133. Re­
cently, Lesimple and colleagues showed 
that intralymphatic delivery into a lymph 
vessel in the dorsum o f the foot is also
feasible134.
Migration o f administered cells however, 
is only a surrogate endpoint. The true 
value o f the different routes of delivery 
can only be determined with immune re­
sponse or even clinical response as an 
endpoint. One study in melanoma patients 
found a small benefit in peptide-specific T 
cell responses after intranodal injection as 
compared to intradermal or intravenous 
injection78. Another study in advanced 
melanoma patients showed no benefit for 
intranodal vaccination as compared to in­
tradermal vaccination: o f 22 evaluable pa­
tients a positive DTH reaction against the 
vaccine was detected in 7/10 intradermal 
vaccinated patients and in 3/12 intranodal 
vaccinated patients135. Fong et al compared
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vaccination with DCs enriched from pe­
ripheral blood mononuclear cells injected 
via three different routes in advanced 
prostate cancer patients: intradermal, in­
travenous and intralymphatic injection via 
a canule in a lymphatic channel in the dor­
sum o f the foot136.
Antigen-specific T cell responses were ob­
served regardless o f the route of delivery, 
although IFNy production after antigen 
stimulation in vitro was only demonstrated
in the intradermally and intralymphaticly 
vaccinated patients. However, the intrave­
nous route gave rise to a more pronounced 
antibody response. In an important study 
performed by the same group intravenous 
injection o f DCs was shown to be essen­
tial for immune responses against visceral 
melanoma metastases, whereas for subcu­
taneous vaccination this was true for non­
visceral metastases137.
Figure 2. DC migration 
and administration. (a)
DCs that reside in the pe­
riphery migrate to draining 
lymph nodes through af­
ferent lymphatic vessels 
following chemotactic gra­
dients of CCL19 and 21. 
These chemokines are ex­
pressed by lymphatic en­
dothelial cells and lymph 
node-residing cells. Blood 
D Cs enter the lymph 
nodes through high endo­
thelial venules (HEV). Af­
ter interaction with DCs, 
the T cells leave the lymph 
node through efferent 
lymphatic vessels and dis­
seminate throughout the 
body via the circulation. 
(b) Several routes of ad­
ministration are used in 
clinical DC vaccination 
trials: intradermal, subcu­
taneous, intratumoural, 
intralymphatic, intranodal 
and intraveneous.
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These findings indicate that the combina­
tion o f different routes of administration 
may be beneficial to target different tu­
mour locations in the entire body138.
In conclusion, to date no specific route of 
administration has unequivocally been 
shown to be superior in terms o f induc­
tion o f immune or clinical responses.
6.1 Tolerance
The immune system has several pathways 
to tune down immune responses in order 
to prevent autoimmunity or excessively 
long or vigorous inflammatory reactions. 
These many pathways include antigen­
presentation by tolerizing DCs (as dis­
cussed above), the suppressive activity of 
so-called regulatory T cells (Tregs) and tol­
erance induction via inhibitory molecules 
on T cells.
According to current insights there are two 
major distinct populations of Treg: natu­
rally occurring C D 4+/C D 25+ Treg which 
by the time they leave the thymus already 
have a suppressive potential, and induced 
Treg that are ‘conventional’ CD4+ or 
CD8+ T cells but transformed into cells 
with an immunosuppressive function un­
der the influence o f tolerizing condi- 
tions139,140. Tregs can affect immune re­
sponses at the level o f antigen- presenta­
tion and during the effector phase o f T 
cells at the site o f inflammation or tumour 
growth139. Treg function is controlled by 
cytokines and cross-talk with antigen- 
presenting cells, but also by direct interac­
tion with pathogens via TLRs141. The 
mechanisms by which Tregs exert their 
suppressive function are not completely 
elucidated, but it may happen in a cell-cell 
contact dependent manner via camp as 
second messenger142 as well as through cy­
tokines such as IL-10 or TGF-P140. The 
clinical importance o f Treg in cancer has 
been demonstrated by Curiel et al.143. A 
high number o f Treg in tumours of ovar­
ian cancer patients correlated with poor 
survival. In other tumor types, these data 
have been confirmed144-146. Furthermore, 
depletion o f naturally occurring Treg by 
anti-CD25 or anti-GITR monoclonal anti­
bodies in murine models resulted in en­
hanced therapeutic efficacy o f a cancer 
vaccine147,148. Since T effector cells also 
upregulate CD25 upon activation (the |3- 
chain o f the IL-2 receptor), a potential 
drawback o f targeting Tregs via CD25 may 
be the depletion o f newly activated T ef­
fector cells along with the Tregs148. It may 
therefore be a meticulous task to find the 
optimal dosing and timing of anti-CD25 
treatment to deplete Tregs via anti-CD25 
antibodies without affecting the activated 
T cell population.
Another important pathway through 
which tolerance or anergy may be induced 
involves inhibitory molecules on the T 
cells, such as cytotoxic T lymphocyte- 
associated antigen-4 (CTLA-4) or pro­
grammed death-1 receptor (PD-1)149.
The ligands o f CTLA-4 are the DC co­
stimulatory molecules CD80 and CD86. 
Binding o f these costimulatory molecules 
to the inhibitory molecule CTLA-4 instead 
of the activating T cell molecule CD28, 
results in suppression of T cell activation 
and proliferation. Activated T cells express 
CTLA-4. Since the affinity o f CTLA-4 for 
CD80 and CD86 is higher than that of 
CD28, eventually the tolerogenic pathway 
prevails, thereby terminating immune reac- 
tions149,150.
PD-1 is another inhibitory T cell surface 
molecule that upon binding to its ligands
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PD-L1 and PD-L2 induces anergy or tol- 
erance149. Interestingly, PD-L1 and 2 are 
expressed by several types o f cancer, 
which may allow the tumour to escape 
from immune surveillance151,152. This phe­
nomenon can be reversed in mice by 
treatment with an anti-PD-L1 anti-
body152,153. Although this has been con­
firmed in vitro for the human situation, 
studies using PD-L1 blockade in cancer 
patients have not been reported yet154.
6.2 Breaking tolerance in melanoma 
patents
Several new drugs have entered the clinic 
that target immunosuppressive mecha­
nisms and may therefore be relevant in 
combination with anti-cancer vaccines. 
Treg can be efficiently depleted in prostate 
cancer patients with denileukin diftitox, a 
compound that consists o f a diphteria 
toxin coupled to IL-2, resulting in en­
hanced antigen-specific T cell responses 
after DC vaccination155. Denileukin difti- 
tox as a single agent has shown promising 
immunological and clinical results in phase
I and II studies in ovarian cancer [Barnet 
ASCO 2006]. In melanoma however, thus 
far the data are conflicting, with one study 
failing to show any efficient Treg156, while 
another preliminary study showed tumour 
regression in two patients [Chesney ASCO 
2006]. Mahnke et al. found enhanced anti­
genic immune responses after peptide vac­
cination and a significant reduction in Treg 
frequencies in melanoma patients after 
denileukin diftitox157. The combination of 
DC vaccination with denileukin diftitox 
has not yet been reported in melanoma 
patients. This also holds true for the com­
bination with anti-CD25 antibodies, de­
spite the fact that these are commonly 
used in transplant patients.
The recent unexpected results with the 
anti-CD28 monoclonal antibody TGN
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1412-trial again demonstrated the enor­
mous potency o f drugs that manipulate
the co-stimulatory pathways158,159. Block­
ade o f CTLA-4 has been shown to induce 
durable objective responses in metastatic 
melanoma patients, at the cost o f autoim­
mune side effects160-163. Anti-CTLA-4 
treatment in melanoma patients did not 
result in depletion or decreased suppres­
sive activity o f Treg (which highly express 
CTLA-4), suggesting that the anti-tumour 
efficacy o f the treatment is caused by an 
increased T cell activation and not by inhi­
bition or depletion of Treg164. Since treat­
ment with anti-CTLA-4 is antigen is non­
specific, the combination with a vaccine 
could potentially direct the T cell response 
in a more specific manner, thereby dimin­
ishing autoimmune side effects. There is 
anecdotal information that anti-CTLA4 
treatment after DC vaccination may indeed 
enhance DC vaccine-induced T cell re- 
sponses163, however clinical trials that are 
specifically designed to answer this ques­
tion are lacking.
7.1 Clinical results of DC vaccination 
studies in melanoma
Proof-of-principle studies were performed 
in the late nineties, showing the feasibility 
and the potential efficacy o f DC vaccina­
tion in cancer patients49,50,56. Since then 
numerous small studies have been per­
formed, especially in melanoma patients 
(table 1 and 2). Given the enormous varia­
tions in culturing protocols and frequency, 
dose and route o f administration, it is not 
possible to pool all these data in a meta­
analysis. Nevertheless, some general ob­
servations can be made. Objective re­
sponse rates in these selected patients do 
not exceed 5-10%, with disease stabiliza­
tion and mixed responses being observed 
more often. As discussed above, there is 
convincing evidence from preclinical and
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clinical studies that immature DCs are not 
proper T cell activators, and could even 
induce tolerance. Strikingly however, this 
does not translate into a dramatic differ­
ence in clinical outcome when studies with 
immature DCs are compared with studies 
in which matured DCs have been used (ta­
ble 1 and 2). Perhaps this hints at the rela­
tively low immunogenicity o f the mature 
DC vaccines that are currently applied: us­
ing cytokines to mature the DCs without 
activation by Toll-like receptor triggers.
In a recent phase III multi-institutional, 
randomized controlled trial the standard 
chemotherapy regimen for patients with 
metastatic melanoma, DTIC, was com­
pared with cytokine-matured DC vaccina­
tion and no difference in survival was ob­
served after inclusion o f all patients, upon 
which the study was discontinued87.
How can this disappointing result be ex­
plained? As reported by the authors them­
selves, the DCs displayed a variable matu­
ration status and the subcutaneous route 
o f administration that was used is inferior.
In addition, not all patients received the 
anticipated numbers of DCs. Others have 
pointed out the enormous complexity of 
performing a multi-center study with 
patient-specific vaccines and the difficul­
ties in establishing a standardized vaccine 
product as a possible explanation o f the 
negative outcome of this study90. Together 
these factors may explain why no clinical 
benefit was found for the DC vaccine. In a 
subgroup-analysis a correlation was found 
between response to DC vaccination and 
HLA-type, with a favorable outcome for 
the HLA-2+/HLA-B44- haplotype. Al­
though this trial could be interpreted as a 
negative trial for DC vaccination, in our 
view equality with the standard therapy for 
the last 30 years is perhaps not a bad start­
ing point, given the fact that there are 
many parameters regarding DC vaccina­
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tion that can still be optimized, as we have 
discussed above.
7.2 Immunological results of DC vac­
cination studies in melanoma
Successful development o f DC vaccines in 
cancer patients much depends on obtain­
ing biological information that correlates 
with clinical efficacy. A clear correlation 
between immunological response and 
clinical outcome has been observed in 
some studies15,165, but not in all93. Moni­
toring immune responses in DC vaccina­
tion trials is difficult and laborious, since 
very low frequencies o f high-affinity 
melanoma antigen-specific T cells in pe­
ripheral blood may be sufficient for tu­
mour rejection. These frequencies can be 
as low as 1 in 40.000 T cells166. These low 
responses are often not detected by the 
most frequently used techniques such as 
Elispot-analysis and direct tetramer- 
staining of peripheral blood lymphocytes. 
In order to detect these low frequencies 
Coulie et al. stimulated blood lymphocyte 
cultures from peptide-vaccinated mela­
noma patients in vitro with melanoma an­
tigens, followed by cloning o f the antigen- 
specific cells and T-cell receptor sequence 
analysis o f the clones166. We took another 
approach by analyzing T cell responses in 
vaccinated patients from biopsies o f de­
layed type hypersensitivity reactions 
(DTH) that were performed with the 
peptide-loaded DC vaccine165,167. In these 
DTH biopsies we found evidence for 
functional antigen-specific T cell responses 
after vaccination. Moreover, the presence 
of these specific T cells was significantly 
correlated with a prolonged progression­
free survival in metastatic melanoma pa­
tients165. These data suggest that the suc­
cess or failure o f tumour-specific T cels to 
migrate towards the DTH site reflects the
potency o f the T cells at the site o f dis­
ease.
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D C  culture 
m ethod
A ntigens A g-load in g
m eth od
R oute N o.
pts
C linical re­
spon ses
Im m un olog ical 
respon se  1
Ref.
IL-4/GM-
CSF/FCS
moDCs
tyrosinase, gp100, 
MART-1, MAGE-1, 
MAGE-3 or lysate
peptides/lysate in 16 2 CR, 2 PR not tested 49
IL-4/GM-
CSF/FCS
moDCs
MAGE-3A.2, tyrosinase, 
gp100, MART-1 or lysate
peptides/lysate in 33 3 PR, 1MR, 6 
SD
13 93
IL-4/GM- 
CSF moDCs
MART-1, gp100 MHC-I pep­
tides
iv 10 1 PR 1 85
IL-4/GM- 
CSF moDCs
autologous peptides autologous
peptides
id 22 1 CR, 1 PR not tested 96
IL-4/GM- 
CSF moDCs
lysate lysate id 14 1 PR, 1 SD 4 91
IL-4/GM- 
CSF moDCs
MART-1, gp100, tyrosi­
nase
MHC-I pep­
tides
iv 16 1 CR, 2 PR, 2 
MR
5 76
IL-4/GM- 
CSF moDCs
MART-1 MHC-I pep­
tides
id 4 1 CR2, 1 SD2, 
1 MR
4 86
IL-4/GM-
CSF/FCS
moDCs
lysate lysate in/sc 4 1 PR, 1 CR 3 94
IL-4/GM- 
CSF moDCs
gp100/tyrosinase MHC-1 pep­
tides
iv/id 9 - - 52
Table 1. Results of published DC-vaccination trials with non-matured DCs in metastatic mela­
noma
Results of published DC-vaccination trials in which non-matured DCs were used. Only melanoma pa­
tients with distant metastases and evaluable disease are included. Abbreviations: IL, interleukin; GM- 
CSF, granulocyte macrophage-colony stimulating factor; FCS, fetal calf serum; moDCs, monocyte- 
derived DCs; sc, subcutaneous; in, intranodal; id, intradermal; iv, intraveneous; CR, complete response; 
PR, partial response; MR, mixed response; SD, stable disease (> 4 months).
immunological response is defined as any evidence of melanoma peptide or tumor-specific T cell re­
sponse after vaccination by one or more test methods; the number of patients with an immune reponse 
are given. 2After DC-vaccination these patients received treatment with an anti-CTLA4 blocking anti­
body.
In a provocative study Lonchay et al. 
showed that although frequencies o f 
vaccine-specific T cell may be higher after 
vaccinations, this does not necessarily 
mean that these cells are the true effector 
cells that actually cause the tumour regres- 
sion168. They found that other tumour- 
specific T cells that were already present 
prior to vaccination were much more ex­
panded after vaccination than the vaccine-
specific T cells. The current hypothesis is 
that vaccine-specific T cells ignite a certain 
‘spark’ in the tumour, causing the non­
active tumour-residing specific T cells to 
become active and proliferative. Thus, the 
expanded specific T cell frequencies that 
are observed upon DC vaccination and 
correlate with an improved clinical out­
come may cause tumour regression either 
in a direct or in an indirect manner.
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7.3 Study design and clinical endpoints 
in DC vaccination
The study design and clinical endpoints 
that should be used in therapeutic cancer 
vaccine studies, were recently defined in a 
consensus process by the Cancer Vaccine 
Clinical Trial Working Group, representing 
academia and pharmaceutical and biotech­
nology industries with participation from 
the US Food and Drug Administration169. 
There are several differences between cy­
tostatic drugs and therapeutic vaccines that 
should be taken into account when design­
ing and evaluating clinical cancer vaccine 
trials.
Firstly, conventional RECIST criteria may 
not always be the most appropriate end­
point to decide which DC vaccine will be 
the most optimal vaccine to be tested in 
large clinical trials. Because vaccine- 
induced immune responses will take some 
time before they become clinically appar­
ent, initial minor progression could be ac- 
ceptable169. In fact, adequate immune in­
duction could theoretically first induce en­
largement o f tumour lesions through T 
cell infiltration and local inflammation. For 
these reasons, it may be proper to deviate 
from standard RECIST criteria, provided 
that the new criteria are pre-defined and 
clearly described, as proposed before4. 
Whether functional imaging has a role in 
the monitoring of clinical responses in 
cancer vaccine trials remains to be deter­
mined. It has been shown that upon DC 
vaccination regional non-tumourous 
lymph nodes become FDG-positive on 
positron emission tomography-scanning, 
reflecting immune activation rather than 
tumour progression170.
A second major difference between con­
ventional cytostatic therapy and DC vacci­
nation is that the highest dose is not nec­
essarily the most effective one. And be­
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cause DC vaccines have an almost negligi­
ble toxicity, conventional dose-escalating 
phase I trials with toxicity as the primary 
endpoint would not result in the selection 
of the optimal dose to be used in further 
clinical testing. This problem has been cir­
cumvented by performing dose-escalation 
studies with immune response as the pri­
mary endpoint rather than toxicity (see for 
example ref. 15).
Another difference is that in patients with 
advanced disease, the patient group in 
which phase I trials are usually performed, 
immunotherapy will probably have little 
chance of being successful because of 
immunosuppressive mechanisms at the 
tumour site. For these reasons, the conven­
tional phase I-II-III trial paradigm that is 
applied in the field o f cytostatic therapy, 
may not be the most optimal trial design 
for DC vaccination.
The Cancer Vaccine Clinical Trial Working 
Group concensus recently proposed a 
two-step development in clinical trial de­
sign in cancer vaccination: proof-of- 
principle trials and efficacy trials169. The 
following criteria were proposed for proof- 
of-principle trials. They should include a 
minimum of 20 patients in a homogenous, 
well-defined population. The disease 
should not be rapidly progressive in order 
to allow the vaccines adequate time to in­
duce immunological activity. Study objec­
tives should include determination o f dose 
and schedule and demonstration o f im­
munological activity as proof-of-principle. 
Immunological activity is demonstrated if 
determined in 2 separate, established and 
reproducible assays at 2 consecutive 
follow-up time points after the baseline 
assessment.
Efficacy trials then formally establish clini­
cal benefit, either directly or through a sur­
rogate endpoint. In contrast with the field
Chapter 10
o f conventional cytostatic therapies, it is We believe that these guidelines are of 
promoted that these trials are randomized. great practical use and could help the field
forward.
D C  culture m ethod A ntigens A g-load in g
m ethod
R oute N o. pts C linical
respon ses
Im m u n e
respo n ses
Ref.
IL-4/GM- CSF/MCM /  
T N F a / moDCs
MAGE-3 MHC I peptides sc, id, 
iv
13 6 MR 9 56
IL-4/GM -CSF/IL-1b/IL- 
6 /T N F a /P G E 2 moDCs
MAGE-3, MAGE-1, 
tyrosinase, MAGE-4, 
MAGE-10, gp100, 
MART-1
MHC I+II pep­
tides
sc 19 1 CR, 4 SD 12 57
IL-4/GM -CSF/M CM / 
T N F a moDCs
MAGE-3 MHCI peptides sc, iv 8 1 SD 8 59
GM-CSF/Calcium- 
ionophore /IL-2/IL-12 
moDCs
MART-1, gp100, 
tyrosinase,
MHC I peptides in, id, 
iv
27 3 PR 13 78
IL-4/GM -CSF/M CM / 
T N F a +PG E2 moDCs
gp 1 0 0 , tyrosinase MHC I peptides id, iv 10 1 PR, 1
MR, 3 SD,
2 52
Flt3L/G M -CSF/TN Fa 
CD34+ DCs
MART-1, MAGE-3, 
gp 1 0 0 , tyrosinase
MHC I peptides sc 18 4 CR1, 4 
PR, 3 SD
17 15,
82,
83
IL-4/G M -C SF/TN Fa/IL- 
3/IL-6/SCF CD34+ DCs
MART-1, gp100, 
tyrosinase, MAGE-1, 
MAGE-3
MHC I peptides iv 14 1 PR, 6 SD 1 18
Flt3L/GM -CSF/TNF a /  
IF N a CD34+ DCs
MART-1, MAGE-3, 
gp 1 0 0 , tyrosinase
MHC I peptides sc 20 1 SD 7 17
IL-4/G M -C SF/T N Fa/ 
CD40L moDCs
Allogeneic lysate Allogeneic lysate sc 20 1 CR, 1 PR 2 61
IL-4/GM- CSF/IL-1 p /IL- 
6 /T N F a /P G E 2 moDCs
Autologous tumor
RNA
RNA-
electroporation
id or in 21 1 MR 9 11 0 ,
111
IL-4/G M -CSF/TN Fa 
moDCs ±  sc IL-2
Allogeneic lysate lysate id 15 6 SD 9 99
IFN/IL-3/polyI:C moDCs NA17, MAGE-3 MHCI + II pep­
tides
sc, id 4 1 SD 1 84
IL-4/GM- CSF/IL-1 p /IL- 
6 /T N F a /P G E 2 moDCs
MAGE-1, MAGE-3, 
tyrosinase, gp10 0 , 
MART-1
MHCI + II pep­
tides
sc 53 2 PR, 8 
SD2
Not given 87
GM-CSF/IL-13 moDCs Allogeneic lysate Allogeneic lysate in, sc, 
id
10 1 SD 3 98
GM -CSF/IL-13/
Ribomunyl/IFNy
MART-1, ±  NA17 M HCI+II peptides il then 
in
14 2 SD 5 133
Table 2. Results of published DC-vaccination trials in which DCs were used that had received 
some form of maturation signals. Only melanoma patients with distant metastases and evaluable dis­
ease are included. Abbreviations: IL, interleukin; GM-CSF, granulocyte macrophage-colony stimulating 
factor; MCM, monocyte-conditioned medium; TN Fa, tumor necrosis factor alpha; PGE2, 
prostaglandin-E2; moDCs, monocyte-derived DCs; Flt3L, Flt3-Ligand; SCF, stem cell factor; IFN, in­
terferon; sc, subcutaneous; in, intranodal; id, intradermal; iv, intraveneous; il, intralymfatic; CR, com­
plete response; PR, partial response; MR, mixed response; SD, stable disease (> 4 months).
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1 In a follow-up report82, all complete responders were still free of disease with a median of 5 years.
2 This is a multi-institutional, randomized phase III trial. In the other treatment-arm 55 patients were 
treated with DTIC, in which 3 PR and 10 SD were seen. No differences in overall or progression-free 
survival were observed.
And although in some instances it may be 
sufficient to include smaller numbers of 
patients (for example in trials investigating 
DC migration in vivo), we believe that ad­
herence to these guidelines should be en­
couraged.
7.4 DC Companies
The preparation of a standard high-quality 
DC vaccine that meets Good Manufactur­
ing Practice/Good Laboratory Practice 
(GMP/GLP), and clinical grade criteria is 
a laborious and costly process. Dedicated 
GM P/GLP cleanrooms are needed. Cul­
turing a DC vaccine for one patient takes 
at least two persons two to three full work­
ing days. Even more costly are the culture 
media and cytokines that need to be toxin­
free, clinical grade materials. Together with 
the fact that the vaccines are patient- 
specific, ‘tailor-made’, these issues gave rise 
to the long-held believe that companies 
would not be interested in DC vaccination. 
However, at the moment several compa­
nies are trying to get approval from official 
regulatory authorities171.
One company-made DC vaccine is 
Sipuleucel-T, which is made o f antigen- 
presenting cells that are collected by two 
density centrifugation steps, pulsed with 
recombinant prostatic acid phosphatase 
fused to GM-CSF172. A placebo-controlled 
phase III trial in hormone-refractory 
metastatic cancer patients was not able to 
show improvement in time to progression, 
the primary endpoint, although overall 
survival was prolonged from 21.4 to 25.9 
months173. Initially an FDA Advisory 
Committee recommended to approve 
Sipuleucel-T, but the FDA decided to 
await further proof o f efficacy. This
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should come from an ongoing phase III 
trial with overall survival as primary end­
point of which the first interim analysis is 
planned in 2008171,174. Other firms are 
seeking approval by the European and US 
regulatory authorities for vaccines targeted 
at lymphoma, sarcoma, glioblastoma and 
acute myelogenous leukaemia171.
7.5 Combination therapies
There is a need to test combinations with 
more cytotoxic therapies, given the low 
frequency o f clinical responses in patients 
with advanced disease upon DC vaccina­
tion alone. Although initially chemother­
apy was believed to be detrimental to T 
cell-directed immunotherapy because most 
chemotherapy regimens have a myelosup- 
pressive effect, now more evidence is ac­
cumulating that some forms o f chemo­
therapy may not harm T cell responses175 
and may in fact have a synergistic effect 
together with immunotherapeutic ap­
proaches (reviewed in ref. 176)75,118. It is 
tempting to speculate on the possibility of 
tumour debulking by chemotherapy, com­
bined with immune surveillance and im­
mune memory induction by vaccination 
therapy to prevent relapses. The same ap­
plies to radiotherapy177 and targeted thera- 
py178. Another interesting approach in­
volves in situ tumor destruction by cryo- 
or radiofrequency ablation in combination 
with immune activation, including injec­
tion o f DCs119-121,179. Clinical data are lack­
ing, but trials combining chemotherapy 
and DC vaccination are in progress.
As discussed above, also combination 
therapy with anti-CTLA4 and DC vaccina­
tion may have a synergistic effect. It is cur­
rently under study whether DC vaccination
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can enhance the graft-versus-tumour effect 
o f stem cell transplantation and donor 
lymphocyte infusions in haematological 
malignancies180. Adoptive T cell transfer 
following non-myeloablative but lympho- 
depleting chemotherapy showed impres­
sive clinical results in advanced melanoma 
patients181,182. Adoptive T cell transfer 
generates a high, but short peak o f 
antigen-specific T cells, whereas DC vac­
cination induces T cell responses more 
gradually that endure longer183, providing a 
rationale to combine the two treatment 
modalities. In preclinical models DC vac­
cination indeed boosted and sustained 
anti-tumour T cell responses after adoptive 
T cell transfer182,183. Trials in the near fu­
ture will have to answer the question 
whether DC vaccination can add to the 
efficacy o f these other anti-cancer treat­
ment modalities.
8 Conclusion and future prospects
DC vaccination has shown to be feasible 
and safe. Immunological responses are 
frequently observed. Clinical responses 
have been reported, but the incidence is 
low Exciting new insights arise from pre- 
clinical studies, some o f which are cur­
rently being applied in clinical studies. For 
example, depletion o f suppressor T cells 
combined with DC vaccination may en­
hance the immunogenicity o f the vaccine, 
as has been shown in prostate cancer pa­
tients155. Also blockade o f the inhibitory T 
cell molecule CTLA-4 by monoclonal an­
tibodies could enhance the immunogenic­
ity o f DC vaccines162. Combination treat­
ment with chemotherapy, radiotherapy or 
other tumour ablative treatments needs to 
be further investigated. Trials with TLR- 
ligand activated DCs are eagerly awaited. 
Although these novel treatment strategies 
are now entering clinical studies, the pace 
o f in vitro and animal research is inevita­
bly faster than that o f clinical research. For 
this reason a lot of crucial questions re­
garding the optimal DC vaccine for clinical 
use remain unanswered to date. These 
questions concern the optimal methods 
for culture, maturation and antigen- 
loading, route o f administration, subsets 
of DCs and effects o f suppressor T cell- 
depletion or blockade o f other inhibitory 
pathways. Significant progress is only to be 
expected from well-designed, properly 
conducted and comparative studies with 
biological endpoints.
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SUMMARY
In chapter 1 we describe the basic im­
munobiology of dendritic cells (DCs) in 
the context o f anti-tumor immunity. The 
principle o f DC vaccination is introduced 
and we address several relevant questions 
on this topic. We emphasize the impor­
tance o f careful study design, the use of 
standardized clinical and immunological 
criteria for response evaluation, and ade­
quate quality control for DC vaccine 
preparation and administration.
In chapter 2 the results are reported of a 
clinical study in metastatic melanoma pa­
tients who were vaccinated with either 
immature or mature DCs, loaded with 
melanoma-associated antigenic peptides 
and the control protein keyhole limpet 
hemocyanin (KLH). Patients that were 
vaccinated with mature DCs showed a ro­
bust T  and B cell response against KLH  
upon vaccination, indicating that a de novo 
immune response was induced. In patients 
who were vaccinated with immature DCs, 
these responses were absent or very weak. 
In addition, only in patients who were vac­
cinated with mature DC, delayed type hy­
persensitivity (DTH) reactions against the 
vaccine were observed after treatment. 
Importantly, tumor antigen-specific T cell 
responses were only observed in patients 
that were vaccinated with mature DCs, and 
the presence of these T  cells correlated 
with a clinical benefit.
DCs can be administered in several man­
ners, such as intravenously, intradermally 
or directly into lymph nodes under ultra­
sound guidance. For the latter method to 
be successful, the accurate delivery into the 
lymph nodes is o f utmost importance. In 
chapter 3 we describe a novel method of 
tracking DCs upon vaccination in lymph
nodes in patients using magnetic reso­
nance imaging (MRI).
Dendritic cells were labeled with 111In- 
oxine and superparamagnetic iron oxide 
particles separately and coinjected in a 
lymph node to be resected. This provided 
a unique opportunity not only to obtain 
MRI scans at 3 Tesla before surgery, but 
also to generate high-resolution magnetic 
resonance images at 7 Tesla o f individual 
resected lymph nodes and to correlate the 
results with scintigraphy and (immu- 
no)histopathology. This is the first report 
of effective tracking o f ex vivo-labeled 
therapeutic cells in humans by MRI. We 
demonstrate that MRI is at least as sensi­
tive as scintigraphic imaging for detecting 
DC migration in vivo. However, MRI in 
contrast to scintigraphy is able to verify the 
anatomic location of injected DCs. Subse­
quent migration upon injection was only 
observed when DCs were correctly in­
jected into the lymph node, demonstrating 
the importance o f accurate administration 
of this cellular therapy. Inadequate delivery 
may explain why only a limited proportion 
of patients is responding in ongoing clini­
cal trials o f intranodally injected DC vac­
cines.
Most DC vaccination protocols use pep­
tide fragments o f tumor-associated anti­
gens. In vitro and animal studies have 
shown that the immunogenicity o f pep­
tides can be improved by modification of 
the amino acid sequence, resulting in en­
hanced MHC class I binding affinity and 
stability o f peptide-MHC complexes. 
When used to load on DCs, this would re­
sult in enhanced immune responses upon 
vaccination. In chapter 4 we tested this 
hypothesis based on preclinical evidence in 
a clinical study. Metastatic melanoma pa­
tients were vaccinated with mature DC 
pulsed with either wildtype or modified
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gp100 peptides. We observed functional T 
cell responses against the vaccine antigens 
in 2 o f 15 patients vaccinated with wild­
type gp100-loaded DCs, versus 1 o f 12 
patients vaccinated with modified peptide- 
loaded DCs. The 3 patients with functional 
T cell responses also had the best clinical 
response, with long-term (>8 years) com­
plete responses in two patients. These data 
show that the use o f modified as com­
pared to wild-type gp100 peptides for DC 
loading does not enhance tumor-specific 
immune responses.
Most studies with DC-based vaccines have 
been performed in melanoma patients. In 
chapter 5 we report the results o f a clini­
cal study in colorectal cancer patients. Pa­
tients with resectable liver metastases were 
vaccinated with carcinoembryonic antigen 
(CEA) peptide-loaded DCs. CEA-specific 
T cell reactivity was monitored in periph­
eral blood, biopsies o f vaccination sites 
and post-treatment DTH skin tests and, 
when available, also in resected abdominal 
lymph nodes and tumor tissue. We ob­
served high numbers o f functional CEA- 
specific T cells in post-treatment DTH bi­
opsies in 7 out of 10 patients. These re­
sponses were not found in biopsies o f first 
vaccination sites, indicating a de novo T 
cell induction or at least a strong potentia­
tion by the vaccine. In addition, CEA- 
specific T cells were detected in a resected 
lymph node in one patient. Thus, vaccina­
tion with CEA-peptide loaded mature 
DCs induced potent CEA-specific T cell 
responses in advanced colorectal cancer 
patients
An alternative method to load antigen on 
DCs consists o f transfection o f mRNA 
encoding the antigen. Theoretically this 
has several advantages including presenta­
tion o f more antigenic epitopes, longer
antigen presentation and availability for all 
patients independent o f HLA-type. In 
chapter 6 we determined the optimal 
conditions for mRNA-electroporation of 
DCs for clinical application in relation to 
different maturation cocktails. This tech­
nique resulted in a rapid and long-enduring 
expression o f tumor antigens and accurate 
T cell activation in vitro. However, activa­
tion o f DCs with polyinosinic—polycyti- 
dylic acid [poly(I:C)], which is often used 
in maturation protocols, resulted in a con­
siderably decreased antigen expression. A 
possible explanation for this observation 
lies in the fact that poly(I:C) is a synthetic 
double-stranded RNA and culturing of 
DCs with this virus-associated molecular 
pattern results in the induction o f IFN- 
induced genes and innate anti-viral effec­
tor molecules and consequently in de­
creased translation of the mRNA encod­
ing the antigen. Thus, electroporation of 
mature DCs with tumor antigen-encoding 
mRNA is attractive for use in DC vaccina­
tion protocols in cancer patients, but pro­
tein expression should be tested for each 
maturation cocktail.
In chapter 7 these data were put to the 
test in a clinical study comparing the im- 
munogenicity o f DCs pulsed with CEA- 
peptide (as described in chapter 5) with 
DCs electroporated with CEA-mRNA in 
colorectal cancer patients. CEA peptide- 
specific T cells were detected in 8 out of
11 patients in the peptide group, but in 
none o f the 5 patients in the RNA group. 
These data demonstrate that CEA-mRNA 
transfection as antigen loading strategy of­
fers no benefit as compared to peptide 
loading, at least in this model.
Next we explored the feasibility o f the 
combination of DC vaccination with cyto­
toxic chemotherapy. The theoretical ad­
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vantage of this combination is that it 
would allow tumor antigen release com­
bined with the recently reported induction 
o f immunogenic tumor cell death1-3. 
However the direct effect o f cytotoxic 
anti-cancer drugs on DC function and 
their effect on immune inhibitory path­
ways that are present in the tumor micro­
environment are largely unknown. We in­
vestigated the effect o f cytotoxic drugs on 
DC function and on tumor cell immuno- 
genicity, and the results are reported in 
chapter 8. In addition to their well-known 
direct cytotoxic effects, we demonstrate 
that platinum-based anti-cancer drugs 
modulate immuno-suppressive pathways 
by acting both at the level of the tumor as 
well as on cells o f the immune system. We 
also detail a novel mechanism underlying 
the action o f these chemotherapeutics: 
that platinum compounds dephosphory- 
late Signal Transducer and Activator of 
Transcription 6 (STAT6) resulting in 
downregulation of the T cell inhibitory 
molecule Programmed Death Receptor- 
Ligand 2 (PD-L2), which is ultimately re­
sponsible for the observed effects. In line 
with these in vitro findings, we observed in 
a retrospective study that patients with 
STAT6-expressing head and neck cancer 
displayed significantly enhanced recur­
rence- free survival upon treatment with 
cisplatin-based chemoradiation compared 
to patients with STAT6-negative tumors, 
demonstrating the clinical relevance of 
platinum-induced STAT6 modulation. 
These findings demonstrate that platinum 
compounds not only directly kill tumor 
cells but also enhance T cell stimulation by 
DCs. At the same time tumor cells are also 
sensitized to lysis by cytotoxic T cells 
through inactivation o f STAT6/PD-L2 
pathway. This novel action of platinum 
compounds may extend their therapeutic 
application and provides a rationale for
their use in combination with other 
immuno-stimulatory compounds to in­
crease the clinical efficacy o f cancer treat­
ment.
To test whether antigen-specific T cell in­
duction can still occur during treatment 
with oxaliplatin-based chemotherapy, we 
performed a small pilot study in 8 stage III 
colon cancer patients, of which the results 
are described in chapter 9. These patients 
received the same CEA-specific DC vac­
cine as described in chapter 5, in addition 
to standard adjuvant treatment with oxali- 
platin and capecitabine. In 4 out of 7 pa­
tients functional CEA-specific T cell re­
sponses were observed. In addition, we 
demonstrated an enhanced non-specific T 
cell reactivity upon oxaliplatin administra­
tion. KLH-specific T cell responses re­
mained unaffected by chemotherapy, 
whereas B cell responses were diminished. 
These results demonstrate that oxaliplatin- 
based chemotherapy does not interfere 
with tumor antigen-specific vaccination 
and even may enhance T cell-mediated 
immune responses, and they strongly sup­
port further testing of the combined use 
of immunotherapeutic approaches with 
oxaliplatin-based chemotherapy.
In chapter 10 we review the current status 
of the field of DC vaccination, focusing 
on melanoma.
FUTURE PROSPECTS
More than a decade has passed since the 
first clinical DC vaccination studies were 
reported4,5. Since then, numerous clinical 
and preclinical studies have been per­
formed. Although much progress has been 
made as described in the previous chapter, 
unfortunately the majority of patients have
175
Chapter 11
no clinical benefit from DC vaccination.
So what are we doing wrong? There is 
more than one answer to this question.
DC activation
Most studies used cytokines to mature the 
DCs, but we know now that full matura­
tion using pathogen-associated molecular 
patterns to activate the DCs is crucial for 
the induction of robust, functional anti­
tumor T cells6. Many novel experimental 
compounds are currently being developed 
that can be used as potent DC-activating 
stimuli.
Immune escape
Tumors use numerous mechanisms to es­
cape from the immune system7. Even if 
very potent T cells are induced by DC vac­
cines, clinical efficacy will be limited if 
these inhibitory pathways are not over­
come. Important therapeutic possibilities 
include CTLA-4 blocking antibodies or 
antibodies blocking the PD -1/PD -L  
pathway. In a recent study treatment with 
an anti-CTLA4 antibody resulted in a 
clinical benefit in metastatic melanoma pa­
tients, demonstrating that the concept of 
blocking inhibitory pathways is indeed a 
promising strategy5. Studies investigating 
the combination of vaccination therapy 
with these antibodies are currently ongo­
ing and the results are eagerly awaited. Re­
cently it has been shown that melanoma 
stem cells may not express tumor anti­
gens9, which could result in immune es­
cape despite robust vaccine-induced anti­
tumor immune responses. A surface- 
marker for these stem cells has been dis­
covered, possibly allowing new therapeutic 
approaches9.
Tumor stage
Most studies have tested the immunologi­
cal and clinical efficacy of DC vaccination
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in end-stage cancer patients. In these pa­
tients, the immune system is often sup­
pressed, either systemically or locally in the 
tumor microenvironment. In these pa­
tients with gross tumor volume it is ques­
tionable whether DC vaccination, which 
needs some time to result in proper T cell 
activation, is able to induce clinical re­
sponses. Rather, it will often be ‘too little, 
too late’10. Patients with limited tumor 
burden, such as in the adjuvant setting, 
may provide a better platform to test the 
efficacy o f DC vaccines.
Combination therapies
The above-mentioned mechanisms of 
immune escape and the rationale for prior 
tumor debulking provide strong arguments 
to combine DC-based therapy with other 
treatment modalities11-13. A promising ex­
ample is platinum-based chemotherapy, 
since it provides tumor debulking (antigen 
release), immunogenic tumor cell death, 
DC activation and disarmament o f 
immune-suppressive mechanisms at the 
tumor site (as described in chapter 8)1-3.
So what have we learned? DC vaccination 
is able to induce tumor-specific immune 
responses. Importantly, the presence of 
these vaccine-induced immune responses 
correlates with the induction of clinical 
responses in cancer patients. Several as­
pects of DC vaccination, such as activa­
tion, culturing, administration and antigen- 
loading have been optimized . And finally, 
DC vaccination can be combined with 
chemotherapy without compromising its 
immunogenicity.
Where should we go from here? The use 
of fully TLR-activated DCs appears most 
promising, as well as the combination of 
DCs with treatment modalities that block 
immune suppression and/or chemothera- 
peutics that allow T cell induction, but at
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the same time break immunosuppressive 
networks at the tumor microenvironment. 
Furthermore, the combination o f (plati­
num- based) chemotherapy with immune 
activating signals could obviate the need of 
the administration of ex vivo cultured DCs: 
in this concept the chemotherapy-induced 
cytotoxicity provides antigen release, im­
munogenic cell death, reduction of im­
mune suppression at the tumor site and 
down-regulation of inhibitory molecules 
on the DCs; the immune stimuli provide 
full T cell and DC activation. There are 
several good candidate compounds that 
have recently entered the clinic (some of 
which still in a experimental phase), such 
as anti-CTLA4, CD40-ligand, PD-1 block­
ing antibodies and Toll-like receptor trig- 
gers8’14’15. Therefore, the road to clinical 
studies and hence clinical application may 
be short. Hopefully, these treatments will 
result in better treatment options for can­
cer patients in the near future.
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Nederlandse samenvaffing voor niet-ingewijden
Vaak wordt kanker voorgesteld als een vij­
and die we de oorlog moeten verklaren. 
Als je die vergelijking door zou trekken 
zou je het afweersysteem kunnen zien als 
het verdedigende leger. De soldaten van 
dat leger zijn de zgn. T cellen, de cellen die 
in staat zijn kankercellen te doden. Echter, 
T cellen zijn van nature niet in staat de 
kankercellen op te ruimen. Daarvoor moe­
ten ze eerst gealarmeerd worden. Daar 
komen dendritische cellen (DCs) bij kijken. 
Dat zijn cellen die door het hele lichaam 
zwerven op zoek naar indringers. Hoewel 
ze zelf niet in staat zijn tumorcellen te do­
den, kunnen ze wel stukjes van dode kan­
kercellen opnemen. Dode kankercellen zijn 
altijd ruim aanwezig in tumoren. Zie het 
als een slagveld waar de zwarte helmen van 
de vijand op de grond liggen en de DCs 
pikken die op (figuur 1).
Figuur 2
DCs zijn dus aanvankelijk de verkenners 
en nadat ze de vijand hebben gezien, pro­
moveren ze snel tot generaal1. Nadat ze 
geactiveerd zijn, kunnen T cellen zichzelf 
vermenigvuldigen tot wel 10.000 keer, ze 
verlaten de lymfeklier en verspreiden zich 
door het hele lijf. Als ze nu een kankercel 
tegenkomen die de antigenen op zijn op­
pervlakte heeft waartegen de T cel is geac­
tiveerd (‘draagt een zwarte helm’), zal de T 
cel dit herkennen en de kankercel dood­
maken (figuur 3).
Figuur 1
Vervolgens bewegen ze zich naar de lym­
feklieren om daar de T cellen te activeren. 
Als ze dan in de lymfeklier aankomen pre­
senteren ze deze tumor-fragmenten, antige­
nen genaamd, aan de T cellen en geven ze 
daarnaast een activatie-signaal (“als je ie­
mand met een zwarte helm ziet: doodma­
ken” - figuur 2).
Figuur 3
Sinds enkele jaren is het mogelijk DCs in 
grote hoeveelheden te kweken door voor­
lopercellen te isoleren uit het bloed van 
patiënten en ze gedurende enkele dagen te
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kweken in de aanwezigheid van groeifacto­
ren. Vervolgens kunnen ze beladen wor­
den met de tumor-antigenen en terugge­
geven worden aan de patiënt door injectie. 
De DCs moeten dan de lymfeklieren in de 
patiënt bereiken om daar de T cellen te ac­
tiveren tegen de tumor-antigenen. De ge­
activeerde T cellen moeten dan de klieren 
verlaten, zich verspreiden door het lijf, de 
tumor infiltreren en de kankercellen her­
kennen en uiteindelijk doden. Het doel van 
deze techniek is dus heel specifiek het af­
weersysteem te alarmeren en te activeren 
tegen de kankercellen, zodat deze opge­
ruimd worden.
In hoofdstuk 1 beschrijven wij de achter­
gronden van DC-vaccinatie, de resultaten 
van klinische studies in kankerpatiënten en 
de moeilijkheden die zich voordoen bij het 
onderzoek van deze behandelmethode.
Het activatie signaal dat DCs geven als ze 
antigenen presenteren aan de T cellen, 
wordt gegeven door co-stimulatie-moleculen 
op het oppervlakte van de cel (in figuur 2 
het waarschuwingsbord). Voor goede T 
celactivatie is dat signaal cruciaal. Als DCs 
door het lichaam zwerven, zonder de aan­
wezigheid van een ‘gevaar-signaal’, zijn ze 
in een immature staat. In het immature sta­
dium bezitten ze de juiste eigenschappen 
om antigenen op te nemen en te verwer­
ken. In de aanwezigheid van een gevaar- 
signaal worden de DCs matuur (denk aan 
de vergelijking van net: de immature DCs 
zijn uitstekende verkenners, bij maturatie 
worden ze als het ware gepromoveerd tot 
generaal en delen ze de lakens uit, bepalen 
wie wanneer en hoe wordt aangevallen). 
De gevaars-signalen die leiden tot matura- 
tie kunnen bepaalde herkenningsmoleculen 
zijn van bacterien of virussen, maar ook 
immunologische signaalmoleculen die vrij­
komen in een tumormilieu. Door deze 
maturatie-signalen veranderen DCs in cel­
len die met name goed zijn in snelle migra­
tie naar lymfeklieren en het presenteren 
van antigeen. Daarnaast zetten ze hun cos- 
timulatie-moleculen in hoge mate op hun 
oppervlak. Dit leidt ertoe dat DCs in ma­
ture staat alle eigenschappen bezitten om 
T cellen goed te kunnen activeren.
Het was niet bekend welk type DC het 
best gebruikt kon worden om kankerpa­
tiënten te behandelen met DC vaccinatie. 
In de meeste studies die werden verricht 
werden immature DCs gebruikt.
In hoofdstuk 2 beschrijven we een klini­
sche studie waarbij wij patiënten met uit­
gezaaid melanoom (een zeer kwaadaardige 
vorm van huidkanker) behandelden met 
immature of mature DCs die waren bela­
den met tumor-antigenen. We vonden dat 
alleen bij patiënten die waren behandeld 
met mature DCs er een sterke afweerreac­
tie tot stand was gekomen tegen de antige­
nen in het vaccin. Bovendien vonden we 
alleen bij patiënten die waren behandeld 
met mature DCs een stabilisatie van het 
ziekteproces, danwel een afname van de 
uitzaaiingen. Uit deze studie blijkt dat voor 
vaccinatie van kankerpatiënten mature 
DCs gebruikt dienen te worden, geen im­
mature.
DCs kunnen op verschillende manieren 
toegediend worden: onder de huid, via de 
bloedbaan, of via directe injectie in lymfe­
klieren. Bij de laatste methode vonden we 
eerder dat na injectie de verdere verdeling 
naar overige klieren buitengewoon wissel­
vallig was. Om meer inzicht te krijgen in 
de accuratesse van injectie, testten wij de 
mogelijkheid van het labelen van DCs met 
ijzerbolletjes. Het betreft minuscule ijzer- 
bolletjes waar een dun laagje suiker om- 
heenzit. Deze bolletjes zijn geregistreerd 
als contrastvloeistof bij MRI-scans. In
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hoofdstuk 3 beschrijven we de resultaten 
van deze studie. We vonden dat DCs deze 
bolletjes uitstekend konden internaliseren 
zonder aantasting van hun immunologi­
sche eigenschappen. Na injectie in mela- 
noompatiënten konden we de lokatie van 
de DCs goed zien met behulp van MRI 
scans. Zo vonden we ook dat in sommige 
patiënten de DCs naast de lymfeklieren 
werden geinjecteerd ondanks dat injectie 
onder geleide van een echo-apparaat werd 
verricht. En het was juist bij deze patiënten 
dat we geen verdere verspreiding naar vol­
gende klieren konden zien.
Deze bevindingen laten het belang van 
adequate toediening van DCs zien. Daar­
naast blijkt uit deze studie voor het eerst 
dat cellen uitstekend te volgen zijn na in­
jectie in patiënten met behulp van ijzerpar- 
tikels en MRI. Deze resultaten kunnen ook 
van belang zijn voor andere terreinen van 
onderzoek waarbij cellen op een accurate 
wijze moeten worden toegediend op exact 
de juiste anatomische lokatie, zoals bij­
voorbeeld bij stamcelonderzoek.
In hoofdstuk 4 beschrijven we een studie 
waarbij we patiënten behandelden met 
DCs met daarop twee verschillende vor­
men van hetzelfde antigeen (de ‘zwarte 
helm’). De ene helft van de patiënten kreeg 
DCs beladen met normale melanoom-ei- 
witfragmenten (peptiden), de andere helft 
kreeg DCs beladen met gemodificeerde 
peptiden. De modificatie bestond eruit dat 
een aminozuur van het peptide was veran­
derd, waardoor het beter bindt aan zgn. 
HLA-moleculen op de DC (dat zijn mole­
culen die het antigeen op het oppervlak 
van de DC presenteren; zie ze als de hand 
die de zwarte helm vasthoudt). Dat lijdt er 
toe dat er meer peptiden op de DC blijven 
plakken en daardoor beter aangeboden 
worden aan de T cellen. Daarnaast is uit 
kweekbuisonderzoek gebleken dat de T
celreactiviteit daarbij hoger is dan bij ‘ge­
wone’ peptiden. O f dat in patiënten na 
toediening ook zo zou zijn was niet be­
kend. Om die reden hebben wij dit onder­
zocht in patiënten met gemetastaseerd me- 
lanoom. We vonden dat zowel in de groep 
patiënten die behandeld waren met DCs 
beladen met gewone peptiden, als in de 
patiënten bij wie de peptide waren gemo­
dificeerd afweeractivatie optrad tegen de 
melanoomatigenen. Ook waren er in beide 
groepen klinisch relevante afnames te zien 
van de melanoomactiviteit bij enkele pa­
tiënten, bij 1 patiënt was er zelfs een volle­
dige verdwijning van melanoomuitzaaiïn- 
gen. Echter, er was geen duidelijke toena­
me in de afweeractivatie te zien bij de pa­
tiënten die waren behandeld met de gemo­
dificeerde peptiden. Uit deze studie bleek 
derhalve geen duidelijke meerwaarde van 
het gebruik van gemodificeerde peptiden 
voor DC vaccinatie.
Veruit de meeste DC vacinatie studies zijn 
verricht in patiënten met gemetastaseerd 
melanoom. Of deze methode ook potentie 
zou kunnen hebben in andere tumortypes 
was onvoldoende bekend. Om die reden 
hebben wij de mogelijkheid onderzocht in 
darmkankerpatiënten (hoofdstuk 5). Dit 
deden wij bij patiënten met leveruitzaaiïn- 
gen van darmkanker die zouden kunnen 
worden verwijderd door de chirurg. Vooraf 
vaccineerden wij de patiënten. Ten eerste 
was dit omdat op het moment van de stu­
die deze groep patiënten niet standaard 
chemotherapie kreeg en wij op dat mo­
ment meenden dat chemotherapie moge­
lijk slecht zou zijn voor het afweersysteem 
(hierover later meer). En ten tweede kon­
den we zo goed de afweerreactie bekijken 
na vaccinatie in tumorweefsel zelf en in 
klieren in de buik, omdat die toch zouden 
worden verwijderd. Als antigeen om de 
DCs te beladen gebruikten we CEA. Dat
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is een eiwit dat eigenlijk altijd als herken- 
ningsmoelcuul op darmtumoren voor­
komt. We konden in de meeste van de 10 
patiënten die we vaccineerden een zeer 
duidelijke T cel afweerreactie vinden tegen 
CEA na vaccinatie.
Het is ontzettend lastig om in bloed anti- 
geen-specifieke T cellen aan te tonen, dat 
wil zeggen de T cellen die alleen een be­
paald eiwit van interesse herkennen, in dit 
geval CEA. Uit andere studies is bekend 
dat als 1 op de milljoen T cellen specifiek 
tumorantigeen kan herkennen na vaccina­
tie, dit al genoeg kan zijn om een klinisch 
relevante afname te bereiken. Je kunt je 
voorstellen dat het heel lastig is om die ene 
op de miljoen T cellen te vinden. Om deze 
reden gebruikten we een speciale methode 
om specifieke T cellen op te sporen in de 
patiënt na vaccinatie: we injecteerden een 
klein beetje DC vaccin in de huid van pa­
tiënten reeds nadat ze de vaccinatiebehan- 
deling hadden afgerond. Lokaal in de huid 
ontstaat dan wat ontsteking, waardoor T 
cellen aangetrokken worden. Als daar een 
CEA-specifieke T cel bijzit wordt die geac­
tiveerd (omdat de DCs zijn beladen met 
CEA) en gaat delen. Lokaal krijg je dan 
dus veel CEA specifieke T cellen. Na 48 
uur nemen we van dat stuk huid een kleine 
biopsie, wat we daarna op kweek zetten. 
vervolgens kweekten we de T cellen uit dat 
biopt en testten dat op de herkenning van 
CEA. Op deze manier vonden we dat in 
de meerderheid van de patiënten een af- 
weerreachte tot stand was gebracht tegen 
CEA na vaccinatie. Omdat bij deze patiën­
ten na vaccinatie de tumoren werden ver­
wijderd, kan over de klinische effectiviteit 
vooralsnog niets geconcludeerd worden op 
basis van deze studie.
Er zijn verschillende manieren om de DCs 
met antigeen te beladen. In de normale si­
tuatie in het lichaam neemt de DC stukken
van tumorcellen (eiwitten) op en knipt de­
ze zelf in zijn binnenste in kleine stukjes, 
dan heten ze peptiden. Deze peptiden 
brengt hij dan in de HLA moleculen op 
het oppervlakte en presenteert ze zo aan 
de T cellen. In de eerder genoemde studies 
hebben wij telkens peptiden gebruikt om 
de DCs te beladen, dus kant-en-klaar ge­
knipte stukjes eiwit. Dit heeft als voordeel 
dat je precies weet waar je de T cel reactie 
tegen aanzet, en dat dus ook heel precies 
kunt meten na vaccinatie. Nadelen zijn 
onder meer dat peptiden makkelijk loslaten 
uit de HLA-moleculen van de DCs en 
daarnaast is de ‘breedte’ van de afweerre­
actie erg beperkt; immers, alleen tegen 1 
specifiek peptide. Een nieuwe techniek 
kent deze nadelen niet: electroporatie van 
RNA. RNA is de tussenstap tussen DNA 
en eiwit, dat wil zeggen genen in de cel­
kern worden omgezet in RNA, wat weer 
wordt omgezet in eiwitten die uiteindelijk 
allerlei functies voor de cel vervullen. Het 
is mogelijk om ook RNA van tumoranti­
genen in een DC te brengen, vervolgens 
wordt dat door de cel zelf omgezet in het 
eiwit, dat wordt door de cel zelf in stukjes 
geknipt en in HLA-moleculen op het op­
pervlakte gebracht en aan T cellen gepre­
senteerd. Dit leidt ertoe dat er allerei ver­
schillende peptiden van eenzelfde eiwit 
worden gepresenteerd en dat de binding 
met HLA-moleculen beter is, wat mogelijk 
tot een betere en bredere T cel-activatie 
zou kunnen leiden.
Wij testten in hoofdstuk 6 de techniek van 
electroporatie. Hierbij breng je gedurende 
een aantal milliseconden DCs een kleine 
schok toe, waardoor de celwand zich heel 
kort opent. Bijgevoegd RNA kan dan naar 
binnen gaan. We tonen aan dat met deze 
techniek het mogelijk is om goede eiwit- 
productie te krijgen van de relevante tu­
morantigenen (zowel melanoom als darm- 
kanker-antigenen) en we laten zien dat de
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DCs T cellen specifiek tegen deze antige­
nen kunnen activeren. Wel vonden we dat 
bij verschillende maturatie-methoden er 
verschillende uitkomsten waren.
In hoofdstuk 7 kijken we vervolgens in 
patiënten of vaccinatie met DCs die ge- 
electroporeerd zijn met RNA inderdaad 
ook beter zijn dan DCs die zijn beladen 
met peptiden. We deden dit in darmkan- 
kerpatiënten met hetzelfde stadium als in 
hoofdstuk 4, dus met leveruitzaaiïngen die 
verwijderd konden worden. We vaccineer­
den deze patiënten met DCs die waren ge- 
electroporeerd met CEA-RNA. De immu­
nologische resultaten vergeleken we met 
de resultaten van de eerdere studie, waarbij 
we patiënten vaccineerden met CEA-pep- 
tide beladen DCs. Door een moeizame pa- 
tiënteninclusie hebben we helaas slechts 5 
patiënten op deze manier kunnen behan­
delen. In die 5 patiënten vonden wij geen 
tekenen van CEA-specifieke T cel reactvi- 
teit na vaccinatie. Hoewel op basis van dit 
kleine aantal patiënten beperkte conclusies 
getrokken kunnen worden, lijkt CEA-elec- 
troporatie niet tot betere resultaten te lei­
den dan CEA-peptide als methode van an- 
tigeenbelading van DCs voor vaccinatie.
In hoofdstuk 8 beschrijven we onderzoek 
naar het effect van chemotherapie op DC 
functie. Als DC vaccinatie gecombineerd 
zou kunnen worden met chemotherapie 
zou dit welicht de klinische effectiviteit 
kunnen verbeteren. We kweekten DCs in 
de aanwezigheid van een breed scala aan 
chemotherapeutica en gebruikten vervol­
gens deze DCs om in kweekbuisjes T cel­
len te activeren. We vonden dat DCs die 
waren gekweekt in de aanwezigheid van 
platinum-bevattende chemotherapie een 
sterk toegenomen potentie hadden om T 
cellen te stimuleren. Het betreft de chemo- 
therapeutica oxaliplatin, carboplatin en
cisplatin die bij zeer veel verschillende 
vormen van kanker dagelijks gebruikt 
worden in de kliniek. We vonden dat onder 
invloed van platinum-chemotherapie het 
molecuul PD-L2 op het oppervlak van de 
DC naar binnen werd geklapt. PD-L2 is 
een remmend eiwit dat normaal gesproken 
er voor zorgt dat T cel activatie niet te veel 
‘doorschiet’ en is dus van belang bij het in 
toom houden van afweerreacties. Doordat 
PD-L2 als het ware naar binnen klapt on­
der invloed van platinum-chemotherapie, 
resulteert dat in een verhoogde T celactiva- 
tie. We hebben nog verder gekeken waar­
om de hoeveelheid PD-L2 op de DC ver­
mindert door platinum-chemotherapie en 
dit bleek te berusten op inactivatie van het 
eiwit STAT6 dat de hoeveelheid PD-L2 op 
de cel reguleert.
Nu is het zo dat niet alleen DCs PD-L2 op 
hun oppervlak hebben, maar tumorcellen 
ook. Ze gebruiken dit molecuul als verde- 
digingsschild tegen T cellen (figuur 4).
Figuur 4
We vonden dat platinum-chemotherapie 
ook in tumorcellen PD-L2 naar beneden 
brengt als gevolg van inactivatie van 
STAT6 en daarmee een verdedigingsme­
chanisme van de kankercellen afpakt (fi­
guur 5). Onze hypothese was dat platinum- 
chemotherapie niet alleen werkt door di­
rect kankercellen dood te maken, maar ook 
door het immuunsysteem te activeren en 
tumorcellen te ‘ontwapenen’ tegen het af­
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weersysteem. Om dit te testen hebben wij 
gekeken naar STAT6 aanwezigheid in tu­
moren van patiënten met mond-keelkanker 
die werden behandeld met cisplatin en be­
straling. We vonden inderdaad dat patiën­
ten die STAT6 in hun tumor hadden, een 
beduidend betere reactie lieten zien op de 
cisplatin therapie, hetgeen impliceert dat 
het immunologische effect van platinum- 
chemotherapie ook van klinisch belang is.
Figuur 5
Platinum-chemotherapie leidt dus tot ver­
hoogde DC activatie en ‘ontwapening’ van 
kankercellen. Om te kijken of het gecom­
bineerd kan worden met immuuntherapie 
is het van belang om te weten wat er ge­
beurt met de T cellen tijdens de chemothe­
rapie. In hoofdstuk 9 onderzoeken we dit 
door darmkankerpatiënten te vaccineren 
met CEA-beladen DCs in combinatie met 
oxaliplatin chemotherapie. Het betrof pa­
tiënten die darmkanker hadden zonder uit­
zaaiingen op afstand, maar wel in lokale 
klierstations. Dat betekent dat ze een hoge 
kans hebben op het krijgen van uitzaaiin­
gen op afstand op den duur en om die re­
den wordt deze patiëntencategorie stan­
daard na operatie behandeld met twee 
chemotherapeutische middelen: oxaliplatin 
en capecitabine. Wij gaven naast deze 
standaard therapie 7 patiënten ook DC 
vaccinatie en vergeleken de immunologi­
sche resultaten met die van de patiënten
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van hoofdstuk 5. We vonden dat ondanks 
de chemotherapeutische behandeling het 
merendeel van de patiënten een goede 
immuunreactie tegen CEA kreeg na vaci- 
natie. Ook zagen we in het bloed van deze 
patiënten dat de mate waarin T cellen ge­
activeerd konden worden omhoog ging na 
toediening van oxaliplatin. Het lijkt dus op 
basis van de resultaten van hoofdstuk 8 en 
9 dat chemotherapie en immuuntherapie 
elkaar uitstekend kunnen aanvullen, en dat 
nieuwe combinaties van deze twee ver­
schillende vormen van therapie mogelijk 
kunnen leiden tot een betere behandeling 
van kanker.
In hoofdstuk 10 en 11 vatten we alle resul­
taten met DC vaccinatie studies in mela- 
noom samen en bespreken we de proble­
men die er nog zijn en ook de weg die ons 
inziens bewandeld dient te worden om tot 
een betere immuuntherapeutische behan­
deling van kanker te komen.
V oetnoot
1De beschrijving van deze snelle promotie van de D C  heb ik ont­
leend aan de inaugurele rede van prof. Adema.
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samenwerken. Boven alles is wetenschap bedrijven gewoonweg ontzettend spannend!
Bij translationeel onderzoek, zoals dat ook beschreven is in dit proefschrift, ligt de 
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Speciaal wil ik iedereen die mij heeft begeleid bij het leren van onderzoek doen 
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nette pipeteur annex klinisch onderzoeker te maken.
Bedankt allemaal!
Joost
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